









THE THERAPEUTIC IMPORTANCE OF ISONIAZID 
METABOLISM IN ELDERLY PATIENTS. 
A Thesis submitted for the degree of Doctor of Medicine (M. D.), in 
Clinical Pharmacology. 
BY 
Dr. ANDREW WALUBO 
M.B.Ch.B (Makerere); M.Phil. (Hong Kong) 
Department of Pharmacology, 
University of Cape Town. 












The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 












I, Andrew WALUBO, declare that this thesis represents my own 
work and that it has not been submitted to this or any other 
institution in application for admission to a degree or any other 
qualification. 
ii 
V ARIABTLITY IN DF.UG RESPONSE 
People vary not only in their appearance and philosophy but also in their 
physiology and biocber tistry, and in their occupations and habits that may bear on the 
way in which they resp ,nd to drugs. 
(Tucker, 1994) 
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ABSTRACT 
This is a study of the role of oxygen free radicals in isoniazid 
induced toxicity and its implications on the safety of isoniazid 
containing regimens in elderly patients. During isoniazid 
metabolism, toxic metabolites are produced which, together with 
isoniazid, may lead to toxicity by mechanism (s) yet unknown. 
Understanding the mechanism of toxicity is important for effective 
management and prevention of isoniazid induced toxicity. Elderly 
patients take priority for this consideration because isoniazid is more 
toxic in these people. Consequently, "the therapeutic importance 
of isoniazid metabolism in elderly patients" was found a suitable title 
for this work. 
lsoniazid metabolites; acetylisoniazid, monoacetyl-hydrazine and 
diacetylhydrazine were synthesized and characterized by thin layer 
chromatography, high performance liquid chromatography (HPLC), 
ultra-violet absorption spectra and mass spectrometry. Thereafter, 
these compounds together with hydrazine were used in the 
subsequent experiments. 
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First, a comprehensive assay for determination of pyrazinamide, 
rifampicin, isoniazid and the four hydrazine metabolites is described. 
It involves organic solvent extraction of pyrazinamide and rifampicin, 
followed by derivatization of isoniazid, monoacetylhydrazine and 
hydrazine with salicylaldehyde and thereafter extracted into 
diethylether. Acetylisoniazid and diacetylhydrazine were hydrolyzed 
to isoniazid and monoacetylhydrazine, respectively, and processed 
as above. Using a gradient solvent programer, pyrazinamide and 
rifampicin were analyzed on a C8 (5 um) column at 248 nm, while 
isoniazid and metabolites were analyzed on a C18 (5 um) ODS2 col-
umn at 280 nm. 
In another experiment, the three drugs and four metabolites were 
screened in vitro for production of reactive oxygen species, in 
particular, superoxide anion and hydrogen peroxide radicals. The 
reaction mixture consisted of oxyhaemoglobin in K2P04 buffer, at pH 
9.2, 30°C with or without superoxide dismutase (SOD) or catalase 
or both. lsoniazid reaction was the most sensitive to inhibition by 
SOD while acetylisoniazid and monoacetylhydrazine reactions were 
sensitive to both SOD and catalase. lsoniazid, 
monoacetylhydrazine, acetylisoniazid and hydrazine activated 
V 
oxygen to reactive oxygen species while pyrazinamide, rifampicin 
and diacetylhydrazine did not. Therefore, only isoniazid, 
acetylisoniazid, monoacetylhydrazine and hydrazine were selected 
for further studies of reactive oxygen species. 
Involvement of reactive oxygen species in isoniazid-induced 
hepatotoxicity was investigated by incubation of rat liver slices with 
isoniazid and each of the selected hydrazide metabolites (hydrazine, 
monoacetylhydrazine and acetylisoniazid), separately. Reactive 
oxygen species were detected by measuring lipid peroxides using 
the thiobarbituric acid-reacting-substances (TBARS) test while 
hepatotoxicity was assessed histologically. Hydrazine induced lipid 
peroxidation but isoniazid, acetylisoniazid and monoacetylhydrazine 
did not, most probably because the three compounds interfered with 
the TBARS test. Therefore, the TBARS test was found unsuitable 
for detecting lipid peroxidation induced by hydrazide compounds. 
Because hydrazine is a metabolite of isoniazid, it was concluded 
here that reactive oxygen species may contribute to isoniazid 
induced hepatotoxicity. 
Since occurrence of toxicity depends on the amount of toxic agent 
in the body, disposition of the three drugs and four metabolites was 
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compared in 10 young (25 + 1 years old) and 9 elderly (72 + 3 
years old) patients during treatment with pyrazinamide, rifampicin 
and isoniazid on days 1, 30, and 90. The pharmacokinetics of the 
three drugs and the four metabolites were similar on the three oc-
casions in both young and elderly patients. For the metabolites, 
maximum concentration (Cmax), time to reach Cmax (Tmax) and 
area under curve (AUC) in both groups, were comparable. In 
general, during antituberculosis therapy with isoniazid, rifampicin 
and pyrazinamide, the metabolism of isoniazid to hydrazide metabo-
lites is not related to age. 
As plasma concentrations of the metabolites and drugs were lower 
than those used in the in vitro experiments, it was necessary show 
whether generation of reactive oxygen species in vivo occurs. 
Allantoin, a product of purine metabolism, was used to detect 
reactive oxygen species in patients. Oxidative stress during 
antituberculosis therapy was compared in 10 young and 9 elderly 
patients. Before treatment, allantoin plasma concentrations in 
young and elderly patients were similar. Administration of a 
combination of isoniazid, rifampicin and pyrazinamide increased the 
plasma concentration of allantoin in both groups of patients. 
Allantoin concentrations (mean + s.e.) at six hours were higher (P 
vii 
< 0.05) in elderly than in young patients on day one, (8.22 + 1 .50 
vs 1.89 + 0.98 ug/ml); day 30, (5.85 + 0.82 vs 0.87 + 0.57 
ug/ml); and day 90, (4.84 ± 1.24 vs 0.52 + 0.50 ug/ml). 
Although the total amount of allantoin excreted and the rate of 
allantoin formation at steady state were similar in both groups on 
the three occasions, allantoin clearance was nine times higher in 
young than in elderly patients. It was concluded that the high 
allantoin concentrations in the elderly was due to decreased renal 
excretion, while the increase in plasma allantoin concentration when 
the drugs were administered implies that these antituberculosis 
drugs induced oxidative stress in both the young and elderly 
patients. 
In general, depending on the amount of hydrazine formed during 
isoniazid metabolism, reactive oxygen species may contribute to 
isoniazid induced toxicity. 
viii 
PUBLICATIONS RELATED TO THIS PROJECT 
1 . Comprehensive assay for pyrazinamide, rifampicin and isoniazid with 
its hydrazine metabolites in human plasma by column liquid 
chromatography. J. Chromatogr. 1994~ 658: 391-396. 
2. The generation of oxygen free radicals by antituberculosis drugs in 
vitro. Proc. of the South African Pharmacology Society Congress, 
22-24 Sept., 1994. Cape Town. Manuscript submitted to 
Biophysica et Biochemica. 
3. The disposition of isoniazid metabolites during anti-tuberculosis 
therapy. Proc. of the 7th South East Asia Drug Metabolism 
Workshop, 6-9th Nov., 1994, Bangkok, Thailand. Manuscript 
submitted to The J. Clin. Pharmacol. Ther. 
4. Oxidative stress during antituberculosis therapy. 
Proc. of the 12th International Congress of Pharmacology, 24-
29th, July, 1994. Montreal, Canada. Can. J. Physic.& Pharmacol. 
vol. 72, Suppl.1, pg 595, 1994. Also, published in J. Biomed. 
Envir. Sci., 1995; 8: 106 -113. 
ix 














GENERAL INTRODUCTION. 1 
Chapter two. ANTITUBERCULOSIS CHEMOTHERAPY 
PART 0: INTRODUCTION. 8 
PART I: ISONIAZID & HYDRAZINE METABOLITES. 11 
PART II: THE CHALLENGES OF TREATING 
TUBERCULOSIS IN THE ELDERLY. 26 
X 
PART 111: FREE RADICALS, OXIDATIVE STRESS, AGING AND 
DISEASE. 35 
PART IV: INTRODUCTION TO LIPOSOMES. 52 
Chapter three 
OBSERVATIONS FROM REVIEW, HYPOTHESIS AND 
OBJECTIVES. 55 
Chapter four 
A COMPREHENSIVE ASSAY FOR PYRAZINAMIDE, RIFAMPICIN 
AND ISONIAZID WITH ITS HYDRAZIDE METABOLITES IN 
HUMAN PLASMA BY COLUMN LIQUID CHROMATOGRAPHY. 
65 
Chapter five 
THE GENERATION OF OXYGEN FREE RADICALS BY 
ANTITUBERCULOSIS DRUGS AND HYDRAZINE MET ABO LITES 
IN VITRO. 85 
XI 
Chapter six 




THE DISPOSITION OF ISONIAZID METABOLITES DURING 
ANTITUBERCULOSIS THERAPY. 144 
Chapter eight 
OXIDATIVE STRESS DURING ANTITUBERCULOSIS THERAPY 
IN YOUNG AND ELDERLY PATIENTS. 166 
Chapter nine 
PART 1 CONCLUSIONS. 










1 . 0 The elderly 
"Elderly" refers to people aged 65 years and over. At a growth rate 
of 2.5 per cent per year, the world's elderly population is growing 
faster than the total population (Suzman, 1992). In thirty-two 
developed countries, it was estimated that 16 - 26% of the 
population will be elderly by the year 2020, versus 10 - 16% in 
1990. For example, in the next forty years, twenty percent of the 
U.S. population will be elderly compared to 12.6% in 1990 
(Suzman, 1992; Holden, 1990). The fastest growing segment of 
the elderly population are the "old old" (persons aged 80 years and 
over). The "old old" constitute 20% of the elderly population of 
the U.S.A. and this is expeGted to triple between 1980 and 2020 
(U.S. Bureau of the Census, 1989; U.S. Senate Spec., 1986). 
While developed countries are far ahead in the age demographic 
transition, developing countries have yet to show this trend. In 
developing countries, the number of elderly people is small 
compared to other age groups. This is depicted by the pyramidal 
shape of their population age structure (Fig. 1 . 1), a feature 
characteristic of communities with high infant mortality and fertility 
rates, and a low life expectancy (Macfadyen, 1992). However, due 
to effective World Health Organisation (WHO) programmes, some 
developing countries are beginning to experience a culture of 
demographic aging that has swept through the developing world. 
1 




















































































































































































































































































































Indeed, the fastest growing population of elderly people in the world 
is in developing countries. Of the 1.2 million annual world increase 
in people over 55 years, 80% occur in developing countries (Kane 
et al, 1990). For instance, in Indonesia, population change in 
people over 75 years of age from 1988 to 2005 ( 17 years) is 
estimated to be 12% while that of USA from 1990 to 2020 (30 
years) shall rise by only 5.1 % (Torrey et al, 1987; Kinsella, 1988; 
Brody, 1985; Suzman, 1992). Life expectancy over the same 
period ( 17 years) is to increase from 60. 7 to 66.6 years for Asia and 
52.6 to 59.8 years for Africa. In the U.S.A., life expectancy is to 
change in 10 years (1990 to 2000) from 72 to 73 years for males 
and 78 to 81 years for females (Natl. Res. Counc., 1987). 
Therefore, in developing countries the population of aged persons is 
growing fast and there will be a need in the coming years for all 
health personnel to pay attention to health issues associated with 
aging. 
1. 1 Tuberculosis 
Tuberculosis is an infectious disease caused by Mycobacteria and 
is characterised by formation of tubercles and caseous necrosis in 
tissues (Friels, 1 981). The disease has been in existence since the 
earliest times; a similar condition having been described by the 
ancient Chinese (Dubas, 1952), and was found in the Egyptian 
skeletons dating 2,500 B.C.(Morse, 1964). Nevertheless, it was 
only in 1882 that the causative organism was discovered by Dr. 
Robert Kochs as Mycobacteria tuberculosis (Kochs, 1882). Many 
other species have since been described but Mycobacteria 
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tuberculosis humanus remains the most common cause of 
tuberculosis in man. Infections due to Mycobacteria bovis and 
avium are rare. Occasionally Mycobacteria kansasii and other 
unclassified Mycobacteria are isolated in some atypical tuberculosis 
like infections. 
1.2 Epidemiology of tuberculosis 
Tuberculosis is a world wide problem. According to WHO, it was 
estimated that every year 30 million people are infected with 
tuberculosis, 10 million are newly infected and 3 million die from the 
disease (Bulla, 1981). Tuberculosis is more prevalent in developing 
countries where, even before the advent of human 
immunodeficiency virus (HIV), tuberculosis was one of the major 
causes of morbidity and mortality in young adults (Holdiness, 1985). 
Epidemiology of the disease has been well studied in developed 
countries. Tuberculosis was the leading cause of deaths among 38 
communicable diseases reported in 1979 to the centres for Disease 
Control in the United States, and the number of deaths exceeded 
the combined total for the other 37 communicable diseases 
(Youmans, 1979). Due to good tuberculosis control programs in 
the U.S.A., in past 3 decades, the incidence of tuberculosis was 
falling at a case rate of 5 to 6% per year up to 1985 when the HIV 
epidemic struck. This fall was negatively correlated by an increase 
in tuberculosis cases in elderly people where between 1968 and 
1982 the percentage of patients above 65 years with newly 
diagnosed tuberculosis increased from 18.9% to 29.1 % (Stead et 
al, 1985). In the same period the percentage increase in the elderly 
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population was from 9.2% to 11.3%. In Arkansas state, 
tuberculosis case rate was 60 per 100,000 for the elderly versus 23 
per 100,00 in those 40-60 years of age (Stead et al, 1985). 
Whether this was reactivated tuberculosis or nosocomial infection, 
it denotes a higher incidence of tuberculosis in elderly people of 
developed countries. 
The implication here is that such catastrophes are higher in 
developing countries where the disease is highly prevalent and many 
cases and deaths are not reported or recorded. The prevalence of 
tuberculosis in elderly people of developing countries is not well 
documented. Nevertheless, there is a need to improve quality of 
life in elderly people during treatment for tuberculosis. 
1.3 Tuberculosis in the elderly 
Tuberculosis in the elderly is a syndrome whose features, except for 
age of the patient, are difficult to characterise. In spite of similar 
causative bacilli, the manifestations of tuberculosis in elderly 
patients are atypical (Alverez et al, 1987; Katz et al, 1987; Nagami 
and Yoshikawa, 1984; Rudd, 1985). A low incidence of fever, 
weight loss, night sweats, sputum production and heamoptysis was 
noted in the older group (n = 35; mean age 7 4. 3 years) (Alvarez et 
al, 1987). In the same report, four elderly patients had no 
symptoms while all young patients (n = 29; mean age 45 years) 
were symptomatic. Tuberculosis related deaths occurred in 20% 
of the elderly (7 patients) versus 3 % of the young ( 1 patient). 
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In another study, none of the elderly patients (n = 52; mean age 70 
years) presented with heamoptysis (Katz et al, 1987). The 
prevalence of fever, anorexia, weight loss and cough in these elderly 
were similar to that in young patients (n = 17; mean age 51 years) 
patients. Radiographic findings also differed between young and 
elderly patients. Right lower lobe infiltrates were more prevalent in 
young patients (33%}, than in elderly patients (9 .6 % ) , (Khan et al, 
1977; Hadlock et al, 1980; Miller and Macgregor, 1978}. 
Diagnosis of tuberculosis in old people is more often difficult 
because in the elderly, active pulmonary tuberculosis cannot be 
ruled out on the basis of absence of symptoms or a negative 
mantoux test. A high level of suspicion is necessary and a two-
step (booster) mantoux test is recommended in anergenic patients 
or a therapeutic trial in difficult cases (Hadlock et al, 1980; 
Comstock, 1986). 
Having made a diagnosis of tuberculosis in an elderly patient, 
administration of antituberculosis chemotherapy to this patient 
results in a pharmacological complex about which little is known. 
There is little information regarding a combination of tuberculosis, 
the elderly and antituberculosis drugs (Teale et al, 1993). 
Treatment of tuberculosis in the elderly poses a challenge to 
tuberculosis therapeutic policy. As in the case of young patients, 
the standard antituberculosis regimen consists of isoniazid, 
pyrazinamide and rifampicin. This regimen is used despite reports 
of severe adverse reactions in elderly patients on this regimen (Woo 
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et al, 1987 and 1992; Teale et al, 1993). It is also known that the 
incidence of isoniazid induced hepatitis rises with age (i.e. rare under 
20 years of age, up to 0.3% between 20 and 34 years, up tp 1 .2% 
between 35 and 49 years, and up to 2.3% at 50 years and over) 
(Kopanoff et al, 1978; Riska et al, 1976), and that the risk of 
isoniazid toxicity is worsened by addition of pyrazinamide (8 % ; 
Hong Kong, 1976) and rifampicin (4%; Brouet, 197 4). The regimen 
is still used and there is no hope for a substitute. There is a need 
to improve quality of life of elderly patients during treatment for 
tuberculosis. 
In the present project, a mechanism of isoniazid induced toxicity is 
investigated. The pharmacokinetics of rifampicin, pyrazinamide, 
isoniazid and its hydrazide metabolites have been determined 
because these seven compounds co-exist during tuberculosis 
therapy, are potentially hepatotoxic (Girling, 1978), and have been 
associated with severe adverse effects in elderly patients (Woo et 
al, 1987 and 1992). Hydrazide metabolites of isoniazid were 
studied because they are more toxic than isoniazid, and were 
suggested to cause isoniazid related hepatotoxicity (Mitchel et, 
1976; Sarma et al, 1986). Very little is known about the 
disposition of hydrazide metabolites in elderly patients during 
antituberculosis therapy and the mechanism of isoniazid induced 
toxicity is still unknown. 
This project is based on the concept of understanding the 
mechanism of drug-induced toxicity as a prerequisite to formulating 







Treatment of tuberculosis has improved during this century. The 
old fashioned course of observation, rest, sunshine and collapse 
therapy is no longer applied. The past 55 years have been marked 
by a series of inventions of new and modern antituberculosis 
chemotherapeutic agents with higher efficacy rates such that with 
the right treatment a cure rate of 100 per cent is predictable, in the 
shortest possible time of treatment and at the cost within reach of 
most countries. 
In 1940 a sulphonamide promin (glucosulfone sodium), a derivative 
of dapsone, was demonstrated to have bacteriostatic effects on 
Mycobacteria tuberculosis (Youmans, 1979). Although this 
compound arrested progress of the disease in experimentally 
infected guinea pigs, it was abandoned because high concentrations 
were required for this action. Further investigations on 
antituberculosis activity of benzoic and salicylic acid related 
compounds lead to discovery of p-aminosalicylic acid (PAS) in 
1946. Antituberculosis activity of streptomycin was demonstrated 
in animals in 1944 (Feldman, 1944), and has been used in man 
since 194 7, the year when thiacetazone was introduced. Later in 
1952, workers in three independent laboratories in America and 
Germany, reported the antituberculosis activity of isoniazid 
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(Bernstein, 1952; Fox, 1952; Offe, 1952). lsoniazid has proven a 
wonder drug in the treatment of tuberculosis; it is used for 
prophylaxis and is a keystone of the most effective antituberculosis 
regimens. Introduction of ethambutol in 1961, and rifampicin in 
1968 (Crossland, 1980) has revolutionised antituberculosis 
chemotherapy not only by increasing efficacy but also by reducing 
the period of treatment and frequency of dosing. 
Currently, there are over ten antituberculosis drugs on the market. 
They have been classified in different ways such as popular use, 
bactericidal or bacteriostatic, and naturally occurring or synthetic. 
Classification as first and second-line drugs is easier and is more 
frequently used. lsoniazid, rifampicin, pyrazinamide, streptomycin 
and ethambutol are considered first line drugs because of their 
higher potency, relatively low toxicity and ease of administration. 
P-aminosalicylic acid (PAS), thiacetazone, ethionamide, cycloserine, 
kanamycin, capreomycin, and viomycin are second line drugs 
because they are less potent and more toxic. They are used to 
supplement the actions of first line drugs and to guard against 
emergence of resistance. 
Therefore, for treatment of tuberculosis, a combination of three to 
four drugs, preferably two or three first line drugs and one second 
line drug, are used for the first two or three months and there-after 
treatment is continued with two drugs for such a period depending 
on the form of tuberculosis and drugs being used. When isoniazid, 
streptomycin, and thiacetazone or PAS are used, treatment is 
continued for twelve to twenty four months, while, in case of 
9 
isoniazid, rifampicin, pyrazinamide, streptomycin and or ethambutol 
it is continued for six to twelve months. Tuberculosis of the central 
nervous system and milliary tuberculosis are treated for longer 
periods than other forms of tuberculosis. The long period of 
treatment for this disease is to avoid relapses due to the persistent 
semidormant bacilli which are killed slowly with time. 
10 
CHAPTER TWO; PART I 
ISONIAZD AND HYDRAZIDE MET ABO LITES 
2. 1 ISONIAZID 
2.1.1 Chemistry 
lsoniazid (isonicotyl hydrazine) is one of the most widely used 
antituberculosis drugs. It is used in the treatment of active disease 
as well as for prophylaxis in those at risk and below 35 years of 
age. The structure of isoniazid is as shown in Figure 2. 1. It is a 
derivative of isonicotinic acid with a molecular weight of 137 .2 and 
a melting point of 172°C. It is highly water soluble and has 
dissociation constants of 1.8, 3.5, and 10.8 at 20°c (Clarke's, 
1986). 
It is a white crystalline powder that is dispensed in form of tablets 
of 100 mg or 300 mg each, syrup of 10 mg/ml, and injection 
solution of 100 mg/ml. It is commonly given orally; 5-1 0 
mg/kg/day in adults and 10-1 5 mg/kg/day in children less than 4 
years. However, with the advent of short course and intermittent 
chemotherapy there is a wide variation in dosages today. 
2.1.2 Antimycobacterial activity 
lsoniazid is tuberculocidal against actively multiplying bacilli and 
tuberculostatic to slowly growing bacilli. In vitro minimum 



































































































































































order 0.025 to 0.05 µg/ml (Mandell, 1985). The drug is more 
effective against extracellular organisms at neutral pH. When 
isoniazid is used alone to treat tuberculosis, resistance develops 
within a few weeks. Fortunately, there is no cross resistance 
between isoniazid and other antituberculosis agents, making 
combined drug therapy essential to avoid emergence of resistant 
organisms. 
The mechanism of action of isoniazid is not fully known. Takayama 
et al ( 1975) proposed that isoniazid inhibits synthesis of mycolic 
acid in Mycobacterial cell wall. This explains the highly selective 
action of isoniazid to mycobacteria. Later, Herman and Weber 
( 1977) suggested that isoniazid also interferes with lipid and nucleic 
acid synthesis and the glycolytic processes of mycobacteria. 
2. 1.3 Absorption and distribution 
lsoniazid is rapidly and completely absorbed in man after oral and 
parenteral administration (Barclay et al, 1953; Des Prez and Boone, 
1961; Elmendorf et al, 1952; Robson and Sulliva, 1963). It is 
absorbed mainly in the small intestines (Barley et al, 1972) and peak 
concentrations are achieved within 1 to 2 hours after ingestion 
(Robson and Sulliva, 1963). Absorption is reduced by presence of 
anti-acids like aluminium hydroxide gel (Hurtwitzand Schlozman, 
1974), simultaneous intake of food (Melander et al, 1976) and some 
types of sugars (Rao et al, 1971). Plasma concentrations tend to 
be lower in fast acetylators than slow acetylators and it was 
proposed that there is appreciable first pass effect in rapid 
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acetylators because acetylator polymorphism is well expressed in 
the mucosal cell lining of small intestines (Hearse and Weber, 1973; 
Jenne, 1965). 
lsoniazid is distributed in total body water with apparent volume of 
distribution of approximately 61 + 11 % of body weight (Jenne et 
al, 1961). Since there is no appreciable plasma protein binding 
(Boxenbaum et al, 1975) this indicates that the distribution is both 
extracellular and intracellular. Significant amounts of the drug were 
detected in cerebrospinal fluid, pleural effusion, saliva and faeces of 
healthy volunteers and patients with tuberculous meningitis (Barclay 
et al, 1953; Boxenbaum and Riegelman, 1973; Elmendorf et al, 
1952). Nevertheless, data from these studies has been insufficient 
for proper use of isoniazid in treatment of tuberculous meningitis. 
Higher doses ( > 10 mg/kg/day) are still used in the treatment of this 
form of tuberculosis (Lam et al, 1989). Since therapeutic 
effectiveness and toxicity of isoniazid depend on extent and 
intensity of exposure of the body to the drug, kinetic studies in this 
aspect are essential to understanding of how long and to what 
extent the drug stays in the central nervous system. This, in turn, 
leads to a rational approach on the use of isoniazid for treatment of 
tuberculosis of the central nervous system. 
2.1.4 Metabolism and elimination 
lsoniazid is cleared from plasma mainly by acetylation at a rate 
which is determined by type of the hereditarily polymorphic N-
acetyltransferase enzyme an individual carries (Evan, 1965; Evan 
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and White, 1964; Glowinsk et al, 1978; Jenne, 1965). Individuals 
are therefore classified as either rapid or slow acetylators depending 
on the rate at which they eliminate isoniazid (Weber and Hein, 
1979). Therefore, elimination half-life of isoniazid is determined by 
acetylator status. After an intravenous dose of isoniazid, rapid 
acetylators were considered as having isoniazid elimination half-life 
shorter, and slow acetylators longer than 110 minutes (Weber and 
Hein, 1979). However, different antimodes have been observed by 
other workers. Paulsen et al (1985) and Kergueris et al (1986) 
used antimode 1 20 minutes, most probably due to difficulties in 
classifying heterozygous (Rr) individuals when small populations are 
studied. Also, oral administration of drugs is associated with longer 
half-life values compared to values after intravenous administration 
(Chan and Wong, 1988; Walubo et al, 1991 b). Man and rabbit 
species exhibit this acetylating capacity (Hearse and Weber, 1973) 
not only for isoniazid but other drugs as well, for example; 
hydrallazine, procainamide, and sulphonamides. The optimum pH 
for inactivation of isoniazid is 6.5 to 7 .0. The enzyme is resistant 
to sulphhydryl inhibition and is insensitive to induction (Schulte et 
al, 1974). Furthermore, evidence from studies in rabbits suggests 
that rapid and slow N-acetyltransferase are structurally different 
enzymes (Weber et al, 1978). 
Figure 2.2 shows important metabolic pathways for elimination of 
isoniazid (Boxenbaum and Reigelman, 1976; Ellard and Gammon, 
1976). The major metabolic step is acetylation of isoniazid to 
acetylisoniazid (Mitchell et al, 1976). Acetylisoniazid is 
















































































































































































































































































































et al, 197 2). lsonicotinic acid is then conjugated with glycine and 
excreted in urine. Most monoacetylhydrazine is acetylated to 
diacetylhydrazine which together with some free 
monoacetylhydrazine are excreted by the kidneys. Some isoniazid 
is conjugated to form pyruvic and ketoglutaric hydrazones, and a 
smaller proportion is hydrolysed to hydrazine and isonicotinic acid. 
Some hydrazine is lost via the renal route while the rest 1s 
presumably biotransformed by yet unexplained mechanism. 
The metabolic fate of hydrazine and monoacetylhydrazine is still 
uncertain because of the low recovery of these compounds in urine 
and plasma (Weber and Hein, 1979). However, it has been shown 
that monoacetylhydrazine is the only metabolite which exhibits 
polymorphic metabolism in a manner similar to that of isoniazid 
(Ellard and Gammon, 1976). It was reported in the same 
communication, that there is little or no difference between plasma 
concentrations of monoacetylhydrazine in the two phenotypes. 
This contradicted earlier proposals that rapid acetylators produce 
more monoacetylhydrazine, and are therefore more prone to suffer 
from isoniazid induced hepatotoxicity (Black etal, 1975). It was 
demonstrated in rats that monoacetylhydrazine can be 
biotransformed by liver microsomal enzymes to a potent acylating 
agent that can cause hepatic necrosis, and thereby concluded, with 
clinical evidence (Mitchel et al, 1976), that it is the major toxic 
metabolite responsible for isoniazid induced liver toxicity. A lot of 
clinical evidence against this hypothesis has accumulated (Ellard et 
al, 1978; Girling, 1978; Ellard, 1984; Gurumurthy et al, 1984). It 
was suggested that, since a rapid acetylator also converts 
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monoacetylhydrazine more rapidly to diacetylhydrazine, the risk of 
liver toxicity should be the same in both phenotypes (Ellard and 
Gammon, 1976; Timbrell et al, 1977). Further studies on 
monoacetylhydrazine have shown that at concentrations of 1 µg/ml 
this metabolite can inhibit the antimycobacterial activity of isoniazid 
in vitro (Weber and Heine, 1979). The clinical significance of this 
is yet to be established. 
Renal elimination of isoniazid is approximately 11 to 27 per cent of 
total body clearance for rapid and slow acetylators, respectively. 
This is considered unimportant compared to the metabolic pathway. 
About 75 to 95 per cent of a dose of isoniazid is excreted in urine 
within 24 hours as metabolites. N-acetylisoniazid and isonicotinic 
acid are the major urinary metabolites. 
2. 1.4. 1 Hydrazine 
Hydrazine is a metabolite of isoniazid that had been neglected on 
grounds that it is formed in negligible amounts. The structure of 
hydrazine is as shown in figure 2. 1 e. 
Hydrazine is a potent toxin and carcinogen as classified by the 
American Conference of Government and Industrial Hygiene (Albert 
et al, 1977). Hydrazine was incriminated in causing lupus-like 
syndrome in man when hydrallazine and isoniazid were administered 
(Durant et al, 1980). In animal studies, hydrazine caused 
convulsions, hepatic toxicity, renal damage, blood injury and 
affected many metabolic processes (Back and Thomas, 1970). It is 
associated with causation of choroidal carcinoma in man, and 
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questions arise as to whether it may contribute to hepatic 
angiosarcoma, which is a tumour associated with all hydrazide 
compounds (Daneshmend et al, 1979; Toth, 1975 and 1976). 
Hydrazine is a potent inhibitor of many enzyme systems in the body 
and can cause hepatic necrosis. There is a variation in sensitivity 
to hydrazine toxicity in different species. Massive hepatic necrosis 
was observed in monkeys at doses that caused a less severe liver 
injury in rats (Back and Thomas, 1970). This suggests that humans 
may be more susceptible to hydrazine toxicity. As cited earlier, 
recovery of hydrazine metabolites in urine cannot account for the 
total amount presumably formed during isoniazid metabolism. 
Recently, it was reported that rifampicin increased hydrazine 
formation from isoniazid after two weeks of co-administration of the 
two drugs in healthy volunteers (Sarma et al, 1986). Therefore, in 
wake of the unproven role of monoacetylhydrazine in isoniazid 
related hepatotoxicity, hydrazine metabolite has been implicated as 
a possible culprit. Recent studies have shown that hydrazine is 
produced in significant quantities during treatment with isoniazid, 
rifampicin and pyazinamide (Gent et al, 1992; Walubo et al, 1991 d). 
In one report, hydrazine was incriminated in the death of an elderly 
patient (Woo et al, 1992). Consequently, further studies on the 
kinetics of hydrazine as a metabolite of isoniazid are essential to 
explore and perhaps prevent its role in isoniazid related toxicity. 
2. 1 . 5 Side effects of isoniazid 
The major side effect of this drug is liver toxicity which is clinically, 
biochemically, and histologically indistinguishable from viral 
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hepatitis. The risk of developing severe isoniazid induced 
hepatotoxity increases with age; it is rare in persons under 20 years 
of age, up to 0.3 percent in those 20 to 34 years of age, up to 1.2 
per cent at 35 to 49 years, and up to 2.3 per cent at 50 years and 
over (Kopanoff et al, 1974). Stead et al (1981 and 1987) reported 
that the risk of developing isoniazid related hepatitis is about 5 per 
cent in persons above 65 years of age and over. The frequency of 
isoniazid induced hepatitis is not related to acetylator phenotype 
(Singapore Tuberculous Service, 1977). Therefore, it 1s 
recommended that base line liver function tests should be 
determined in patients on isoniazid containing regimens. lsoniazid 
can cause peripheral neuropathy by interfering with pyridoxine 
metabolism. This is common in patients with predisposing factors 
like chronic alcoholism, diabetes mellitus and malnutrition. 
Pyridoxine 10 mg/day has been prescribed as prevention therapy 
while 100 mg/day has been used to treat the established lesion. 
Other side effects include allergy, skin rashes, gastric upsets, febrile 
reactions and, rarely, red cell aplasia (Claiborne and Dutt, 1985), 
psychosis, and depression. 
2.1.6 Drug interactions 
There is an increased risk of hepatotoxicity when isoniazid and 
rifampicin are used together (Bistritzer eta I, 1 980), and the induced 
toxic hepatitis is different from that by either drug (Gronhage-Riska 
et al, 1978). P-aminosalicylic acid led to elevated isoniazid plasma 
concentrations and prolonged the serum half-life of isoniazid 
(Schneck et al, 1979). lsoniazid inhibits phenytoin metabolism 
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predisposing some patients, especially slow acetylators, to 
phenytoin toxicity (Kutt et al, 1970). Many interactions with other 
drugs have been reported but their clinical significance is not yet 
known. This includes drugs like, warfarin, procainamide, 
carbamazepine, primidone, prednisolone, diazepam, 25-
hydroxyvitamin D3, and enflurane to mention but a few. 
2.1.7 Patho-physiological factors 
Table 2. 1 compares the pharmacokinetic parameters of isoniazid in 
relation to age and acetylator status (Advenier et al, 1980). For 
unexplained reasons the dose of isoniazid was higher in the elderly 
group than in the young group. There was no difference in the 
pharmacokinetics of isoniazid between elderly and young people 
(Advenier et al, 1980; Paulsen and Nilsson, 1985; Kergueris et al, 
1986). Although not proven by liver biopsy, it was concluded that 
age is an insignificant factor in the acetylator status of an individual 
(Evans et al, 1960; Advenier et al, 1980). Nevertheless, as 
mentioned earlier, the risk of developing isoniazid induced 
hepatotoxicity increases with age. The reason for this phenomenon 
is not well explained. Liver disease in a patient is an indicator for 
reassessing and adjusting the dosage of isoniazid if deemed 
necessary. Renal disease has limited effect on isoniazid clearance 
such that dosage adjustment is not usually considered until 
creatinine clearance is less that 30 ml/min. However, some 
workers have demonstrated reduced acetylation of isoniazid in 
chronic renal failure (Kim et al, 1993). Chronic diseases such as 







































































































































































































































































































































































































































































































































































(Airaksinen et al, 1969), obesity (Reidenberg, 1973), tuberculosis 
(Tiitinen, 1969), and chronic alcoholism (Tiitinen, 1969) did not 
effect isoniazid metabolism. However insulin enhances the 
intestinal uptake of isoniazid (Daysz and Wisniewski, 1970). 
2.1.8 Acetylator phenotype 
There are several procedures for determination of acetylator status 
of individuals (Weber et al, 1979). Two procedures have been used 
widely in the clinic because they require urine samples which is 
more convenient to the patient and clinician. One is by estimation 
of acetylisoniazid as a proportion of total hydrazides excreted in the 
urine 6 to 8 hours after oral administration of isoniazid (Eidus et al, 
1973). The other classifies individuals according to proportion of 
total sulphadimidine excreted in acetylated form at 4 to 5 hours 
after oral ingestion of sulphadimidine (Evan, 1960; Weber and 
Brenner, 1974). In conditions where renal clearance is much 
reduced, determination of acetylator status is best done by 
estimating the metabolic clearance of a drug (Fine and Sumner, 
1975). The racio-geographical distribution of acetylator phenotype 
shows a high prevalence of rapid acetylators in the far east 
populations; Chinese (85 % ) , Japanese (90%), and Hong Kong 
Chinese (78 % ) , and a low prevalence in the mid-eastern 
populations; East Africa (45%), and United States Caucasians 
(41 % ) ( Weber and Heine, 1979). 
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2.1.9 Assay of isoniazid and metabolites 
Further studies on isoniazid metabolism have been hampered by lack 
of a methodology for the assay of the drug and its metabolites in 
plasma for routine therapeutic monitoring. Secondly, the four 
hydrazine metabolites are not readily available on the market and 
their synthesis is difficult and costly. lsoniazid and its metabolites 
are highly ionic compounds which are difficult to extract from 
plasma and absorb UV-light poorly, necesstating derivatisation for 
optimal extraction and detection in plasma. 
Several procedures for the assay of isoniazid and metabolites in 
biological fluids have been reported. Unfortunately, none of these 
procedures was favorable in our circumstances. The Gas 
chromatography mass spectrometer (GC-MS) procedure (Lauteburg 
et al, 1981) cannot be adopted in our laboratory, while the 
fluorometric assay by Ellard et al ( 197 2) and liquid chromatography 
method by Von Sassen et al (1987) are complex and laborious. 
Generally, the three procedures are too expensive for routine 
practice. 
The procedures described for assay of isoniazid with: acetylisoniazid 
(Holdiness, 1982;), acetylhydrazine (Jenner and Ellard, 1987) and 
hydrazine (Walubo et al, 1991 a) cannot be used on a single plasma 
sample. Furthermore, the procedure by Holdiness ( 1982) required 
adverse chromatographic conditions (e.g. pH 2.5, flow rate 4.0 
ml/min and injection volume 250 ul), while that by Jenner and Ellard 
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( 198 7) was an assay for monoacetylhydrazine in urine. The assay 
for isoniazid and hydrazine reported by Walubo et al ( 1 991 a) failed 
to show monoacetylhydrazine and suffered a poor limit of detection 
for isoniazid (0. 2 ugiml). 
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CHAPTER TWO; PART II 
THE CHALLENGES OF TREATING TUBERCULOSIS IN THE 
ELDERLY. 
2.2. 1 Introduction 
The incidence of tuberculosis and mortality from the disease 
increases with age , so that in some developing countries, it is the 
leading cause of death among the elderly (Chest Service, 1985; 
Mackay and Cole, 1984; Ramos, 1991). Although potentially 
serious adverse reactions are said to be uncommon with 
antituberculosis drugs (Girling, 1984), data on adverse reactions to 
various regimens had been gathered from ambulant middle-aged 
patients only (Hong Kong, 1976; Black et al, 1976). Thus it is 
unclear whether the same regimens apply to elderly patients and 
whether adverse effects are equally uncommon. It is known that 
adverse reactions to antituberculosis drugs are more common in the 
elderly, particularly isoniazid induced hepatitis (Mackay and Cole, 
1984; Gulliford et al, 1986; Walubo et al, 1991 c; Umeki, 1991; 
Riska, 1976; Woo et al, 1987 and 1992). Therefore it was found 
worth-while to review information available on variations in 
pharmacokinetics and pharmacodynamics of antituberculosis drugs 
with age, to emphasize the need for studying antituberculosis drug 
toxicity in elderly patients. 
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2.2.2 Pharmacokinetic changes with age 
Of the commonly used antituberculosis drugs, isoniazid, rifampicin 
and pyrazinamide are predominantly metabolised by the liver 
(Holdness, 1984). Hepatic blood volume and blood flow decrease 
with age (Wyne et al, 1989), and the rate of hepatic metabolism 
may be reduced for certain drugs (Bach et al, 1981; Castleden et al, 
1989). There are few studies on the effect of age on the 
pharmacokinetics of antituberculosis drugs, and most studies are of 
single drugs in isolation in healthy elderly individuals. For isoniazid, 
acetylator phenotype and half-life were not affected by age in one 
study (Weber and Heine, 1979), while in another study a positive 
correlation was found between age and plasma isoniazid 
concentrations when corrected for sex and weight (lselius and 
Evans, 1983). 
No age related changes in the pharmacokinetics of isoniazid, given 
alone, were observed in three studies (Advenier et al, 1980; 
Kergueris et al, 1986; Paulsen et al, 1985). One study of 
rifampicin given alone did not show any difference in 
pharmacokinetic parameters between six elderly individuals and five 
young subjects (Advenier et al, 1983). There are no reports on the 
influence of age on pharmacokinetic parameters for pyrazinamide 
given as a single drug in elderly individuals. Only one study 
examined the effect of age on the pharmacokinetic parameters of 
antituberculosis drugs given in combination in hospitalised patients 
with tuberculosis (Walubo et al, 1991 c). No differences in 
parameters for isoniazid, rifampicin and pyrazinamide were observed 
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with initial dosing. However, one month after therapy, the 
clearances for isoniazid and rifampicin at steady state among 
subjects age 65 years and over were significantly lower compared 
to that at first dose, suggesting an interaction between the drugs. 
In that study, elevations in serum liver enzyme levels and other side 
effects were more common among elderly than younger patients 
(Fig 2.3). 
2.2.3 Protein binding 
Another factor which may affect the disposition of antituberculosis 
drugs in elderly patients is protein binding. In general, acidic drugs 
bind to albumin while basic drugs bind to alpha-1-acid glycoprotein, 
although there are exceptions (Kremer, 1988). In the elderly, 
chronic disease or malnutrition result in lower serum albumin 
concentrations, while alpha-1-acid glycoprotein increases with age 
(Woodford et al, 1964; Upton et al, 1984). Therefore, free drug 
concentrations of acidic drugs may rise, while that of basic drugs 
may fall with age. In healthy individuals, isoniazid is little bound to 
serum proteins, while the percentage bindings for rifampicin are 
quoted as 5 7 - 80% (Holdness, 1984). Protein binding data is not 
available for pyrazinamide. 
The effect of age on protein binding of antituberculosis drugs has 
not been reported. Therefore, in spite of a similar pharmacokinetic 
profiles between young and elderly subjects described in the 
previous studies, there may still be a difference if free drug 





























































free drug concentration and toxicity or bactericidal effect has not 
been established for antituberculosis drugs, it is important to 
address this issue since dosage adjustment may be indicated with 
a view to minimising toxicity. For example in the study by Walubo 
et al ( 1991 c), patients aged 65 years and over had lower serum 
albumin concentrations compared with those below 65 years of age, 
and although the drug plasma concentrations were the same in both 
groups, more side effects were noted in the elderly group (Fig. 2. 3). 
Studies on the influence of age and disease on the percentage 
binding of antituberculosis drugs to individual serum proteins and 
the relationship of free drug concentrations to toxicity are needed to 
clarify these issues. 
2.2.4 Toxic metabolites 
The role of toxic metabolites in the age related increase in incidence 
of adverse effects of antituberculosis drugs is largely unexplored. 
Susceptibility to hepatotoxicity increases with age (Umeki, 1991; 
Riska, 1976), even in those with no previous liver disease. 
However it is unclear whether isoniazid, rifampicin or metabolites of 
these drugs are responsible. lsoniazid is metabolised to isonicotinic 
acid either by direct hydrolysis, or indirectly via acetylation to 
acetylisoniazid and then hydrolysis. In the direct pathway, a 
metabolite hydrazine 1s formed, while in the indirect pathway, 
monoacetylhydrazine is the product. Both metabolites are 
hepatotoxic. Plasma half-life of monoacetylhydrazine is five times 
longer than that of isoniazid which may result in greater 
accumulation following repeated doses (Gangadharam, 1986). 
Rapid acetylators may be expected to have a greater incidence of 
30 
hepatotoxicity as more monoacetylhydrazine will be formed; 
however, in these subjects, monoacetylhydrazine will also be more 
quickly acetylated to the less toxic metabolite diacetylhydrazine so 
that the risk of hepatic reactions during treatment with isoniazid is 
no greater in rapid than slow acetylators. 
Hydrazine is a potent hepatotoxin and also affects many metabolic 
processes in the body (Back and Thomas, 1970). The age related 
reduction in acetylation rate may result in a greater proportion of 
isoniazid being metabolised to hydrazine, particularly in slow 
acetylator phenotypes. Hydrazine has been detected in plasma of 
healthy male volunteers taking isoniazid 300 mg daily for 2 weeks 
(Blair et al, 1985). In patients on antituberculosis therapy 
consisting of similar dosages of isoniazid, rifampicin and 
pyrazinamide per Kg body weight, the maximum concentration of 
hydrazine after the first dose was significantly higher in elderly than 
in young patients (Walubo et al, 1991 d). Steady state hydrazine 
concentrations in one subject aged 7 2 years, who died of 
submassive liver necrosis 8 days after initiation of antituberculosis 
chemotherapy, exceeded twice the mean + SD value for the group 
of elderly patients who did not develop hepatotoxicity (Woo et al, 
1992). 
2.2.5 Drug combination 
The concomitant administration of several drugs may predispose to 
increased incidence of adverse side effects. It has been suggested 
that concomitant administration of isoniazid and rifampicin may 
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produce more hepatotoxicity than isoniazid alone (Lees et al, 1971; 
Centers for disease Control, 1980). Metabolic induction by 
rifampicin may result in increased production of hepatotoxic 
metabolites of isoniazid. However, pre-treatment with rifampicin 
did not modify the metabolism of acetylisoniazid (Jenner and Ellard, 
1989). On the other hand, it has been suggested that concomitant 
administration of isoniazid and rifampicin may result in increased 
levels of hydrazine, particularly among slow acetylators (Sarma et 
al, 1986). It has been postulated that an age related difference in 
the hepatic microsomal drug detoxification system may account for 
the high incidence of isoniazid-rifampicin induced jaundice in children 
(Umeki, 1991). By analogy, a similar change could also occur in 
the elderly, so that concomitant administration of isoniazid and 
rifampicin may partly account for the increased occurrence of 
hepatotoxicity in the elderly. 
2.2.6 Non-pharmacological factors 
Non-pharmacological factors in the elderly may predispose to 
toxicity from antituberculosis drugs. Tuberculosis is commonly 
diagnosed in advanced stage in the elderly due to atypical 
presentation and difficulty in diagnosis (Umeki, 1991), so that 
miliary tuberculosis, for example, is more common among elderly 
people (Farer et al, 1979) Therefore, there may be a higher chance 
of liver involvement by Mycobacteria, predisposing to hepatotoxicity 
even in the absence of chronic liver disease or alcoholism. Poor 
nutritional status may be another predisposing factor, particularly in 
the absence of infection. Drug metabolism and toxicity is affected 
by dietary intake (Campbell and Hayes, 197 4). Thus a higher 
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incidence of hepatotoxicity (3-22%) in patients in India compared to 
those in the USA (2-3%) may partly be explained by poor nutrition 
(Gangadharam, 1986). 
2.2. 7 Conclusion 
In conclusion, during treatment of tuberculosis in elderly patients, 
the following factors must be considered in an effort to avoid 
toxicity: consideration of free drug concentrations, disposition of 
hepatotoxic metabolites, drug combinations, nutritional status, and 
hepatic involvement by the disease process. Available data on 
treatment regimens and adverse reactions may not apply to the sick 
elderly. Further studies on the above aspects are needed to 
determine whether the present combination therapy might be 
altered, with omission of one of the potentially hepatotoxic drugs 
without affecting bactericidal activity or recurrence rate. Clinicians 
should also be more aware of these serious adverse effects, monitor 
such patients closely, and provide nutritional support if necessary. 
The view that it is not necessary to monitor liver function tests as 
routine during antituberculosis therapy, unless the patient has liver 
disease, may not be appropriate in this group of patients. 
Moreover, cases of hepatotoxicity in the sick elderly were not mild 
transient biochemical abnormalities which permit continuation of 
drugs. As the absolute number of old people increases, together 
with the increasing incidence of tuberculosis in the elderly, such 
problems ar_e likely to be encountered with increasing frequency. 
With further studies, more definite guidelines should be available on 
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the use of antituberculosis drugs in elderly patients with a view to 
reducing adverse effects, particularly hepatotoxicity. 
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CHAPTER TWO; PART Ill 
FREE RADICALS, OXIDATIVE STRESS, AGING AND DISEASE 
2.3. 1 Introduction 
A free radical is an atom or molecule with a free unpaired electron 
in its orbit. Free radicals are ubiquitous in the body and are 
continuously produced during normal metabolism and during 
metabolism of various chemicals and compounds including 
xenobiotics. Superoxide anion (-02 ), hydrogen peroxide (H20 2 ), 
hydroxyl ion ( OH) and hypochlorous acid (HOCI) radicals are oxygen 
centered free radicals. Their generation requires molecular oxygen 
and an electron donor like NADPH of the respiratory chain system, 
hence they are called reactive oxygen species. Examples of non-
oxygen centered radicals are; sulph-thyl (RS.; a sulphur centered 
radical), trichloromethyl(.CCL3; a carbon centered radical) and nitric 
oxide (NO; the free electron is situated between the two atoms). 
Free radicals can react with other molecules in various ways, such 
as addition, subtraction and sharing of electrons, leading to a chain 
of reactions by generating other radicals that propagate the reaction 
(Leibovitz et al, 1980). 
The initiating event in most biological free radical reactions is the 
production of a superoxide radical, which is formed from molecular 
oxygen by addition of a single electron (Fig. 2.4). Protonation of 
superoxide produces a hydroperoxy radical (H02 ) and addition of a 
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second electron and protonation leads to production of 
hydrogenperoxide radical 
On the other hand, addition of electrons to the oxygen molecule 
weakens the oxygen-oxygen bond which separates to form oxene 
(0) and oxide (02-). The oxide combines with two protons to 
produce water (H20) while oxene combines with a proton to form a 
hydroxyl radical. Under UV light hydrogen peroxide decomposes 
due to fission at the 0-0 bond to produce hydroxyl radicals; 
H20 2 ----> 20H. 
Formation of hydroxyl radicals from hydrogen peroxide may be 
catalysed by trace amounts of metal ions such as in the Fenton 
reaction; 
Fe(III) 
or in the Haber-Weiss reaction; 
0 2 + H20 2 = Fe(III) ---> OH + OH + 0 2 + Fe(II). 
Other sources of oxygen centred radicals include hemolytic cleavage 
of water by ionising radiation. This produces a hydroxyl radical 
while the nitric oxide radical (NO) or the endothelium relaxing factor 
(EDRF) reacts with the superoxide radical to produce, after 
protonation, a hydroxyl radical and nitrogen dioxide; 
0 2 + NO --- > HOONO + H < --- > HOONO --- > OH - NO). 
Finally, hydrogen peroxide and hydroxyl radicals may react with 
halide compounds to produce halogen radicals. For example, during 
the respiratory burst in the neutrophil, H20 2 + Cl + neutrophil 
myeloperoxidase may result in the production of highly reactive 
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radicals such as hypochlorous acid (HOCI), hypochlorate and 
chlorine. These radicals can halogenate micro-organisms, tumour 
cells and normal tissue leading to tissue damage. 
In terms of toxicity, as measured by activity as well as half-life, the 
hydroxyl radicals appear to exceed that of superoxide and hydrogen 
peroxide radicals. Other radicals that may be produced by the 
attack of superoxide or hydroxyl radical on biological molecules 
include, among others: lipid radicals, lipid peroxy radicals, pyrimidine 
radicals, and purine radicals. It is possible that many of the 
damaging effects attributed to the superoxide radical are a 
consequence of these secondary free radicals. 
Superoxide is produced in many body reactions and processes 
during normal physiological functions in the body. Respiring cells 
are a major source of superoxide radicals. This led to a suggestion 
that the mitochondrion is the "molecular clock" of organisms 
whereby the maximal life span of species is related to the rate of 
oxygen consumption. In this regard, low oxygen concentrations 
have been shown to extend the life-span of cultured human diploid 
cells in vitro (Packer and Fuehr, 1977). 
Also, the production of superoxide radicals has been associated with 
or required for the activity of a number of enzymes, including 
xanthine oxidase, aldehyde dehydrogenase, dihydrorotic acid 
dehydrogenase, indoleamine dioxygenase, 2-nitropropane 
dioxygenase, diamine oxidase, and ribulose-1,5-diphosphate 
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carboxylase (Bhargwat and Sane, 1978; Fridovich, 1978; Younes 
and Wester, 1978). 
Superoxide radical production has also been shown during the 
autoxidation of a variety of molecules, including hydroquinones, 
flavins, catecholamines, thiols, tetrahydroptrines, ferrodoxins, 
dialuric acid and hemoglobin (Cohen and Heikkila, 1974; Fridovich, 
1978; Heikkila and Cohen, 1973; Michelson, 1973; Misra and 
Fridovich, 1972). The autoxidation of various chemicals, including 
herbicides (paraquat), alkyl halides (carbon tetrachloride, 
bromotrichloromethane), and medicines (adriamycin, daunomycin) 
also produce superoxide radicals (Diluzio. 1973; Henderson et al, 
1978; Jose and Slater, 1972; Koster et al, 1978; Recknagel et al, 
1977). Free radicals are also present in urban polluted air, in any 
smoke derived from the burning of organic matter (e.g. gasoline, 
paper, tobacco), and in ozone-contaminated air (Boenig, 1966). 
Superoxide radicals are also required for microbiocidal activity in 
neutrophils, monocytes and microphages and are produced in these 
cells during the respiratory burst which accompanies oxidative 
killing. 
One consequence of free radicals is the production of lipid 
peroxides. Free radical attack on polyunsaturated fatty acids yields 
lipid radicals with allylic double bonds, which may add to molecular 
oxygen to produce lipid peroxy radicals which, by abstraction of a 
proton and electron, ultimately produce lipid peroxides. The 
significance of lipid peroxidation is that such lipid peroxides 
decompose to yield aldehydes which cross-link proteins, lipids and 
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nucleic acids. Other reactions include addition reactions, yielding 
covalent bonds as well as novel radicals. Scission reactions are 
important in regard to ionizing radiation, but also during chemical 
oxidations of adriamycin, daunorubicin and reducing agents. 
However, cross-linking reactions are of greater significance with 
regard to the aging process. 
2.3.2 Aging and free radicals 
The theory of aging is based on the action of free radical reactions 
which lead to cell membrane damage and cross-linking of 
biomolecules (Tappel, 1973). This results in decline in cellular 
integrity, primarily due to reduced enzyme activities, error-prone 
nucleic acid metabolism, damaged membrane function, and 
accumulation of aging pigments in lysosomes. 
The cross-linking theory stems from the colloidal theory of aging 
originally proposed by Ruzika in 1924 (cf. Sinex, 1964). The basic 
concept is that unusual cross-links increase with age , and 
contribute to the loss of cellular integrity known to be associated 
with advancing age. Support for this concept was presented by 
Rickert and Forbes ( 1976), who found that collagen isolated from 
lungs of elderly persons had increased ratios of insoluble/acid 
soluble collagen compared with young persons. Cell membranes 
are also known to increase in rigidity with advancing age (Nagy, 
1978), an effect possibly mediated by free radical-induced lipid 
peroxidation. 
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Cross-linking of biomolecules by aldehydes resulting from lipid 
peroxidation is well documented, and may be the most important 
mechanism in vivo. Lipid peroxides are known to decompose and 
yield a variety of products, including ethane, pentane and various 
aldehydes. The most important aldehyde produced is 
malondialdehyde (MDA; CHO-CH2-CHO), which forms Schiff bases 
with amines of proteins, phospholipids and nucleic acids. The 
product of this reaction is a biomolecule many times the size of the 
original, which because of unusual bonds, is not digested in the 
lysosomes and accumulates there with age. These biopolymers are 
fluorescent with a characteristic excitation maxima at 360-380 nm, 
and an emmission maxima at 440-470 nm. Accumulation of these 
pigments, termed "aging pigments", lipofuscin or ceroid, is directly 
related to the age of the animal (Shimasaki et al, 1977); Tappel, 
1973). 
Therefore, the significance of lipid peroxidation and cross-linking in 
relation to aging is the reduction in cellular integrity. Lipid 
peroxides have been shown to inactivate certain enzymes such as 
isocitrate dehydrogenase (Green at al, 1971) which, when 
inactivated by linoleic acid hydroperoxide, yielded a decrease in 
sulfhydryl content of the enzyme. Variations in the ratio of 
sulfhydryl/disulfides may affect a wide variety of enzymes systems. 
For example, oxidised glutathione inhibits adenylcyclase activity of 
the rat brain as a result of increased disulfide levels in this enzyme. 
Lipid peroxidation also affects integrated membrane bound 
enzymes. For example the inhibition of oxidative phosphorylation 
of rat liver mitochondria by linoleate hydroperoxide (Naito et al, 
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1966). Unfortunately, there is no information on how lipid 
peroxidation affects drug metabolising enzymes. 
2.3.3 Enzymatic defence systems. 
Elaborate enzymatic systems have been evolved by anaerobic 
organisms to reduce the fluxes of superoxide and hydrogen peroxide 
radicals which, in turn, will reduce the production of hydroxyl 
radicals. Superoxide dismutase (SOD) is the major defense system 
which protects against elevations in levels of superoxide. SOD 
catalyses the dismutation of two molecules of superoxide radical to 
yield hydrogen peroxide and molecular oxygen. SOD is a 
cytoplasmic as well as mitochondrial enzyme and, in eukaryotes, 
contains either copper and zinc or manganese (Fridovich, 1978). 
Recently, extracellular SOD has been isolated and its role in 
antioxidant mechanism was considered insignificant (Jadot et al, 
1995). The role of SOD in the aging process is not certain. A 
three fold decline with age in levels of SOD between young (6 
months) and old (27 months) rats was reported (Reiss and Gershon, 
1976). 
Catalase and glutathione peroxidase protect against elevation in 
levels of hydrogen peroxide. Generally, catalase is of major 
importance in prokaryotes while glutathione peroxidase is of greater 
significance in eukaryotes. Glutathione peroxidase utilises the 
reducing power of glutathione (gamma-L-glutamyl-L-
cysteinylglycine), and contains selenium as a coordinating mineral. 
Glutathione peroxidase also protects against the damaging effects 
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of lipid peroxidation, reducing lipid peroxides to fatty acid alcohols 
(Tappel, 1974). However, the activity of glutathione peroxidase is 
proportional to the concentration of selenium in the diet. Also, 
vitamin E appears to be required for activity of this enzyme (Chow, 
1977; Fukuzawa and Tokomura, 1976; Scott et al, 1976). 
Furthermore, dietary ascorbic acid has also been shown to increase 
the levels of glutathione peroxidase (Combs and Pesti, 1976). 
2.3.4 Non-enzymatic defense mechanisms 
A variety of molecules have been shown to quench free radicals, 
reduce lipid peroxidation and detoxify hydrogen peroxide. These 
compounds include both dietary factors such as vitamin E, vitamin 
C, hydroquinonoes and sulfhydryl compounds as well as synthetic 
antioxidants including hydroxylated hydroxytoluene, butylated 
hydroxyanisole, sodium benzoate and ethanol. 
Vitamin E is apparently the most important dietary free radical and 
lipid peroxide scavenger, due to its lipid solubility and occurrence in 
membranes. Vitamin E added to diet of animals results in a 
decrease in accumulation of aging pigments; conversely, vitamin E 
deficiency results in greater accumulation of these aging parameters 
(Csallany et al, 1977; Katz et al, 1978; Reddy et al, 1973; Sylven 
and Glavid, 1977; Tappel, 1972, Tappel et al, 1974). A novel 
estimation of aging is based on the exhalation of ethane and 
pentane, hydrocarbons derived from peroxidation of omega-3 and 
omega-6 polysaturated fatty acids, respectively. A combination of 
vitamin E and selenium deficiency in the rat increased ethane 
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production to 7 .4 nmol/100 g body weight/24 hours; 
supplementation of the diet with vitamin E, selenium or both, 
reduced ethane evolution to 0.4, 3.1 and 0.2 nmol/100 g body 
weight/24 hours, respectively (Hafeman and Hoekstra, 1977). 
Lipid peroxidation in vitro, as measured by malondialdehyde 
production, is also related to vitamin E status. Therefore, the 
protective effect of vitamin E is due to its ability to quench free 
radicals such as the superoxide radical (Ozawa et al, 1978) and lipid 
peroxy radicals such as the methyl linoleate radical (lgarashi et al, 
1976). 
Ascorbic acid was shown to be oxidised by superoxide (Nishikimi, 
1975) and hydroxyl radicals (Fessenden and Verma, 1978). 
Ascorbic acid may play a role as an extracellular defense against 
free radicals in such tissues as the lung, where approximately 59% 
of the ascorbic acid is found in the fluid lining of the respiratory 
epithelium in the rat (Willis and Kratzing, 197 4). This is of 
considerable interest in that enzymatic defense mechanisms 
including SOD and glutathione peroxidase are found only 
intracellulary, and would not be available for reaction with 
extracellular free radicals or oxidants. Dietary ascorbic acid has 
been shown to reduce the extent of lipid peroxidation in both the 
mouse (Tappel et al, 1974) and the guinea pig (Chen and Chang, 
1978). Although there are suggestions that low levels of ascorbic 
acid may induce lipid peroxidation in vitro, such phenomena has not 
been demonstrated in vivo. Therefore, ascorbic acid is a molecule 
which may quench free radicals without leading to further free 
radical reactions in vivo. 
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2.3.5 Levels of antioxidants as a function of age 
A progressive decrease with advancing age for the following 
antioxidants has been observed; SOD (Reiss and Gershon, 1976), 
selenium (Thomson et al, 1977), mercaptan (Harman, 1960) and 
ascorbic acid (Attwood et al, 1978). Data on variation of vitamin 
E with age is not available. 
The ability of antioxidants to quench free radical reactions should 
lead to enhanced longevity. Preliminary studies have reported that 
synthetic antioxidants extend the lifespans of AKR, C3H and LAF1 
mice (Harman, 1957; Harman, 1961 and Harman, 1968). 
2.3.6 Oxidative stress 
Oxidative stress refers to a state where the pro-oxidant processes 
out-weigh the antioxidant mechanisms. This can occur when 
formation of reactive oxygen species is accelerated or levels of 
antioxidants are decreased or the protective mechanisms are 
impaired. However mild oxidative stress may render the cell 
resistant to further stress by increased synthesis of antioxidant 
systems such as SOD and heat shock proteins. It is the inhibition, 
deactivation and exhaustion of the antioxidant systems in acute 
oxidative stress which are of relevance in the events preceding a 
particular disease or in production of pathological symptoms of 
disease and drug toxicity. 
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2.3. 7 Free radicals and disease 
a) Atherosclerosis: This is a disease of the arteries. It is 
produced by local thickening of the intima and is thought to start 
with damage to vascular endothelium. One of the early processes 
in its pathogenesis is formation of phagocytic foam cells in fatty 
streaks. It has been shown that oxidised lipids, initiated by free 
radical reactions play a great role in this process. It is the 
damaging effects of reactive oxygen species combined with the 
cytotoxic effects of oxidised low density lipoproteins (LDL) that 
leads to endothelial damage and consequently the development of 
the atherosclerotic lesion (Streinbrecher et al, 1990;). Oxidation of 
LDL occurs only when endogenous antioxidants in the LDL particles 
are depleted (Jessup et al, 1990; Esterbaur et al, 1990). Clinical 
trials for antioxidant therapy for this disease have recently been 
suggested (Steinberg, 1992). Probucol, the hypocholesterolemic 
drug, has been show to have antioxidant activity. 
b) Rheumatoid arthritis: This is a chronic inflammatory disease 
affecting mainly the joints. The destructive processes of 
rheumatoid arthritis have been related to increased production of 
reactive oxygen species. During an acute attack of rheumatoid 
arthritis, reactive oxygen species are produced in the inflammed 
joints by activated macrophages in the synovial membrane and by 
neutrophils in the synovial cavity. It is thought that reactive 
oxygen species then lead or propagate mechanisms that cause bone 
or cartilage damage (Unsworth et al, 1988). Lipid peroxidation is 
increased in synovial fluid of patients with rheumatoid arthritis and 
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the extent lipid peroxidation correlated with severity of the disease 
(Rowley et al, 1984). Also, the levels of ascorbate, a natural 
antioxidant, are below normal in synovial fluid and plasma of 
patients with rheumatoid arthritis (Lunec and Blade, 1985). Iron, 
in the form of ferritin and haemosederin is increased in the synovial 
membranes of these patients. Clinical trials with SOD and 
desferrioxamine have shown hope (Giordano, 1 984). 
c) Cancer: It has been shown that exposure to free radicals can 
lead to mutations, transformations, or activation of specific 
oncogenes (Weitzman and Stossel, 1981). Oxidative stress 
produces alterations in the c-abl gene methylation and also induction 
in the proto-oncogenes c-fos and c-myc in mouse epidermal cells 
(Weitzman et al, 1989; Crawford et al, 1988). In the same 
perspective, antioxidants have been found to inhibit neoplastic 
processes (Ames, 1983; Ames and Saul, 1987; Borek and Troll, 
1983). SOD inhibits transformation induced by radiation and 
suppresses free radical induced tumor promoters, the phorbol esters 
(Borek and Troll, 1983). Similar protective roles have been shown 
for vitamins E and C, and selenium (Niki, 1987; Borek et al, 1986). 
Many more disease processes, including aetiology and 
manifestations of diseases, where reactive oxygen species are 
involved, are being described. This is important because 
knowledge of the involvement of reactive oxygen species in disease 
or other toxic processes may help to provide information on factors 
that control these pro-oxidant systems with the aim of interfering 
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with a correct antioxidant system at the right time and at the right 
place to prevent and inhibit the disease or toxic process. 
2.3.8 Assays for free radicals 
a) Trapping: This is the identification of free radicals in 
biological systems by reacting free radicals with a trap molecule to 
give one or more stable products which are then measured. 
Reaction of free radicals with spin traps such as phenyl-tert-butyl 
nitrone, leads to formation of products that are detected by electron 
magnetic spin resonance (ESR). However, the currently available 
spin traps are not good detectors of reactive oxygen species in vivo, 
and they cannot be administered safely to man. Another trapping 
technique for free radicals is by measuring the products of aromatic 
hydroxylation of salicylates. 
b) Uric acid oxidation: In primates, including man, uric acid is an 
end product of purine metabolism because urate oxidase enzyme 
(Uricase) is absent (Fig. 2.5). It has been suggested that uric acid 
acts as an antioxidant in vivo (Ames, 1981). Hence, measuring 
products of the interaction of reactive oxygen species with uric acid 
might be a potential marker of oxidative stress uniquely applicable 
to human beings. Uric acid is degraded on exposure to OH, HOCL 
and mixtures of haemoglobin (or myoglobin) with hydrogen peroxide 
but it is not affected by hydrogen peroxide alone, or by superoxide. 
The major product of uric acid oxidation by the first three systems 
is allantoin, but others include oxonic acid, oxaluric acid, cyanuric 
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FIG• 2.5 
Degradation of purines to uric acid, allantoin, and urea. 
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acid and parabanic acid. Uric acid may be an important antioxidant 
defense against ozone in the upper respiratory tract (Hatch, 1991). 
Concentrations of uric acid oxidation products were increased in 
synovial fluid and serum of patients with rheumatoid arthritis 
(Grootveld and Halliwell, 1987). Such an observation is consistent 
with oxidative stress associated with this condition and illustrate an 
application of measuring uric acid oxidation products. 
c) Fingerprint assays: These are methods where reactive oxygen 
species are detected by measuring products of their interaction with 
biological molecule e.g. DNA products (termed DNA-fingerprinting) 
and lipid peroxide assay. Measurement of end products of lipid 
peroxidation in human material is the assay most commonly used for 
detection of reactive oxygen species in human beings. However, 
there is no single fool-proof method of measuring lipid peroxidation. 
Each of the available methods measures only part of the oxidation 
process. Lipid hydroperoxides breakdown to other products and a 
huge number of different aldehydes. Also, other carbonyls and 
different compounds are produced by peroxide decomposition. To 
learn as much as possible about lipid peroxidation in human material, 
it is important to use techniques that give specific chemical 
information about what is present and to use more than one such 
technique. Some of the methods used to detect lipid peroxidation 
include (summary by Halliwell et al, 1992; Esterbauer et al, 1991; 
and Thomas et al, 1991): 
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1) Analysis of fatty acids by gas chromatography (GC) and high 
performance liquid chroatography (HPLC). 
2) Measuring uptake of oxygen by carbon-centered radicals and 
during peroxide decomposition using the oxygen electrode. 
3) Measuring lipid peroxides by iodine liberation, heme degradation 
of peroxides, cylooxygenase, fluorescence and GC-mass 
spectroscopy (GC-MS). 
4) Measuring excited carbonyl and singlet oxygen by light emission. 
5) Measuring cytotoxic aldehydes by HPLC antibody techniques. 
6) Measuring the diene-conjugated structures by diene conjugation. 
7) Measuring thiobarbituric acid (TBA) reactive material by the TBA 
test. 
Prostaglandin F2 like compouds have been suggested as promising for 
detection of reactive oxygen species in vivo while measuring end 
products of oxidative damage to proteins is equally good. 
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CHAPTER TWO; PART IV 
INTRODUCTION TO LIPOSOMES 
Liposomes are stable microscopic lipid vesicles ranging in diameter 
from 0.1 to 20 µm. They are composed of one or more lipid 
membranes surrounding an internal aqueous compartment (Naessander 
et al, 1990; Ostro and Cullis, 1989). The lipid layers are similar in 
structure to those found in living cell membranes and it is for this 
reason that liposomes can be used to carry soluble substances across 
cell membranes. Also, liposomes can carry lipophilic substances 
within their bilipid layers just as sterols and hydrophobic proteins are 
intercalated into cell membranes. 
Liposomes are classified according to their size viz: 
1) The large multi-layered liposomes of variable size are termed 
multilamellar vesicles (MLV). 
2) The large one-layered liposomes with homogenous particle size 
are called large unlamellar vesicles (LUV). 
3) The small one-layered liposomes with particle size less than 1.5 
µm are termed the small unilamellar vesicles (SUV). 
After administration, the disposition of liposomes depends on, size, 
bilayer rigidity, temperature and charge. Temperature is important for 
stability of liposomes because at higher temperatures the phospholipids 
turn from a stable gel state to a leaky fluid-like crystalline state. 
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Cholesterol has been shown to improve the stability of liposomes, even 
in the fluid-like crystalline state (Scherphof et al, 1978). Positively 
charged and neutral liposomes circulate longer than those of similar 
size that are negatively charged. 
The small liposomes (SUV) are taken up slowly by the mononuclear 
phagocyte system thus have a long circulation half-life (up to 24 
hours). These SUV extravasate through fenestrations in the 
endothelium of liver sinusoids and interact with liver parenchymal cells. 
Therefore, their uptake by phagocytic cells is relatively low (Hwang et 
al, 1987; Senior, 1987). The larger liposomes (MLV and LUV) are 
rapidly and efficiently taken up by phagocytic cells of the mononuclear 
phagocyte system, mainly in the liver and spleen. These liposomes 
therefore, tend to have a shorter half-life in blood. Also, total lipid 
dose can influence half-life of liposomes because at higher lipid doses 
the mononuclear phagocyte system becomes saturated and the half-life 
of liposomes increases (Ostro and Cullis, 1989). 
Uptake of liposomal associated drugs into the cell may occur through 
adsorption, followed by release of the drug into the extracellular fluid 
and diffusion of the drug into the cell, or liposomes may enter the cell 
intact by phagocytosis and then degraded by lysosomal enzymes to 
release the drug. Phagocytosis is the most important uptake 
mechanism for MLV and LUV. Also, liposomes may be taken up by 
pinocytosis. 
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Importance of liposomes 
Liposomes have been used to transport therapeutic agents across cell 
membranes. With new technologies, modification of liposomal 
properties has led to use of liposomes as prolonged release drug 
reservoirs and for localisation of drugs within particular areas in the 
body to avoid or target specific tissue or subcellular sites. 
Amphotericin-8 (Patterson and Andriole, 1990; Tollemar, 1990) and 
daunorubicin (Gabzon et al, 1989) are drugs where liposomal delivery 
is a success. Liposomal amphotericin-8 is associated with a decreased 
risk of nephrotoxicity (Mufson et al, 1990; Wassan et al, 1990). The 
use of liposomal entrapped drug in the treatment of tuberculosis is still 
in experimental stage (Oronzco et al, 1 990). Because SOD does not 
cross cell membranes, it is intended in this study, to use liposomal 
entrapped SOD to deliver this enzyme into the cells of rat liver slices. 
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CHARPTER THREE 
OBSERVATIONS FROM THE REVIEW, HYPOTHESIS AND 
OBJECTIVES. 
3.1 Hydrazine metabolites 
Although isoniazid is considered a safe drug, the fatalities in elderly 
patients due to this widely used drug have warranted the need to re-
assess its metabolism in this group of people. There is little 
information on the metabolism of isoniazid in patients over 65 years of 
age. Furthermore, the mechanism by which isoniazid induces toxicity 
remains unknown although its hydrazide metabolites have been 
implicated by several reports (Mitchell et al, 1976; Woo et al, 1992). 
lsoniazid induced toxicity can be related to its hydrazide metabolites 
because: 
1 . Concentrations of isoniazid in plasma do not correlate with the 
occurrence of side effects (Bowersox et al, 1973). 
2. There is no correlation of isoniazid toxicity to acetylator status 
(Weber and Heine, 1985) 
3. Toxicological studies have shown that hydrazide metabolites of 
isoniazid are potentially more toxic than the parent drug (Mitchell 
et al, 1976; Back and Thomas, 1970). 
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4. Severe renal impairment can lead to significant elevation of 
isoniazid plasma concentration (Bowersox et al, 1973; Kim et al, 
1993), yet isoniazid is only 11-20% renally excreted compared 
to metabolites which are > 60% excreted by this route (Ellard 
and Gammon, 1976). 
Metabolites of toxicological importance are; hydrazine, acetylisoniazid, 
monoacetylhydrazine, and diacetylhydrazine. Hydrazine is toxic to all 
tissues (Back and Thomas, 1970) while monoacetylhydrazine induces 
hepatotoxicity presumably by covalent binding to liver macromolecules 
and is thought to be the toxic intermediate for acetylisoniazid and 
diacetylhydrazine (Mitchell et al, 1976). Elimination of these 
metabolites is mainly by renal route with half-lives in young volunteers, 
after a single dose of isoniazid, of 4.9 and 8.0 times that of isoniazid, 
for monoacetylhydrazine and diacetylhydrazine, respectively (Ellard and 
Gammon, 1976; Lauterburg et al, 1985). 
The long half-lives for these metabolites indicates their potential to 
accumulate during chronic dosing and especially in patients with 
altered metabolism or excretion of any of the metabolites. Since renal 
function falls with age (Schmucker, 1985), elderly people are more 
prone to suffer from the consequences of metabolite accumulation than 
young ones thereby obviating the need for more information on plasma 
profiles of isoniazid metabolites during antituberculous chemotherapy 
in elderly patients. 
However, the incidence of isoniazid toxicity seem not to be related to 
renal function, implying that other factors have a major role in its 
56 
pathogenesis. Such factors include reduced ability to quench toxic 
products of drug metabolism (Leibovitz and Siegel, 1980) and poor cell 
regeneration mechanisms after injury in elderly people. 
Therefore, during chronic treatment with isoniazid, the steady state 
concentration of hydrazide metabolites and isoniazid in elderly patients 
may be unsafe. 
3.2 Mechanism of isoniazid induced hepatotoxicity. 
The consequences of metabolite accumulation cannot be realized 
without adequate knowledge of the toxic potential of individual 
metabolites. lsoniazid and its hydrazide metabolites are potentially toxic 
and little is known about the mechanism of toxicity associated with 
these compounds. Mitchel et al ( 1976) explained that isoniazid 
induced hepatotoxicity is due to a metabolite, monoacetyhydrazine. 
This proposal has been widely criticized because it failed to explain the 
pattern of isoniazid related hepatitis in the population. 
lsoniazid and the four metabolites (hydrazine, monoacetylhydrazine, 
diacetylhydrazine and acetylisoniazid) are hydrazides. They contain a 
hydrazine group, and this could explain many properties these 
compounds have in common, such as hydrophilia, basicity and toxicity 
(Martha, 1976). Hydrazine group has been implicated in lupus 
syndrome associated with isoniazid and hydrallazine (Durant and Harris, 
1980), haemolysis by phenylhydrazine (Jain and Hochstein, 1979), P-
450 inhibition by isoniazid and iproniazid (Muakkassah et al, 1981) and 
tumors induced by hydrazides in general (Toth, 1975). Unfortunately, 
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as for toxicity, the mechanism by which the above disorders occur 
remains unknown and understanding one mechanism may reveal a lot 
about the others. 
It is possible that under certain conditions (pH, catalyst etc.), isoniazid 
and its hydrazine metabolites mentioned above can lead to generation 
of reactive oxygen species which may cause tissue injury. Therefore, 
when the defence system fails to quench free radicals, as in the case 
of excessive free radical generation due to xenobiotic metabolism or 
incompetent anti-oxidant defence mechanisms in the aged, the 
deleterious effects of free radicals begin to be observed. And, as for 
other injuries, the manifestations and severity of tissue injury (or 
oxidative stress) will depend on the amount of free radicals produced 
and tissues affected. 
The possibility that isoniazid and its four metabolites can cause toxicity 
through oxygen reactive species has been entertained in view of the 
following observations: 
1 . lsoniazid and the four metabolites have a hydrazine group that 
can generate superoxide. 
2. Phenylhydrazine, and acetylphenylhydrazine induce haemolysis by 
generation of superoxide via the hydrazine group (Jain and 
Hochstein, 1979). 
3. The ability to generate superoxide by the hydrazine group is 
modified by molecular structures or other functional groups 
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attached to hydrazine group. For instance, haemolysis was 
greater with phenylhydrazine than acetylphenylhydrazine which 
in turn was greater than for hydrazine (Jain and Hochstein, 
1979). 
4. Mycobacterial action: 
a) Action of isoniazid against Mycobacteria is reduced under 
hypoxic conditions (Youatt, 1958). Could this be due to 
insufficient oxygen and NADPH for free radical production?. The 
importance of oxygen in superoxide formation was shown by 
Packer and Fuehr ( 1977), who observed an extended life span of 
cultured human diploid cells in low oxygen concentrations in 
vitro. However, not all oxygen dependent reactions generate 
superoxide. 
b) Action of isoniazid is enhanced in presence of trace amounts of 
copper (Maher et al, 1959). Copper is a powerful oxidant in 
metal catalyzed oxidation reactions leading to production of 
reactive oxygen species. 
c) Mycobacterial sensitivity to isoniazid is associated with the 
presence of mycobacterial enzyme catalase and peroxidase. 
Although catalase is an anti-oxidant (destroys hydrogen 
peroxide), it can be a pre-oxidant through its heme nucleus, 
leading to enzymatic catalyzed oxidation reactions that generate 
radicals. 
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5. Inhibition of P-450 by isoniazid requires, and is enhanced in 
presence of, oxygen and NADPH, and is postulated to involve the 
hydrazine group (Muakkassah et al, 1981). 
6. Enzyme inducers like phenobarbitone and 
3-methylchlolanthrene increase production of superoxide by 
increasing activity of NADPH cytochrome-c reductase and other 
superoxide generating enzymes thereby out-witting the reducing 
potential of tissue anti-oxidants (Puntarulo and Cederbaum, 
1992). 
7. The fate of hydrazine group during isoniazid metabolism has not 
been adequately understood. 
3.3 Oxidative stress and drug metabolism 
Uric acid has been shown to be an antioxidant whereby, in the 
process, it is oxidized to allantoin (Ames et al, 1981). As humans do 
not have the enzyme uricase, that converts uric acid to allantoin, the 
amount of allantoin produced in the body may be an indicator of 
oxidative stress during antituberculosis chemotherapy. Uric acid 
products such as allantoin may be indicators of free radical reactions 
or oxidative stress during drug administration. The importance of uric 
acid in alleviating or predicting susceptibility to antituberculosis drug 
adverse reactions has not been evaluated. 
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3.4 Summary 
In summary, It has been observed that; 
1 . A convenient and sensitive procedure for assay of isoniazid and 
metabolites is required for studying isoniazid metabolites in 
elderly patients and for therapeutic monitoring of patients in the 
clinic. 
2. There is no information on the pharmacokinetics of hydrazide 
metabolites of isoniazid in elderly patients. 
3. The role of oxygen radicals in isoniazid induced hepatotoxicity is 
not known. 
4. The importance of uric acid metabolism in assessing oxidative 
stress during anti-tuberculous chemotherapy has not been 
explored. 




'lsoniazid induces hepatotoxicity by generation of reactive 
oxygen species'. 
By this hypothesis, it is intended here to show that oxygen 
reactive species are involved in isoniazid induced hepatotoxicity; 
that isoniazid metabolism leads to formation of metabolites which 
too can generate reactive oxygen species, and as a result, there 
is significant oxidative stress in elderly patients when on 
treatment with isoniazid containing regimen. This would indicate 
how isoniazid could pose a risk to elderly patients (i.e. the 
therapeutic importance of isoniazid metabolism in elderly 
patients). 
This undertaking will involve a clinical study on the disposition of 
isoniazid and four of its hydrazide metabolites during 
antituberculsis treatment with isoniazid, rifampicin and 
pyrazinamide in young adults (20-30 years) and elderly (over 65 
years) patients; and a study on the use of allantoin to estimate 
oxidative stress induced by the above antituberculosis drugs as 
well as its implications for antituberculosis chemotherapy in 
elderly patients. In vitro experiments will be done to pursue 
underlying mechanisms. It is only after establishing the toxic 
potential of isoniazid and its four metabolites, and the degree of 
oxidative stress they induce, in presence of other antituberculosis 
drugs, that it can be possible to determine how these compounds 
can be unsafe for elderly patients. 
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3.6 Objectives of the study. 
Investigations will aim: 
1 . To develop a procedure for assay of isoniazid and metabolites, 
monoacetylhydrazine, acetylisoniazid, diacetylhydrazine and 
hydrazine in plasma by high performance liquid chromatography. 
2. To compare the disposition of isoniazid metabolites in young and 
elderly patients during treatment with isoniazid, rifampicin and 
pyrazinamide after the first dose and at steady state. 
3. To measure plasma concentration of the co-administered drugs; 
rifampicin and pyrazinamide (but not ethambutol) to elucidate 
their influence on isoniazid metabolism or vise versa. 
4. To determine whether isoniazid and its four metabolites can 
generate oxygen reactive species. 
5. To investigate, using rat liver slices, whether oxygen reactive 
species are involved in isoniazid and metabolites induced 
hepatotoxicity. 
6. To compare oxidative stress in young and elderly patients during 
antituberculosis therapy, after the first dose and at steady state. 
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3. 7 Expected results 
The results of this study shall be: 
1) A procedure for assay of isoniazid and hydrazide metabolites in 
plasma. 
2) Understanding whether isoniazid and metabolites can generate 
oxygen free radicals. 
3) Information on the pharmacokinetics of isoniazid metabolites in 
elderly patients. 
4) Knowledge on the mechanism of isoniazid and metabolites 
induced hepatotoxicity. This is vital not only to understand risks 
associated with administration of isoniazid but is an aid to the 
prediction and therefore prevention of adverse effects by this 
drug. It is by understanding the mechanism of toxicity that 
accurate predictions on the toxicological consequeces of the 
observed concentrations of isoniazid and or metabolites can be 
made. 
5) The use of allantoin to estimate oxidative stress due to anti-
tuberculous drugs. 
6) Understanding how isoniazid can be risk to the elderly person. 
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CHAPTER FOUR 
A COMPREHENSIVE ASSAY FOR PYRAZINAMIDE, 
RIFAMPICIN, AND ISONIAZID WITH ITS HYDRAZINE MET ABO LITES 
IN HUMAN PLASMA BY COLUMN LIQUID CHROMATOGRAPHY. 
4.0 SUMMARY 
A comprehensive assay for determination of pyrazinamide, rifampicin, 
isoniazid and hydrazine metabolites is described. The assay involves 
organic solvent extraction of pyrazinamide and rifampicin, followed by 
derivatization of isoniazid, monoacetylhydrazine and hydrazine with 
salicyladehyde and thereafter extracted into diethylether. 
Acetylisoniazid and diacetylhydrazine were hydrolyzed to isoniazid and 
monoacetylhydrazine, respectively, and processed as above. Using a 
gradient solvent program er, pyrazinamide and rifampicin were analyzed 
on a RP C8 column (Spherisorb, 250 mm x 4.6 mm I.D., 5 um) at 248 
nm, while isoniazid and metabolites were analyzed on a RP C18 column 
(Spherisorb, 250 mm x 4.6 mm I.D., S5 ODS2) at 280 nm. 
4.1 INTRODUCTION 
lsoniazid, rifampicin and pyrazinamide form one of the most effective 
antituberculous regimens used in many countries, and as a result 
considerable effort has been spent on improving the efficacy of this 
regimen. Combined formulations like Rifater were introduced to 
improve acceptability and compliance, while intermittent short course 
therapy was to reduce adverse reactions and improve the quality of 
life. In spite of this, there is a continued threat of drug toxicity, 
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especially in the elderly and in patients with human immunodeficiency 
virus (HIV) (Barnes and Barrows, 1993), during treatment with these 
agents, and there has been a global increase in the prevalence of drug 
resistant tuberculosis (Iseman, 1993; Woo et al, 1992). Complicated 
tuberculosis in form of multidrug resistant tuberculosis or tuberculosis 
with HIV or tuberculosis in the elderly do not conform to the original 
tuberculosis syndrome for which the present regimens were prescribed. 
The effect of these complications on the disposition of anti-
tuberculosis drugs is not yet clear and adjustments in treatment 
regimens during these complications is still empirical (Iseman, 1993). 
Knowledge of the drug plasma concentrations is important in case of 
drug resistance and toxicity, and concentrations of the toxic 
metabolites may be important in case of toxicity (Grosset, 1992). 
Therefore, drug monitoring during anti-tuberculosis therapy has become 
necessary in some patients and a methodology for use in therapeutic 
monitoring is needed. 
Unfortunately, none of the existing procedures was suitable for this 
task because the assay conditions were favorable for only one 
(Jamaluddin et al, 1990; Swart and Papgis, 1992) or two drugs 
(Gaitonde, 1990) and no metabolites were measured. Furthermore, 
the use of separate procedures would require large sample volumes 
which could not be obtained at the time when there is more blood 
letting for other laboratory evaluations. Therefore, it was found 
necessary to develop a procedure that would be more helpful in the 
clinic and allow an optimum sample volume for processing to minimise 
interference with other investigations as well as inconvenience to the 
patient. 
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Using a modification of the previously reported procedures (Chan, 
1988; Von Sassen et al, 1985; Jenner and Ellard, 1987; Walubo et al, 
1991 a) we describe a comprehensive methodology for determination 
of rifampicin, pyrazinamide and isoniazid with its hydrazine metabolites 
acetylisoniazid, hydrazine, monoacetylhydrazine and diacetylhydrazine 
in human plasma by high performance liquid chromatography (HPLC) 
for use in drug monitoring during treatment of complicated 
tuberculosis. 
5.2 EXPERIMENTAL 
5.2. 1 Materials 
lsoniazid, rifampicin, pyrazinamide, hydrazine hydrate, phenelzine, N-
butarylaminophenol, heptane sulfonic acid, and acetic acid were 
obtained from Sigma Chemical Co.(U.S.A). 
Acetylisoniazid, monoacetylhydrazine and diacetylhydrazine were 
synthesised in the laboratory according to the procedures described by 
Turner ( 1947). See below. 
5.2.1.1. Synthesis of metabolites. 
Monoacetylhydrazine: Hydrazine hydrate 25 ml (equivalent to 392 
mmol of hydrazine) was reacted with 10 ml (98 mmol) of acetic 
anhydride. The mixture was stirred continuously for 1 2 hours at room 
temperature in a fume board. Excess hydrazine was removed by 
evaporation under vacuum and monoacetylhydrazine was recrystallised 
in a mixture of dichloromethane and n-hexane (2: 1). As 
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monoacetylhydrazine is deliquescent, it was converted to a non-
deliquescent hydrochloride form before use. 10 mg of dried 
monoacetylhydrazine was dissolved in 10 ml of a solution of hydrogen 
chloride and diethyl ether ( 1: 1). The mixture was let stand for 1 hour 
and then filtered. The crystalline residue was dried for 10 hours at 
80°C. Taking molecular weights of monoacetylhydrazine and 
monoacetylhydrazine-hydrogen chloride to be 7 4 and 109, 
respectively, 4.3 g (588 mmol) of monoacetylhydrazine were produced 
from which 3.2 g (29 mmol) of monoacetylhydrazine-hydrogen chloride 
was made. 
Diacetylhydrazine: Hydrazine hydrate 25 ml (equivalent to 392 mmol 
of hydrazine) was reacted with 10 ml (98 mmol) of acetic anhydride. 
The mixture was stirred continuously for 12 hours at room 
temperature in a fume board. Excess hydrazine was removed by 
evaporation under vacuum and diacetylhydrazine was recrystallised in 
a mixture of dichloromethane and n-hexane ( 1 :4). Approximately 1 .2 
g ( 10 mmol) of diacetylhydrazine was obtained (Mol. Wt. of 
diacetylhydrazine at 116). 
Acetylisoniazid: 3.5 g (25 mmol) of isoniazid was reacted with 5 ml 
( 196 mmol) of acetic anhydride at room temperature for 4 hours with 
continuous stirring. The product was recrystallised in diethyl ether. 
Taking the molecular weight of acetylisoniazid to be 179.6, 
approximately 1 .5 g (8.3 mmol) of this metabolite was made. 
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5.2.1.2 Synthesis of salicylhydrazones. 
The salicyl-hydrazones (HDZ) of isoniazid (isoniazid-hydrazone; INH-
H DZ), phenelzine (phenelzine-hydrazone; PHEN-HDZ), 
monoacetylhydrazine (monoacetylhydrazine-hydrazone; mHYD-HDZ), 
and hydrazine (azine; Azine) were synthesised and identified as 
described earlier (Jenner and Ellard, 1987; Walubo et al, 1991 a; Yale, 
1953). Briefly, 7 .3 mmol of each of the compounds (isoniazid 100 
mg; phenelzine sulphate 100mg; hydrazine hydrate 35 mg; 
monoacetylhydrazine 54 mg; acetylisoniazid 130 mg; and 
diacetylhydrazine 85 mg) was shaken with 120 mg of the 
salicylaldehyde in 5 ml of ethanol in a tight screw-capped 10 ml 
centrifuge tube. The mixture was incubated in a water bath at 60°C 
for 30 minutes. The product were purified by crystallisation in 
ethylacetate . 
Mass reaction ratio for derivatisation 1s 1 : 1 (Cram and Hammond, 
1964) viz: 
Hydrazide + Salicylaldehyde --- acid catalysis --- > Hydrazone + 
Water. 
Molecular weights of the salicylhydrazones were assumed (not 
confirmed) to be; 241 .4 for INH-HDZ, 240.4 for PHEN-HDZ, 240.5 for 
Azine and 178.4 for mHYD-HDZ. 
All compounds and their salicylhydrazones were characterised by high-
performance liquid chromatography, UV absorption, mass spectra, and 
thin-layer chromatography (TLC: system T1) (Curry and Clarke, 1975). 
69 
TLC procedure: The compounds, in methanolic solutions of 1 mg/ml, 
were spotted on a silica plate (coated with G 60, 0.2 mm thick; Sigma) 
1.5 cm from the bottom line. The plate was placed in a tank 
containing ammonia-methanol (1.5:100) to a depth of 0.5-1 cm, and 
the tank was made air-tight with a lid. After 30 min the plate was 
dried in air and compounds were located by potassiumiodoplatinate 
(Sigma). 
5.2.2. HPLC Apparatus 
HPLC assays were done on SpectraPhysics (San Jose, CA, U.S.A) 
instruments which consisted of a pump model SP 8800, a degasser 
SCM 400, autosampler SP 8780 and integrator SP 4290 connected to 
a variable wavelength UV detector model 0200-4000, Linear Corpor. 
(Reno., Nevada, U.S.A.). 
5.2.3. Mobile phase systems 
System 1: 100 % acetonitrile in bottle A and 5 mM phosphate buffer 
at pH 3.5 in bottle 8 which were run at 2 ml/min on a gradient 
from 6% A to 90% A within 5 min and then continued at this 
concentration (90% A) for 1 2 min. A reversed-phase Ca 
analytical column (Spherisorb, 250 mm x 4.6 mm I.D., 5 um; 
Phase Sep., U.S.A.) linked to a Ca pre-column (30 um, 50 mm x 
4.6 mm I.D.) was used. Maximum pressure was 124 Bars. 
System 2: 100% acetonitrile in bottle A, 5 mM heptanesulphonic acid 
in acetonitrile-water-triethylamine (70:30:0.4 v/v) at pH 6 in 
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bottle B and 100% water in bottle C. These were run at 1 
ml/min as: 75% 8 with 25% C for the first 5 min and then 85% 
B with 15% A for 12 min. A reversed-phase C, 8 analytical 
column (Spherisorb, 250 mm x 4.6 mm I.D., S5 ODS2; Phase 
Sep.) linked to a C8 pre-column (30 um, 50 mm x 4.6 mm 1.D.) 
was used. Maximum pressure was 103 Bars. 
5.2.4. Sample preparation 
a) Determination of rifampicin and pyrazinamide. 
After addition of internal standards (50 ul of N-butarylaminophenol 50 
ug/ml and 50 ul of phenelzine 50 ug/ml) to 2 ml of plasma in a 1 5 ml 
test-tube, 0.4 ml 10% (v/v) aqueous acetic acid was added to adjust 
pH to 4.2. Rifampicin and pyrazinamide were extracted by shaking 
with 7 ml of diethylether-dichloromethane (2: 1) which, after 
centrifugation for 10 min at 2,059 g, was transferred to a tapered test-
tube and evaporated under nitrogen (N 2) at 40 °C. The residue was 
dissolved in 200 ul of methanol of which 20 ul were injected into the 
HPLC and eluted with system 1 . The eluate was detected at 248 nm. 
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b} Determination of isoniazid, monoacetylhydrazine and hydrazine 
To the aqueous fraction, after extraction of rifampicin and 
pyrazinamide, further 10% aq. AA (0.6 ml) is added to lower the pH 
to 3.2. Ethanolic solution (0.3 ml) of 0.1 % (v/v) salicylaldehyde was 
added and derivatisation was completed by incubation in a water bath 
at 60 °C for 30 min. The mixture was then cooled to room 
temperature (25 + 1 °C), 1 ml of 1 M K2P04 added and extracted twice 
with 7 ml of diethylether which, after centrifugation for 10 min at 
2,059 g, was transferred to a tapered test-tube and evaporated under 
nitrogen at 40 °C. The residue was dissolved in 200 ul of mobile 
phase B from system 2 of which 20 ul were injected into the HPLC and 
eluted with system 2. The eluate was detected at 280 nm. 
c) Determination of acetylisoniazid and diacetylhydrazine 
The aqueous fraction after organic extraction in (b) was transferred to 
a fresh 15 ml test-tube and 0.5 ml of 5 M HCL was added. 
Acetylisoniazid and diacetylhydrazine were hydrolysed to isoniazid and 
monoacetylhydrazine respectively by incubating in a water bath at 60 
°C for 45 min. The mixture was then cooled to room temperature (25 
°C) and 0.45 ml of 5 M NaOH was added to adjust pH to 2.2 followed 
by internal standard phenelzine of 50 ug/ml) and 0.3 ml of ethanolic 
solution of 0.1 % (v/v) salicylaldehyde were added. Derivatisation was 
completed by incubation in a water bath at 60 °C for 30 min. The 
mixture was then cooled to room temperature (25 + 1 °C), 1 ml of 1 M 
K2P04 added, extracted with 7 ml of diethylether which, after 
centrifugation for 10 min at 2059 g, was transferred to a tapered test-
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tube and evaporated under nitrogen at 40°C . The residue was 
dissolved in 200 ul of mobile phase B of system 2 of which 20 ul were 
injected into the HPLC and eluted with system 2. The eluate was 
detected at 280 nm. 
5.3 RESULTS 
5.3.1. Characterisation of compounds 
Figures 4. 1 and 4. 2, respectively, illustrate TLC RF (retention factor) 
values and UV absorption spectra of the made compouds. The TLC 
RF values are: isoniazid (INH) = 0. 5 5, isoniazid-hydrazone (INH-HDZ) 
= 0.68, acetylisoniazid (aclNH) = 0.55, monoacetylhydrazine (mHYD) 
= 0.65, monoacetylhydrazine- hydrazone (mHYD-HDZ) = 0. 71, 
diacetylhydrazine (dHYD) = 0.45, hydrazine (HYD) = 0.09, Azine = 
0. 76, phenelzine (PHEN) = 0.60, phenelzine-hydrazone (PHEN-HDZ) 
= 0. 78 and salicylaldehyde = 0.64. 
The salicylhydrazone of each compound is less polar and has a longer 
TLC RF. These hydrazones absorbed more UV light than their parent 
compounds. The mass-spectra for isoniazid and the three synthetic 
metabolites are shown in figure 4.3a-d. Acetylisoniazid has a peak at 
179 (molecular weight is 1 79-180; Fig. 4. 3b), monoacetyhydrazine at 
69 and 70 (molecular weight is 76; Fig. 4.3c) and diacetylhydrazine at 
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Figure 4. 1 Thin Layer Chromatogram of the reference and parent 
compounds with retention factors in-printed. 
lsoniazid (INH) and its hydrazone (INH-HDZ), 
monoacetylhydrazine (acHYD) and its hydrazone (acHDZ), 
diacetylhydrazine (diacHYD), hydrazine (HYO) and its hydrazone 
(Azine), phenelzine (PHEN) and its hydrazone (PHEN-HDZ) and 
salicylaldehyde (SALIC). 
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Figure 4.2 Ultra-Violet absorption spectra of the reference and 
parent compounds compared. 
a) lsoniazid (INH) and its hydrazone (INH-HDZ), 
b) Acetylisoniazid (aclNH) and its hydrazone (INH-HDZ) 
c) Monoacetylhydrazine (acHYD) and its hydrazone (acHDZ), 
d) Hydrazine (HYD) and its hydrazone (Azine), 
e) Phenelzine (PHEN) and its hydrazone (PHEN-HDZ), 
f) Salicylaldehyde (SALIC) and 
g) Acetic anhydride 
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Figure 4.3 Mass spectrometry of 
a) isoniazid (INH) 
b) Acetylisoniazid {aclNH) 
c) Monoacetylhydrazine (MonoacHYD) and 
d) Diacetylhydrazine {DiacHYD) 
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5.3.2. Performance of HPLC system 
Figures 4.4 and 4.5 show the representative chromatograms of 
standard solutions, blank plasma and a plasma extract from a patient 
6 hours after dosing, while table 4. 1 illustrates the standardisation data 
of the assay. Retention times in min were: pyrazinamide = 2.91, 
rifampicin = 11.9 and N-butrylaminophenol = 4.22 (Fig. 4.4); 
monoacetylhydrazine = 3.75; isoniazid = 4.68; hydrazine = 13.77; 
phenelzine = 11.09, and excess salicylaldehyde = 5. 78 (Fig. 4.5). 
The use of one internal standard did not affect linearity in the 
concentration ranges used. There was a great variation in the 
washing out of excess salicylaldehyde with 1 M K2P04 (Fig. 4.58 versus 
4.5C and D). This was most probably due to difficulties in attaining 
the optimum conditions for this process (e.g pH). Nevertheless, this 
had no effect on the resolution or recovery of the relevant compounds. 
The run time for the chromatograph of pyrazinamide and rifampicin 
was 15 min while that for isoniazid and metabolites was 17 min. The 
whole extraction and derivatisation procedure takes approximately 4 
hours, a much shorter than if each drug were extracted and run 
separately using different procedures. 
5.3.3. Recovery, precision, linearity and limit of detection 
Recovery was assessed by comparing peak heights of the directly 
injected hydrazones (for isoniazid and metabolites) or drug (for 
pyrazinamide and rifampicin) with those obtained after derivatisation 
and extraction. Peak heights were evaluated automatically by the in 
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Figure 4.4. The representative chromatograms of standard 
solution (A), drug free plasma (B), and a plasma extract from 
a patient 6 hours after dosing (C). 
1 = pyrazinamide (2.91 min); 2 = N-butarylaminophenol 
(internal standard, 4.22 min); 3 = Rifampicin ( 11 .9 min) 
Drug concentrations: A; pyrazinamide = 0.4 ug and 
rifampicin = 0.25 ug. 


























































Figure 4.5. The representative chromatograms of standard solution 
(A), drug free plasma (B), and a plasma extract from a patient 
6 hours after dosing, before (C) and after hydrolysis (D). 
1 = mHYD (3. 75 min); 2 = INH (4.68 min); 3 = 
salicylaldehyde (5. 78 min); 4 = PHEN (internal standard, 
11.09 min); 5 = HYD (13.77 min); 6 = dHYD (3.75 min); 
7 = aclNH (4.68 min). 
Drug concentrations: A; INH-HDZ = 0.25 ug of INH, mHYD-
HDZ = 0.1 ug of mHYD and Azine = 0.02 ug of HYD. 
C and D; mHYD = 1 .2 ug/ml, INH = 3. 75 ug/ml, HYD = 






































































built intergrator and peak height ratios of the drugs to internal standard 
were used for deriving concentrations. 
Concentration ranges of: 0.5, 1, 2, 5, and 8 ug/ml for rifampicin, 
isoniazid, acetylisoniazid, monoacetylhydrazine, and diacetylhydrazine; 
0.1, 0.2, 0.5 and 0.8 ug/ml for hydrazine; and 5, 10, 15, 20, and 30 
ug/ml for pyrazinamide were used for standardisation and regression 
analysis. Calibration equations of five standard curves were as 
follows; y = 0.034x - 0.024 for pyrazinamide; y = 0.143x + 0.012 
for rifampicin; y = 0.209x - 0.034 for isoniazid; y = 0.352x - 0.025 
for acetylisoniazid; y = 0.463x + 0.009 for monoacetylhydrazine; y 
= 1 .435x + 0.022 for hydrazine and y = 3.39x - 0.113 for 
diacetylhydrazine. The mean regression coefficient (r) of the five 
standard curves and inter-assay coefficient of variation (CV%) at mid-
point (5 ug/ml) of the curves are shown in table 1. For pyrazinamide 
and hydrazine the midpoint were 15 and 0.2 ug/ml, respectively. 
Overall recovery at the mid-point of the standard curves is shown in 
Table 4. 1 . These recoveries, although lower, do not significantly 
differ from the original procedures. In the case of pyrazinamide and 
rifampicin, poor recovery could have occurred due to a single organic 
extraction step, failure to precipitate proteins before extraction and, for 
rifampicin, loss of drug due to autoxidation in the absence of vitamin 
C. Lower recovery for isoniazid and metabolites could have arisen 
from solubility limitations of the salicylhydrazones in the organic phase 




















































































































































































































































































































































Minimum reliable concentrations assayed are shown in Table 1. At 
concentrations lower than the limits stated, the coefficient variation is 
high such that the original procedures are preferred. 
5.4. APPLICATION 
The assay has been used to monitor patients with treatment problems 
one of whom is reported here. Briefly, she was a 54 year old patient 
who had been on antituberculosis therapy (rifampicin 8.8 mg/kg, 
isoniazid 8.8 mg/kg, ethambutol [not assayed] and streptomycin [for 
the first two months only]) for four months without improvement in 
spite of the organism sensitivity to the drugs. She was found to have 
moderate gastric outlet obstruction which was causing vomiting and 
it was not clear whether adequate plasma concentrations were being 
achieved. Five hours after dosing, plasma concentrations (ug/ml) 
were: rifampicin = 2.09, isoniazid = 4.77, acetylisoniazid = 6.89, 
monoacetylhydrazine = 1 .8, diacetylhydrazine = 0.56 and hydrazine 
0.35. Except for rifampicin, these levels were similar to those found 
in other patients in this setting where other assay procedures have 
been used, and they did not differ from the usual concentration ranges 
reported elsewhere (Iseman, 1993; Turner, 194 7). The patient 
medications were adjusted to syrup preparations to improve absorption 
and compliance, and pyrazinamide was added to the regimen. 
5.5. DISCUSSION 
The assay described is beneficial in terms of sample utilisation and the 
limited amount of reagents used to analyse many compounds in a few 
83 
hours. It saves the burden of running different assays for each drug, 
and helps the clinician to evaluate all drugs and the relevant 
metabolites in time. The method is reproducible and can be adopted 
in any laboratory with a gradient programmer. For instance, System 
2 is effectively run isocratically at 52.5% acetonitrile for the first five 
minutes, and then 74.5% acetonitrile for the next 12 minutes. It was 
also found that the column in system 2 can be used in system 1 
without affecting the resolution of the compounds. The retention time 
for isoniazid hydrazone was pH sensitive whereby at a pH less than 4 
it co-eluted with the salicylaldehyde. The low sensitivity with this 
procedure does not preclude its usefulness in the circumstances for 
which it has been developed. It is a useful clinical and research tool 
for quantitative assay of the compounds studied. 
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CHAPTER FIVE 
THE GENERATION OF OXYGEN FREE RADICALS BY 
ANTITUBERCULOUS DRUGS AND HYDRAZIDE MET ABO LITES IN 
VITRO. 
5.0 SUMMARY 
Rifampicin, pyrazinamide and isoniazid with its hydrazide metabolites; 
monoacetylhydrazine, acetylisoniazid, hydrazine and diacetylhydrazine 
were screened for production of superoxide anion and hydrogen 
peroxide radicals. lsoniazid, monoacetylhydrazine, acetylisoniazid and 
hydrazine, activated oxygen to superoxide and hydrogen peroxide 
radicals while pyrazinamide, rifampicin and diacetylhydrazine did not 
lsoniazid reaction was most sensitive to superoxide dismutase (SOD) 
inhibition, while acetylisoniazid and monoacetylhydrazine reactions 
were sensitive to both SOD and catalase. In conclusion, isoniazid, 
monoacetylhydrazine, acetylisoniazid and hydrazine can activate 
oxygen to reactive oxygen species in presence of oxyhaemoglobin. 
5.1 INTRODUCTION 
Because of its importance in the treatment of tuberculosis, isoniazid is 
the most widely studied antituberculosis drug. Unfortunately, even 
after four decades in use, a lot remain unknown about its mechanism 
of action and toxicity. Understanding of the mechanism of toxicity is 
vital, not only for preventing occurrence of toxicity, but it may widen 
the use of isoniazid in patients where it is currently contraindicated. 
85 
Hydrazine metabolites have been implicated in isoniazid induced 
toxicity. Monoacetylhydrazine has been proposed as the most toxic 
metabolite (Mitchel et al, 1976). However, this theory emphasizes 
formation of organic radicals (acyl radical) and underscores the 
importance of other radicals (oxygen radicals) that are formed in the 
process. 
Despite several reports showing that the action of isoniazid against 
mycobacteria is partly due to generation of free radicals (Shoeb et al, 
1985a, 1985b and 1985c; Knox et al, 1956) and that hydrazine 
compounds can generate reactive oxygen species through the 
hydrazine group (Jain and Hochstein, 1979; Goldberg and Stern, 1974; 
Misra and Frodovich, 1976; Goldberg and Stern, 1976), there is no 
report relating isoniazid induced toxicity to this form of tissue injury. 
This is important because although isoniazid and the toxic metabolites 
are hydrazides, they are structurally different and thus bound to vary 
in reactivity and amount of each of the free radical species formed. 
Furthermore, as every free radical is potentially toxic, it is important to 
understand the extent of formation of acyl and oxygen free radicals 
formed by each of the metabolites and parent drug. For instance, it 
was shown that production of free radicals by isoniazid varied with 
reaction environment. At alkaline pH, horseradish peroxidase 
catalysed oxidation of isoniazid to superoxide radicals when oxygen 
was utilized, but organic radicals when hydrogen peroxide was 
consumed (Shoeb et al, 1985b). Therefore, during free radical 
reactions_ involving hydrazines, reaction environment may determine the 
dominant radical species produced. 
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I envisaged that during isoniazid metabolism, isoniazid and its 
metabolites (hydrazine, acetylhydrazine, acetylisoniazid and 
diacetylhydrazine) form reactive oxygen species which may lead to 
toxicity. However, because isoniazid is commonly prescribed together 
with pyrazinamide and rifampicin the two drugs were included in this 
evaluation. Using procedures described by Goldberg and Stern 
( 197 4), rifampicin, pyrazinamide, isoniazid and the four metabolites 
were screened for production of superoxide anion and hydrogen 
peroxide radicals by monitoring for oxidation of epinephrine in presence 
of oxyhaemoglobin (HbO) with or without superoxide dismutase (SOD) 
and catalase enzymes. 
Haemoglobin (Hb), a haemo-protein like horse peroxidase and catalase, 
has been shown to oxidise hydrazine and form reactive oxygen species 
(Jain and Hochstein, 1979; Goldberg and Stern, 1974). It is 
ubiquitous in the body and is likely to come in contact with drugs and 
metabolites. Therefore, Hb was found most appropriate and 
toxicologically important to use in this investigation. 
It is hoped that the result of this experiment will contribute to 
understanding the mechanism of isoniazid induced toxicity and allow 
the relocation of efforts to compounds that prove significantly positive 
by this mechanism. 
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5.2 METHODS 
lsoniazid, rifampicin, pyrazinamide, SOD, catalase, Hb, epinephrine, 
and hydrazine hydrate were obtained from Sigma Chemical Co. (U.S.A, 
St. Louis), while acetylisoniazid, diacetylhydrazine and 
monoacetylhydrazine were synthesised in the laboratory as described 
earlier (chapter IV). 
A stock solution of Hb (7 .6 x 10-5 M) was shaken in 0 2-C0 2 mixture 
(95 % /5 % ) to yield HbO which was used in the experiment. The 
reaction volume was 4 ml of 100 mM EDT A in 50 mM sodium 
phosphate buffer containing HbO, 3.8 x 10-5 M; the test drug, 1.4 x 
10-4 M; SOD, 7. 7 µg/ml; Catalase, 3,500 i.u/ml; and epinephrine, 2.01 
X 10-4 M. 
When added to the reaction test tube alone, neither HbO nor the test 
drugs and metabolites could oxidise epinephrine. Oxidation of 
epinephrine occured only in presence of HbO with isoniazid or 
metabolites. At pH 7 .02 the reaction between isoniazid and HbO was 
very slow (Fig. 5.1) while at pH 9.2 the reaction was faster and in 
most cases was complete by 14 minutes. Therefore pH 9.2 was used 
in further experiments. 
Adrenochrome formation was monitored every 2 minutes by a 
spectrophotometer at 475 nm, 30°C and for 25 min. Timing was 
started when the test drug was added. Absorption was read against 
a control cuvette containing only epinephrine and HbO plus catalase 
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each compound and average net absorption was plotted on a graph 
versus time. 
STATISTICAL ANALYSIS: 
Parametric statistics was used. The student-Newman-Keuls Multiple 
test was used for testing level of significance at P < 0.05 and was 
analysed on the lnstat computer package. 
5.3 RESULTS 
Figure 5. 2 is a graphical illustration of adrenochrome formation during 
the reaction of HbO with isoniazid, acetylisoniazid, hydrazine and 
monoacetylhydrazine. In most reactions, adrenochrome formation was 
at maximum by 14 minutes. 
lsoniazid (fig 5.2a): SOD inhibited adrenochrome formation by 74% 
while catalase had no effect. In presence of both enzymes the reaction 
was inhibited by 35 % . 
Acetylisoniazid (fig.5.2b): SOD inhibited adrenochrome formation by 
92% while catalase increased the reaction by 143%. Both enzymes 
completely inhibited the reaction ( 100%). 
Hydrazine (fig 5.2c): SOD inhibited the reaction by 87.8%, catalase by 
53% and both enzymes 24.5% 
Monoacetylhydrazine (fig 5.2d): There was minimal formation of 
reactive oxygen species. SOD inhibited the reaction by 62.5 % and 
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Figure 5.2 Adrenochrome formation (absorption units; a.u.) under 
various conditions by; 
5.2a. isoniazid 
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catalase caused almost total inhibition ( 1 00%), but both enzymes 
increased the reaction by 362.5%. 
Diacetylhydrazine, pyrazinamide and 
adrenochrome production (fig 5. 3a-c). 
rifampicin did not show 
At pH 9.2 and without 
enzymes, absorption reading at 14 minutes was -0.008 a.u. for 
diacetylhydrazine, 0.00 for pyrazinmide and -0.25 for rifampicin. This 
was not significant when compared to others viz: isoniazid, 0.146; 
acetylisoniazid, 0.065; hydrazine, 0.049 and monoacetylhydrazine, 
0.008 (Table 5. 1) 
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Figure 5. 3 An illustration of lack of adrenochrome 
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Inhibition of adrenochrome formation by SOD and catalase implies that 
superoxide anions and hydroperoxide radicals were produced. 
lsoniazid was the most reactive, then acetylisoniazid, hydrazine and 
monoacetylhydrazine, in that order. However, there was variation in 
the extent of free radicals produced as demonstrated by sensitivity of 
each reaction to either SOD or catalase. lsoniazid reaction involved 
superoxide anion while hydrazine, acetylisoniazid and 
monoacetylhydrazine reactions involved both superoxide anion and 
hydrogen peroxide. However, partial inhibition of adrenochrome 
formation by SOD and catalase meant that other free radicals were 
produced. Similary, the increase or persistance of the reaction when 
both enzymes were added to a reaction-mixer of isoniazid, 
monoacetylhydrazine and hydrazine denotes the free radical cascade 
proceeded in alternative pathways to generate radicals other than 
superoxide or hydrogen peroxide. These could be organic 
intermediates viz; akyldiimides, carbanion, acyl and peroxyl radicals or 
hydroxyl radicals (Rapport et al, 1972). 
For acetylisoniazid, increase in the reaction with catalase suggests that 
either hydrogen peroxide reduces an intermediate or catalase interacts 
with an intermediate. Catalase had no effect on the isoniazid reaction. 
Most probably, hydrogen peroxide is not essential in this reaction. 
The mechanism of oxidation of hydrazine in presence of HbO was 
described by Golberg and Stern (1976). It is either enzyme or base 
catalysed, and is a two step, one electron transfer from hydrazine (the 
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electron donor) to produce superoxide and hydrogen peroxide radicals, 
viz: 
NH 2-NH 2 + Hb 2-------> Hb+ + H+ + H2N-HN 
NH 2-NH + 0 2 --- > -0 2 + H + + (NH= NH) 
-0 2 + H + + NH 2-NH 2 ---> H20 2 + NH 2-NH 
20 2 + SOD + 2H+ ---> H20 2 + 0 2 
The present experiment shows that at pH 9.2, isoniazid, 
acetylisoniazid, hydrazine and monoacetylhydrazine, in that order, 
reacted with HbO to produce reactive oxygen species. This reaction 
series relates to presence of a pyridine ring and keto groups. The 
electron rich pyridine ring of isoniazid meets the electron withdrawing 
effect of the keto group such that the nucleophilic properties of 
hydrazine group are unaffected. For acetylisoniazid, the electron 
withdrawing effect by a second keto group reduces the electron 
donating tendency of hydrazine. Hence, hydrazine was less reactive 
than isoniazid. This is more difficult for monoacetylhydrazine where 
the effect of one keto group is unopposed. Therefore for 
monoacetylhydrazine the hydrazine group cannot donate electrons 
easily and almost no reactive oxygen species were produced. 
These results imply that isoniazid, acetylisoniazid, hydrazine and 
monoacetylhydrazine can interact with HbO to generate reactive 
oxygen species and other radicals. Whether this can occur in vivo, it 
is yet to be proven. 
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CHAPTER SIX 
THE ROLE OF OXYGEN FREE RADICALS IN ISONIAZID INDUCED 
HEPATOTOXICITY 
6.0 SUMMARY 
Involvement of reactive oxygen species in isoniazid induced 
hepatotoxicity was investigated by incubating rat liver slices with 
isoniazid and each of its hydrazide metabolites; hydrazine, 
monoacetylhydrazine and acetylisoniazid, separately. Reactive oxygen 
species were detected by measuring lipid peroxides using the 
thiobarbituric acid-reacting-substances (TBARS) test while 
hepatotoxicity was assessed histologically. Hydrazine induced lipid 
peroxidation, but this was difficult to 
acetylisoniazid and monoacetylhydrazine, 
compounds interfered with the TBARS test. 
prove for isoniazid, 
because the three 
Hence, the TBARS test 
was foung unsuitable for detecting lipid peroxidation induced by 
hydrazide compounds. Because hydrazine is a metabolite of isoniazid, 
it was concluded that oxygen free radicals are involved in isoniazid 
induced hepatotoxicity. 
6. 1 INTRODUCTION 
Hepatotoxicity is the most feared side effect of isoniazid, and is often 
used as parameter for estimating incidence and severity of isoniazid 
related toxicity. lsoniazid hepatitis occured in 16 to 20% of patients 
on isoniazid of whom 1-2% it was severe (Gangadharam, 1986; 
Girling, 1984). lsoniazid hepatitis is more frequent in elderly people, 
where fatal hepatic necrosis has been reported, and is rare below 20 
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years of age (Riska et al, 1976; Walubo et al, 1991 c; Woo et al, 1987 
and 1992). 
Efforts to prevent isoniazid induced toxicity have been hampered by 
lack of knowledge of the mechanisms by which it occurs. There is no 
sine qua non symptom or sign of isoniazid toxicity; the biochemical, 
pathological and morphological features of isoniazid hepatitis are 
indistinguishable from other types of hepatitis such as viral and 
alcoholic hepatitis (Black et al, 1975; Mitchel et al, 1976). 
Of the activated metabolites incriminated in isoniazid induced hepatic 
necrosis, monoacetylhydrazine has been considered the most toxic 
metabolite (Mitchel et al, 1976). It was explained that 
monoacetylhydrazine is metabolically activated to an acyl radical which 
binds to macromolecules and thus cause hepatic injury. In the same 
perspective, isoniazid and acetylisoniazid were thought to induce 
toxicity after hydrolysis to monoacetylhydrazine. It was thereby 
suggested that fast acetylators are more likely to suffer isoniazid 
hepatotoxicity than slow acetylators because they produce more 
acetylisoniazid and monoacetylhydrazine. 
Unfortunately, the occurrence of isoniazid induced toxicity does not 
correlate with acetylator phenotype and the pharmacokinetics of 
isoniazid in elderly patients is similar to that in young patients. 
Secondly, it was shown that fast acetylators can acetylate 
monoacetylhydrazine in a similar fashion to isoniazid such that 
exposure to monoacetylhydrazine is not different from slow acetylators 
(Gangadharam, 1986). 
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It was envisioned here that the cause of isoniazid induced 
hepatotoxicity is multi-factorial whereby many mechanisms are 
involved, including host factors. Therefore, depending on the host 
factors, there should be variability in the propagation of one 
mechanism by different individuals leading to variations in occurrence 
and severity of isoniazid hepatitis in different patients. The theory of 
metabolic activation emphasized formation of organic radicals (acyl 
radical) and underscored the importance of other radicals (e.g. oxygen 
radicals) that could be formed in the process. 
Despite several reports showing that isoniazid action against 
mycobacteria is partly due to generation of free radicals (Shoeb et al, 
1985a, 1985b and 1985c; Knox et al, 1956), and that hydrazine 
compounds can generate reactive oxygen species through the 
hydrazine group (Jain and Hochstein, 1979; Goldberg and Stern, 1974; 
Misra and Frodovich, 1976; Goldberg and Stern, 1976), there is no 
report relating isoniazid induced toxicity to this form of tissue injury. 
I envisaged that during isoniazid metabolism, isoniazid and its 
metabolites (hydrazine, monoacetylhydrazine, acetylisoniazid and 
diacetylhydrazine) form reactive oxygen species which may lead to 
toxicity. Having demonstrated that isoniazid, acetylisoniazid, 
monoacetylhydrazine, and hydrazine, could activate oxygen in presence 
of oxyhemoglobin (see chapter five), we monitored formation of 
reactive oxygen species by each of these compouds in rat liver-slices. 
It was hoped that the results of this study would clarify the role of 
reactive oxygen species in isoniazid related hepatotoxicity and help to 
combat isoniazid related toxicity because the only way of controlling 
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free radical reactions is by administering the right antioxidant at the 
right time and place. 
6.2 METHODS 
6.2.1 Materials 
Sodium dodecylsulphate, Acetic acid, thiobarbituric acid, Butanol, 
Pyridine, TMP (Melanondaldehyde), L-dipalmitoyl-phosphodylcholine 
(DPPC; 16 :0), cholesterol, stearylamine, superoxide, SOD source 3000 
i.u./mg protein, catalase 
6.2.2. Procedures 
The study was approved by the University Ethical and Animals 
Research Committee. 
6.2.3. Preparation of liver slices 
Sprauge Dawly male rats weighing 150 - 200 g were used. The 
animals were fasted overnight and, under ether anaesthesia, abdominal 
wall was opened and the liver was perfused in situ with cold Kreb' s-
Henseleit buffer (4°C, pH 7 .4) to remove as much blood as possible. 
The liver was excised and cut into smaller blocks from which slices 
were prepared manually according to procedures described by 
Mcilwain, ( 1961). Briefly, a liver block was put on a filter paper on a 
cutting surface (top of a flat bottom bottle) and, using a microscope 
slide as the guide, a surgical skin graft blade was gently wedged into 
the liver block but against the glass slide to cut a thin slice. 
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After cutting, the slice was immediately put in ice-cold Kreb' s Henseleit 
buffer saturated with 0 2-C0 2 mixture (95%/5%). As the slices were 
non-uniform, they were weighed and trimmed to 150 - 200 mg wet 
slice. 
6.2.4. Culture of liver slices; 
Five Six-well plates were used (Well size 3 cm diameter and 0.5 cm 
height) (Fig 6.1 a and b). In each of the six wells (numbered 1 to 6), 
a liver slice was placed in 3 ml of ice-cold Eagle's MEM saturated with 
0 2-C02 mixture (95%/5%). Nothing was added to well no. 1 which 
was the control; well no. 2 contained the test compound; well no. 3 
had liposomal SOD and test compound; no 4 had empty liposomes and 
test compound; no. 5, diethyldithiocarbamate (DDC) only; and no. 6, 
DDC with test drug. The plates were incubated in a water jacket 
incubator set at 37°C and gassed with 0 2-C02 mixture (95%/5%). 
One plate was removed at intervals of 2, 4, 6, 8 and 10 hours of 
incubation for analysis of TSARS. Timing was started when the test 
compound was added. 
The effect of test compound on formation of TSARS was monitored in 
well no. 1 while the role of SOD on production TSARS was monitored 
in wells 3 to 6. In wells 3 and 4, the effect of exogenous SOD on 
production of TSARS was assessed while in wells 5 and 6 the effect 
of inhibiting endogenous SOD with DDC was examined. Because SOD 
does not cross cell membranes, it was encapsulated into liposomes as 
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6.2.5. Histopathology preparation; 
Slices were placed in 10% formalin and were processed and analysed 
blindly by an independent pathologist. Reported here are the ten hour 
incubated specimens lebelled A, B, C, D, E to F, and the non-incubated 
slice G. A was the Control. The others were incubated separately in 
5 mmol/1 of the respective compounds viz: A with isoniazid; C with 
acetylisoniazid; D monoacetylhydrazine and E with hydrazine. F was 
incubated with all four compounds at 2.5 mmol/1 of each. 
6.2.6. TBARS assay: 
This was according to the method described by Ohkawa et al (1979). 
Briefly, a liver slice was washed three times in ice cold NaCl and 
there-after was homogenised with a Teflon coated homogeniser in 0.2 
ml of 1.15% KCL buffer. A further 1.3 ml 1.15% KCL were added to 
make a 10% (w/v) tissue homogenate. To 0.2 ml of the 10% (w/v) 
homogenate, 0.2 ml 8.1 % SDS, 1.5 ml 20% AA and 1.5 ml 0.8 
thiobarbituric acids were added. Distilled water (0.6 ml) was added 
to make up 4 ml and this was heated in a water bath at 95°C for 60 
min. The mixture was cooled with tap water. Distilled water ( 1 ml) 
and 5 ml of butanol:pyridine solution (BP; 15: 1 v/v) were added and the 
mixture shaken vigorously on a vortex mixture. It was then 
centrifuged at 400 g rpm for 10 min and absorbance of the organic 
layer was read at 540 nm immediately using BP as the blank. 
TMP was used as external standard expressed as nmol of MDA. 
Calibration curve was made over a concentration range; 1. 14, 5 .63, 
11.14, 22. 7, 34.1, 45.4, and 68.1 nmol of MDA. The calibration 
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equation was y = 0.0102 + 0.0151 x (regression coefficient r = 
0.997). The total quantity of lipid peroxides in each liver slice was 
calculated and expressed as nmol/mg weight of the slice. 
6.2.7. Characterisation of reference compounds 
It was found necessary to clarify whether there was interaction 
between TMP and the test compounds, because such interaction may 
influence the results of small tissue samples used in this experiment. 
Liver slices have a limited reservoir of lipids such that encroachment 
on these lipids, of whatever magnitude, is likely to affect extent of lipid 
peroxidation leading to difficulties in interpretation of results. 
An aqueous mixture of TMP 1.5 ml ( 8.87 mmol) and 2.22 mmol of 
each of the four compounds, separately (i.e. 300 mg of isoniazid, 110 
mg hydrazine hydrate, 250 mg monoacetylhydrazine-hydrogen chloride 
and 400 mg of acetylisoniazid), was treated as described in the 
procedure except for SDS and trichloroacetic acid. The butanol 
extract was analysed by TLC, UV absorption and mass spectrum 
6.2.8. Liposomal preparation: 
Positive liposomes were prepared according to procedures described by 
Turrens et al ( 1982). A 15 ml mixture of L-dipalmitoyl-
phosphotidylcholine (DPPC; 16:0), cholesterol and stearylamine in 
chloroform in a molar ratio of 14:7:4 was made ((solutionX; this is 
equivalent to approximately 6.8 umol DPPC/ml or 5 mg DPPC/ml; i.e. 
75 mg of DPPC, 19. 74 mg of cholesterol and 7 .8 mg of Stearylamine). 
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Solution X was mixed with 4.5 ml of SOD solution in 0.15 M NaCl, 10 
mM KP04 pH 7 .4 (5 mg/ml; solution A) and was sonicated to form a 
homogenous emulsion. Chloroform was removed under vacuum by 
rotary evaporation at 46°C and residue was centrifuged at 105,000 g 
for 45 min. The supernatant (supernatant B) was used for validation 
of liposomal SOD encapsulation while the liposomes were resuspend 
in 2.5 ml of 0.15 M NaCl, 10 mM KP04 pH 7 .4 to yield a liposomal 
concentration of approximately 20 umol/ml. (liposomal concentrations 
are expressed per umol phospholipid (DPPC)). 
Empty liposomes were prepared by reverse evaporation in presence 
0. 15 NaCl, 10 mM KP04 pH 7 .4. After centrifugation, the liposomes 
were resuspended in the same potassium buffer as for the enzyme 
containing liposomes. 
Percentage of enzyme associated with liposomes was assessed by 
comparing the percentage inhibition of 6-0HDA oxidation by solution 
A with that of supertant B. Enzyme associated with liposomes 
includes both the encapsulated and the liposomal membrane bound 
SOD. Determination of encapsulated SOD was not done because it is 
more laborious and would exclude the SOD held within the liposomal 
membranes. Liposomes were prepared a day before the experiment 
and were kept at 4°C. 
6.2.9. Estimating SOD associated with liposomes; 
Appropriately diluted solution of SOD in buffer was used for calibration 
of SOD over concentration range; 10, 20, 40, 50, 80, and 100 ng/ml. 
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The samples were treated as described in the procedure below 
(Heikkila and Cabat, 1976). Percentage inhibition of 6-0HDA 
oxidation was plotted against SOD concentrations. Linear regression 
equation was y = 10.075 + 0.562x with a regression coefficient (r) 
of 0.993 (n = 4). 
For estimating SOD associated with liposomes, a portion of the SOD 
solution A, 5 mg/ml was diluted to 50 ng/ml of SOD (linear range) and, 
together with supernatant 8, were shaken for 5-1 5 min at 37°C to 
equilibrate with air before SOD assay. 
SOD assay: 
Using a solution of 1 o-2M 6-hydroxdopamine (6-0HDA) in distilled 
water sparged with N2, 50 ul of this solution were added to 450 µI of 
appropriately diluted tissue supernatant or enzyme solution to make a 
final concentration of 6-0HDA = 1 o-4M. Absorption was read at 
490nm at 20s and percentage inhibition of 6-0HDA oxidation by SOD 
was calculated using the buffer blank as the control ( 100%). The 
amount of SOD associated with liposomes was 16.8 ± 5.07% (n = 
5) 
6.2. 10. Statistical analysis 
Using the lnstat statistical computer package, One Way Analysis of 
Variance (ANOVA) and the student-Newman-Keuls test were used to 
compare results (P < 0.05). 
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6.3. RESULTS 
6.3.1. Characterisation of compounds 
Figures 6. 2 and 6. 3, respectively, illustrate TLC RF (retention factor) 
values and UV absorption spectra of the reference compouds. TLC RF 
values are: isoniazid (INH) = 0.62; isoniazid + TMP (INH-TMP) = 0.81; 
acetylisoniazid (aclNH) = 0.68; monoacetylhydrazine (mHYD) = 0.66; 
monoacetylhydrazine + TMP (mHYD-TMP) = 0. 78; hydrazine (HYO) 
= 0.09; HYD-TMP = 0.76; TBA = 0.78; and TMP = 0.71. 
Each of the four hydrazides reacted with TMP to produce derivatives 
that unlike the TBA derivative, did not absorb in 540 nm region (Fig. 
6.3). The reaction was faster with the aromatic hydrazides of 
isoniazid and acetylisoniazid than with monoacetylhydrazine and 
hydrazine. When the three compounds were reacted with TMP in one 
test-tube, absorption at 540 nm was abolished or just diminished (not 
shown). 
The mass-spectra for INH-TMP, aclNH-TMP, mHYD-TMP and TBA-TMP 
are shown in figure 6.4a-d. As in the case of the TLC above, the final 
product when these compounds react with TMP is similar by weight. 
6.3.2. Liver injury. 
Table 6. 1 shows lipid peroxidation in liver slices after incubation with 
varying concentrations of each compound. By 6 hours at 5 .48 mmol/1 
of the drug, lipid peroxides were highest with isoniazid, then 
acetylisoniazid, monoacetyl-hydrazine and hydrazine in that order. 
Therefore, 5 .48 mmol/1 was used in subsequent experiments. 
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Figure 6. 2 Thin Layer Chromatogram of the reference and parent 
compounds with retention factors in-printed. 
lsoniazid (INH) and its derivative (INH-TMP), 
monoacetylhydrazine (mHYD) with its derivative (mHDZ-TMP), 
hydrazine (HYO) and derivative (HYD-TMP), Acetylisoniazid 
(acl NH) and its derivative (acl NH-TM P), 1 , 1 , 3, 3-
tetraethoxypropane (TMP), and thiobarbituric acid (TBA). 
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Figure 6.3 Ultra-Violet absorption spectra of TMP 
derivatives with; 
A) lsoniazid (INH-TMP). 
B) Acetylisoniazid (aclNH-TMP). 
C) Monoacetylhydrazine (acHYD-TMP). 
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Figure 6.4 Mass spectrometry of TMP derivatives with; 
-lsoniazid -> INH-TMP (6.4a) 
-Acetylisoniazid -> aclNH-TMP (6.4b) 
-Monoacetylhydrazine -> mHYD-TMP (6.4c) 
-Thiobarbituric acid-> TBA-TMP {6.4d). 
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Tables 6.2 to 6.5 (Appendices A 1 to A4) illustrate hepatic injury 
measured by the amount of lipid peroxides during incubation of slices 
with isoniazid (Table 6. 2); acetylisoniazid (table 6. 3); 
monoacetylhydrazine (Table 4) and hydrazine (Table 6. 5). 
By the ANOV A, there was no difference between lipid peroxidation in 
the control wells and in those with isoniazid, acetylisoniazid and 
monoacetylhydrazine, with or without SOD, Liposomes and DDC. For 
hydrazine, there was significant variation in the means (P = 0.0014; 
see statistical calculations in appendix 2xi). 
In general, there was a progressive increase in lipid peroxides with time 
of incubation in both the control and the test slices. Except for 
hydrazine, there was virtually no difference in the amount of lipid 
peroxides produced at 10 hours by the other componds compared to 
the control. At two hours, there was wide variation in the quantity of 
lipid peroxides formed by isoniazid compared to the control (Fig. 6.5a). 
Acetylisoniazid and monoacetylhydrazine did not vary from the control 
(Fig. 6.5b and c). There was significant lipid peroxidation by 
hydrazine at 10 hours (P < 0.05; Fig. 6. 5d), but, as for the other three 
compouds, neither liposomal SOD nor DDC altered the formation of 
lipid peroxides. 
Histopathology results: See the pathology report and the corresponding 
plates on page 1 28. The control slice exhibits a necrotic margin 
which not featured in the normal slice (plates G 1, G3, A 1 and A3). 
lsoniazid and acetylisoniazid exhibited a similar pattern of cell necrosis 
(plates B 1 and C 1). Monoacetylhydrazine caused extensive 
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vacuolation and disentegration of the nuclei, while, in the case of 
hydrazine, there was pyknosis of nuclei and loss of nuclei in necrotic 
cells (Plates D 1, D3, E 1 and E3). Vacuolation, pykinosis and massive 
cell necrosis were observed when the four compounds were combined 
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PATHOLOGY REPORT ON THE LIVER SLICES 
By: Dr. M. Arendse, Department of Anatomical Pathology, University 
of Cape Town. 
Slide G: 
There is no hepatic cell necrosis in this slide (plate G 1, x 100 and plate 
G3, x 10). All hepatocytes and their nuclei are intact. Bile ducts, portal 
veins and the reticulin system (plate G2, x 100) are normal. In general, 
all cells are normal. 
Slide A: 
There is a rim of hepatocellular necrosis on the outer perimeter of the 
sections (plate A 1, x100 and plate A3, x10). Hepatocytes of the inner 
areas are normal. Bile ducts, portal veins and the reticulin system 
(plate A2, x 100) are normal. 
Slide B: 
There is a rim of hepatocellular necrosis on the outer perimeter of the 
sections and patches of similar nature in the inner areas (plate B 1, 
x 100). Nuclei of some hepatocytes are pykinotic while in the necrotic 
areas the nuclei are distengrated and in a few cells vacuolated. 
Bile ducts, portal veins and the reticulin system (plate 82, x 100) are 
normal. 
Slide C: 
There is a rim of hepatocellolar necrosis on the outer perimeter of the 
sections and several patches of cell necrosis in the inner areas (plate 
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C 1, x 100). The nuclei of some hepatocytes are pykinotic while in the 
necrotic areas the nuclei are disentegrated. Necrosis in this section is 
slightly more than in 8. Bile ducts, portal veins and the reticulin 
system (plate C2, x 100) are normal 
Slide D: 
There is massive hepaticellular necrosis in the whole section with 
extensive nuclear vacuolation and distengration (plate D 1, x 100 and 
plate D3, x 10). Cell necrosis in this slide is more than in A, 8 and C. 
Bile ducts, portal veins and the reticulin system (plate D2, x 100) are 
normal 
Slide E: 
There is hepatocellular necrosis in most areas and a few patches of 
normal hepatocytes (plate E 1, x 100 and plate E3, x 10). Unlike for 
slide D, most of the cell disentegration is in the cytoplasm. There is 
pyknosis of the nuclei and nuclear loss in some areas. Cell death here 
is less than for D, but more than for A, 8. and C. Bile ducts, portal 
veins and the reticulin system (plate E2, x 100) are normal 
Slide F: 
There massive hepatocellular necrosis with nuclear loss or distengration 
in all hepatocytes (plate F1, x100 and plates F2 and F3, x10). 
Virtually, no sign of a viable cell. Cell necrosis here is worse than in 
A to E. Bile ducts, portal veins and the reticulin system (plate F2, 
x 100) are normal 
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PLATE A1 CONTROL (X1 Op) 
PLATE A2 
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PLATE G3 FRESH LIVER (X10) 
PLATE A3 CONTROL (X10) 
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PLATE D3 MONOACETYLHYDRAZINE (X10) 
PLATE E3 HYDRAZINE (X10) 
1~8 





Hydrazine led to increased lipid peroxidation while this was difficult to 
prove for isoniazid, acetylisoniazid and monoacetylhydrazine. As the 
hydrazine group is common to isoniazid, acetylisoniazid and 
monoacetylhydrazine, it was ironic that free hydrazine caused lipid 
peroxidation and the three compounds did not. Since the three latter 
compounds reacted with TMP to produce other products which, unlike 
the derivatives of TMP with TBA, do not absorb at 540 nm (fig 6.3), 
it is highly probable that the TBARS test was interfered with by this 
mechanism. The reaction of hydrazides compounds with TBA RS is 
demonstrated by the use of 2-4-dinitrophenylhydrazine instead of 
thiobarbituric acid to detection lipid peroxides (Tomita et al, 1990). 
Despite the lack of signicance difference in the control and drug slices, 
it is possible that three compounds reacted with some products of lipid 
peroxidation thereby interfering with the TSARS test. On further 
incubation, the rise in lipid peroxidation, although not statistically 
significant, was probably due to increase in lipid peroxide species that 
could not react with isoniazid or acetylisoniazid. The smaller 
molecules of monoacetyl-hydrazine and hydrazine did react with TMP, 
but did not interfere with the TSARS test to the same extent as 
isoniazid and acetylisoniazid. This is expected because in the reaction 
with TMP, isoniazid and acetylisoniazid reactions were faster than 
those of monoacetylisoniazid and hydrazine. 
The implications of statistical significance in this experiment need to be 
taken with reservations because extent of lipid peroxidation may be 
limited by; 
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i) the limited quantity of oxidisable (unsaturated) lipids in the small liver 
slices. 
ii) the short a time of incubation for adequate induction of ROS 
cascade by hydrazine compounds. 
iii) use of less sensitive assay to detect lipid peroxidation (TBA RS). 
The lack of effect by exogenous L-SOD and DOC on lipid peroxide 
formation implies that superoxide may not be involved in this reaction. 
However, other factors that could have led to this failure. The enzyme 
(L-SOD) may not have reached the intracellular space adequately due 
to difficulties in enzyme delivery across cell membranes viz; poor 
liposomal carrier efficiency ( 15 % ) including efficiency in release of their 
contents once inside the cell, and phagocytic activity of the host cells 
(Ostro MJ , 1987). After entry into the cell, the limiting factor is 
accessibilty of the enzyme to reaction sites. SOD is a large molecule 
which may exhibit limited access to reaction sites of the membrane 
bound oxidative enzymes (in case enzyme catalysed peroxidation) and 
other reactions (non-enzymatic) in similar locations. 
Another limitation to the effect of SOD on lipid peroxidation is that 
SOD alone is an ineffective antioxidant in complex systems such as 
living tissues (Jadot et al, 1995). This is because SOD leads to 
production of hydrogen peroxide which can interact with transitional 
metals (Habers-Weiss reaction) or other groups to produce radicals 
(OH-) that lead to lipid peroxidation. Hence, a combination of SOD 
and catalase (or hydroxyperoxidase) was a more powerful antioxidant 
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than SOD or catalase alone. In this study, SOD and catalase enzyme 
combination was not used because of complexicity of the experiment, 
and it was uncertain whether the above observations would occur in 
vitro where there were no, or minimal, transitional metals or Hb. 
The histopathology observations showed that although all the four 
compounds are toxic, the extent of cell injury differs for each 
compound. Monoacetylhydrazine lead to extensive vacuolation and 
disintegration of the nuclei, while hydrazine exhibited cytoplsamic 
toxicity and nuclei loss in the late stage. lsoniazid and acetylisoniazid 
exhibited both vacuolation and nuclear loss preceded by nuclear 
pyknosis. Cell necrosis by isoniazid and acetylisoniazid was less 
severe compared to monoacetylhydrazine and hydrazine. When the 
four compounds were combined, there was pykinosis, vacuolation, 
nuclear disintegration and massive necrosis of the cells, implying that 
the three compounds given together are more lethal than when given 
individually. 
It appears that in this isolated system, the pathognomonic feature of 
monoacetylhydrazine hepatocellular injury is "vacuolation", while that 
of hydrazine is cytoplasmic disintegration (plate D3 and E3). This 
observation suggests that the two compounds may have different 
mechanisms of toxicity, and this is reaffirmed by observations that 
monoacetylhydrazine is less likely to induce oxygen free radical than 
hydrazine. 
As only rat liver slices were used, the observations in this study may 
not apply to man. However, it can be predicted that the toxicological 
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profile may be worse in human tissue because rat hepatic tissue has a 
natural resistance to hydrazine induced toxicity (Back and Thomas, 
1970). Most probably, this due to high levels of antioxidants such as 
SOD, reduced GSSG and CAT . 
The liver slice model is ideal for studying mechanisms of toxicity, and, 
in light of these results, there is a need to run this experiment using 
human tissue. In South Africa, tissue slice techniques are still in their 
infancy, and human tissue slices are not available. 
Whether liberation of reactive oxygen species by isoniazid and its 
metabolites occurs in vivo, is not yet known. To prove this, a method 
other than the TSARS test should be used for detection of reactive 
oxygen species. 
In conclusion, hydrazine led to lipid peroxidation but this was difficult 
to prove in the case of isoniazid, acetylisoniazid and 
monoacetylhydrazine. Since hydrazine is a metabolite of isoniazid, it 
is hereby suggested that, depending on the amount of hydrazine 
produced during isoniazid metabolism, reactive oxygen species may be 
involved in isoniazid induced hepatotoxicity. The TBA RS test is not 
suitable for assessing oxidative stress by hydrazide compounds 
because they may interfere with the test. 
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CHAPTER SEVEN 
THE DISPOSITION OF ISONIAZID METABOLITES DURING 
ANTITUBERCULOSIS THERAPY. 
SUMMARY 
The disposition of pyrazinamide, rifampicin, and isoniazid with its 
hydrazide metabolites; acetylisoniazid, monoacetylhydrazine, 
diacetylhydrazine, and hydrazine, was compared in 1 0 young (25 + 1 
years old) and 9 elderly (72 + 3 years old) patients during 
antituberculosis treatment with pyrazinamide, rifampicin and isoniazid 
on days 1, 30, and 90. Pharmacokinetics of the three drugs as well 
as the maximum concentration (Cmax), time to reach Cmax (Tmax) 
and area under curve (AUC) of the metabolites were similar in the two 
groups on the three occasions. In conclusion, during antituberculosis 
therapy with isoniazid, rifampicin and pyrazinamide, the metabolism of 
isoniazid to hydrazide metabolites is not related to age. 
7. 1 INTRODUCTION 
lsoniazid is the most widely used drug for treatment and prophylaxis 
of tuberculosis. It forms the backbone of the most effective 
antituberculosis regimens such that no patient with tuberculosis ought 
to be denied the benefit of using this drug. Unfortunately, isoniazid 
has been associated with severe side effects which have limited its use 
in elderly patients (Black et al, 1975). The incidence of isoniazid 
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induced toxicity rises with age; it is highest in the elderly where some 
reactions have been fatal and tuberculosis prophylaxis with isoniazid 
is not recommended (Riska, 1976; Woo et al, 1987 and 1992). Of 
note however, the pharmacokinetics of isoniazid are similar in all age 
groups and the occurrence of adverse effects are not related to plasma 
concentrations of the drug (Advenier et al, 1980; Kergueris et al, 
1986; Paulsen et al, 1985; Ellard, 1976 and 1984). 
Despite the incrimination of hydrazine metabolites for isoniazid related 
toxicity, the mechanism of isoniazid induced toxicity is still unknown 
(Mitchel et al, 1976). The theory implicating hydrazine metabolites 
has not met wide acceptance because of the failure to explain clinical 
incidence and this is worsened by lack of information on these 
metabolites during tuberculosis treatment. Current knowledge on 
isoniazid metabolites is from studies in young healthy volunteers 
(Lauterburg et al, 1985; Timbrell et al, 1977; Blair et al, 1985), a few 
reports in children (Gent et al, 1992) and elderly patients (Walubo et 
al, 1991 b). This is inadequate because either elderly people or some 
metabolites were excluded or antituberculosis agents commonly used 
with isoniazid were not given. As the number of elderly people with 
tuberculosis and cases of tuberculosis with HIV are on the increase, 
there is a growing need for information regarding plasma profiles of 
these metabolites during antituberculosis therapy in vulnerable difficult 
patients. 
Described here, is the disposition of rifampicin, pyrazinamide and 
isoniazid with its metabolites acetylisoniazid, monoacetylhydrazine, 
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diacetylhydrazine and hydrazine in young and elderly tuberculosis 
patients on day one of treatment and at steady state. 
7.2 METHODS 
7 .2. 1. Materials. 
The Rifater tablets containing (mg) isoniazid, 80; rifampicn, 120 and 
pyrazinamide 250 were from Mer-National (S. A.). 
7 .2.2. Clinical protocol 
Nineteen patients ( 19) of the Xhosa tribe of South Africa participated 
in the study. They were newly diagnosed (sputum positive for acid 
fast bacilli) tuberculosis patients of whom 9 (5F & 4M) were elderly 
(72 + 3 years of age; weight 46. 7 + 3.4 Kg) and 10 (4F & 6M) were 
young adults (25 + 1 years of age; weight 56.1 + 6.1 Kg). 
Antituberculosis drugs (Rifater tablets) were self-administered once 
daily and orally. Average daily doses in young and elderly patients 
were, respectively: 7 .07 + 0. 72 and 7.07 + 0.48 mg/kg for isoniazid; 
10.61 + 1 .07 and 10.60 + 0. 72 mg/kg for rifampicin and 22.10 + 
2.23 and 22.08 + 1.50 mg/kg for pyrazinamide. 
Informed consent was obtained and the study was approved by the 
University Ethics Committee. All patients had normal liver, renal and 
haematological function tests before the study. Patients with history 
of treatment for tuberculosis and/or illnesses or disorders such as 
rheumatoid arthritis or diabetes mellitus were excluded. 
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After overnight fasting, an intravenous cannula connected to a heparin 
line (0.5 i.u./ml in normal saline) via a three-way tap was inserted into 
either arm. Blood samples (6 ml) were obtained before start of 
treatment and at 1, 2, 4, 6, 8, and 10 hours after ingestion of the 
drugs on treatment days one, thirty and ninety. Blood (5 ml) for 
haematological tests was drawn in a separate test tube. 
On each occasion, patients emptied their bladder before starting the 
study and subsequent urine was collected in plastic containers for eight 
hours. No feeds were given for the first two hours and only fluids 
were allowed from 2 to 4 hours. 
Blood samples were centrifuged immediately and plasma was stored at 
-80 °C until assay (within 10 weeks during which no significant loss of 
drugs and metabolites was observed) while urine was kept at 4 °C until 
end of collection (8 hours) when it was pooled, total volume 
determined, 5 ml stored as above and the rest was discarded. Urine 
was assayed for isoniazid and acetylisoniazid. 
Compliance was achieved by home visiting and medicines were 
dispensed on a daily basis at tuberculosis clinics near home where 
patients swallowed the tablets under supervision of a tuberculosis 
nurse (this is standard practice in this region). 
Analysis of compounds; A portion ( 2 ml of plasma) from each sample 
was analysed by HPLC for rifampicin, pyrazinamide, isoniazid and 
metabolites (acetylisoniazid, monoacetyl-hydrazine, diacetylhydrazine 
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and hydrazine) as described earlier (Chapter four; Walubo et al, 1994). 
From the remaining 1.5 ml, 0.5 ml was used for assay of allantoin 
(0.5 ml). The six hour sample was also analysed for TSARS (0.5 ml) 
and other laboratory parameters including uric acid (chapter 8). 
7.2.3. Kinetic analysis 
Pharmacokinetic parameters were obtained from plasma concentration-
time points using standard formulae (Gibaldi 1984). The areas under 
plasma concentrations plotted against time (AUC) were calculated 
using the trapezoidal rule. Apparent first order rate constant for 
decline of plasma concentrations after administration (B) was obtained 
by linear least square regression on log plasma concentration versus 
time. The apparent volume of distribution (V) was calculated 
according to equation: 
DOSE 
V 
B * AUC 
Plasma clearance was derived from DOSE/AUC(tou· 
7 .2.4. Statistical analysis 
The results were analysed by non-parametric methods using the 
StatGraphics computer package. The paired Mann-Whitney U test 
was used to test for level of significance at P value < 0.05. 
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7 .3. RESULTS 
Figures 7. 1 a to 7. 1 c show the concentration time profiles of 
pyrazinamide, rifampicin and isoniazid on the three occasions while 
tables 7. 1 and 7. 2 illustrate the pharmacokinetic parameters of the 
three drugs on days 1 and 30 (Appendices 81 to 84). Concentrations 
on day 90 were unsuitable for regression analysis. 
There was no difference in the pharmacokinetics of the three drugs in 
young and elderly patients. The median half-life for isoniazid on day 
1 ranged from 2.29 to 5.57 hours in the young versus 2.68 to 4.98 in 
the elderly (P = 0.216). All patients were slow acetylators with half-
life greater than 2 hours (Fig. 7 .2; 10; Jackson et al, 1989) and acetyl-
isoniazid to isoniazid ratio less than 1 . 14 (Appendix 85). 
Rifampicin kinetics were similar in both age groups. 
Whereas AUC for pyrazinamide on day 1 was similar (P = 1 .0) in the 
two groups, AUC on day 30 was different (P = 0.032). AUC ranged 
from 422.82 to 876.87 mghr/L in the young versus 262.27 to 973.8 
mghr/L in the elderly on day 1, and 354. 37 to 938. 37 mghr/L in the 
young versus 571.62 to 1003.0 mghr/L in the elderly on day 30. 
Figures 7 .3a to 7 .3d show the plasma concentrations of metabolites 
on the three days, while tables 7. 3 and 7 .4 illustrate their AUC, 
maximum concentration, and time to maximum concentration 
(Appendices 86 to 88). The three kinetic parameters for each of the 
metabolites were similar in the two age groups. AUC for hydrazine on 
day 1 and diacetylhydrazine on day 30 were not different in the two 
groups. AUC for hydrazine on day 1 ranged from 2.24 to 20.2 mghr/L 
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Figure 7. 1 Plasma concentrations of isoniazid (7. 1 a), rifampicin 
(7. 1 b) and pyrazinamide (7. 1 c) in young and elderly patients 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 7.2 .. The distribution of isoniazid plasma half-life in young 
and elderly patients during TB treatment on day 1 
KEY: 
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Figure 7. 3 Plasma concentrations of acetylisoniazid (7. 3a), mono-
acetylhydrazine (7. 3b), hydrazine (7. 3c) and diacetylhydrazine 
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in the young versus 3.02 to 20.83 mghr/L in the elderly (P = 0.603), 
while AUC for diacetylhydrazine on day 30 ranged from 2. 35 to 10. 75 
mghr/L versus 0.92 to 19.47 mghr/L in the elderly (P = 0.54). 
Kinetic parameters such as half-life and clearance could not be 
determined from the concentration-time curves of metabolites because 
the profiles here define rate of formation and elimination. 
Although the concentrations on day 90 appear to decline, they were 
at steady state such that Cmax and AUC were not suitable for 
comparison with day 1 and 30. 
The enzyme inducing effects of rifampicin were not significant at one 
month, and it is unclear whether this had a role in the increase in 
isoniazid clearance and AUC of hydrazine in young patients by day 30. 
Also, there was a slight drop, although not significant, in rifampicin 
clearance in both groups by day 30. 
Overall, the concentration of metabolites ranged from 0.56 to 7 .04 
mg/L for acetylisoniazid, 0.45 to 6.8 mg/L for monoacetylhydrazine, 
0.12 to 0.88 mg/L for hydrazine and 0.06 to 1 .12 mg/L for 
diacetylhydrazine. Therefore, the most reliable concentrations for 
monitoring metabolites should be after the Cmax (i.e. 6 hrs or later). 
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7 .4 DISCUSSION 
The disposition of isoniazid metabolites during antituberculosis therapy 
has been determined and concentration ranges obtained. This is 
important for assessing patients manifesting toxicity and drug 
resistance problems. Toxicity, because these metabolites are 
potentially toxic, and drug resistance, because at less than 1 µg/ml 
monoacetylhydrazine competitively inhibited isoniazid action against 
mycobacteria (Ellard and Gammon, 1976; Pope H, 1956). 
One tribal group was used in the study to minimize genetic influence 
and the Xhosa tribe was chosen because they live within the vicinity 
of the university. Acetylator status for South African blacks was 
reported as 41 percent slow acetylators (Bach et al, 1976), however, 
the use of antimodes from other studies to classify acetylator status of 
these subjects may not be appropriate here. There are outstanding 
differences between this study and those from which these antimodes 
were determined, i.e. the formulation of isoniazid (Rifater tablets), co-
administration with other drugs and disease (tuberculosis) might have 
modified and delayed drug absorption from the gut; leading to a 'slow 
release' kinetics. Characteristically a 'slow release' behavior results 
into a fictitiously prolonged half-life and reduced drug delivery such 
that urinary recovery of metabolites would be lower than expected e.g. 
acetylisoniazid. For the same reason patient 3E shows a discrepancy 
of a high metabolic ratio of 1 .6 (Appendix 85) versus isoniazid half-life 
of 4 hours (Appendix B 1) making it difficult to decide on the acetylator 
status. However, when the patients' own half-lives were used to 
phenotype, an antimode of 3.5 hours was obtained and the subjects 
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were reasonably divided into 10 fast acetylators (7Y and 3E) and 9 
slow acetylators (3Y and 6E; Fig. 7 .4). 
In studies such as this one, acetylator status should be determined 
separately and prior to beginning of the study, but, owing to many 
blood letting in this prolonged study (over three months), and the 
standard practice of tuberculosis therapy where acetylator status is not 
routinely tested, preliminary tests for acetylator status were omitted to 
minimize inconvenience to the patients and avoid a high fallout. The 
study subjects did not receive any treatment different from other 
patients except hospitalization for blood sampling. Hence, this study 
depicts a clinical situation such that the difficulties in classifying 
acetylator status could be another reflection of the insignificant role of 
phenotypic status during antituberculosis therapy. 
The four metabolites were produced in significant quantities. 
However, the maximum concentration (4. 73 mg/L) and AUC (44.0 
mghr/L) of monoacetylhydrazine are twice those reported by Lauterburg 
et al (1985) viz; 2.28 mg/L and 28.88 mghr/L, respectively. This 
could have been due to differences in assay procedures (HPLC vs GC-
MS), dose of isoniazid (7 .07 mg/Kg vs 300 mg oral bolus), presence 
of other drugs (pyrazinamide and rifampicin vs isoniazid), and disease 
(tuberculosis patients vs volunteers). 
A similar controversy was observed with hydrazine concentration 
where, using the gas chromatography-mass spectrometry (GC-MS) 
methods, Seever et al ( 1981) and Blair et al ( 1985) reported Cmax of 



















































































































respectively. To the contrary, recent studies using HPLC assays have 
reported Cmax of hydrazine as; (a) greater than 0. 1 µg/ml in rabbits after 
5 mg/kg of isoniazid; (b) 0.24 + 0.08 µg/ml and 0.4 + 0.2 µg/ml in 
young and elderly tuberculosis patients, respectively, during 
antituberculois therapy at 6.5 + 0. 77 mg/kg of isoniazid (Walubo et al, 
1991 c) and, (c) 0. 1 µg/ml in one pediatric patient at 20 mg/kg of 
isoniazid (Gent et al, 1992). 
It appears that other factors such as disease and the presence of other 
drugs may influence the extent of hydrazine formation whereby the 
enzyme inducing effects of rifampicin and a high catabolic state due to 
tuberculosis disease may increase hydrazine formation. Sarma et al 
( 1984) reported a two-fold rise in the proportion of isoniazid 
metabolized to hydrazine (3% to 6%) when rifampicin was added to 
isoniazid in volunteers. Similarly in this study, the AUC of hydrazine 
in young patients on day 30 was higher than on day 1, most probably 
due to rifampicin induction of hydrolase enzymes. This phenomena 
was not exhibited by elderly patients where the AUC of hydrazine was 
similar on days 1 and 30. This is possibly due to chronic induction of 
enzymes over the years. Therefore, the AUC of hydrazine in elderly 
patients on day 1 was higher, although not statistically different, than 
in young patients. This was in agreement with previous observation 
of a higher Cmax of hydrazine in elderly when compared to young 
Chinese patients (Walubo et al, 1991 d). Neverthless, it is not known 
whether such observations make hydrazine metabolite the cause of a 
higher incidence of isoniazid induced toxicity in elderly than young 
patients. 
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By day 90, concentrations of hydrazine and diacetylhydrazine were at 
steady state, whereby elimination and production seem to be balanced. 
However, the concentrations remained high even after 5 hours, 
indicating accumulation of these metabolites with continued therapy. 
In the later months, pyrazinamide concentrations need to be checked 
because pyrazinamide concentrations increased with time causing high 
steady state levels in the elderly (figure 7. 1). 
Concentrations of the four metabolites varied over a wide range. As 
none of the study patients exhibited toxicity it would be logical to take 
these concentration ranges as the normal. However, it was difficult 
to predict whether concentrations observed in one patient would be 
safe in another. A study of these metabolites during isoniazid toxicity 
is needed to understand their role in this process. 
In conclusion, the disposition of acetylisoniazid, monoacetylhydrazine, 
diacetylhydrazine and hydrazine during antituberculosis treatment are 
similar in young and elderly patients. The four isoniazid metabolites 
(acetylisoniazid, monoacetylhydrazine, diacetylhydrazine and hydrazine) 
were produced in significant quantities and tended to accumulate with 
continued treatment. Therefore, the occurrence of more isoniazid 
adverse reactions in the elderly when compared to young patients is 
due to factors other than disposition of isoniazid metabolites. It is 
hoped that the results of this study will aid the evaluation of difficult 
tuberculosis patients and improve understanding of the mechanism and 
management of isoniazid related toxicity. 
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CHAPTER EIGHT 
OXIDATIVE STRESS DURING ANTITUBERCULOSIS 
THERAPY IN YOUNG AND ELDERLY PATIENTS. 
8.0. SUMMARY 
Using allantoin as a marker for reactive oxygen species, oxidative 
stress during antituberculosis therapy was compared in 1 0 young and 
9 elderly patients. Before treatment, allantoin plasma concentrations 
in patients were similar to that of volunteers. Administration of a 
combination of isoniazid, rifampicin and pyrazinamide increased plasma 
allantoin in both groups of patients. Allantoin concentrations (mean 
+ s.e.) at six hours were higher (P < 0.05) in elderly than in young 
patients on day one, (8 .22 + 1 .50 vs 1 .89 ± 0.98 ug/ml); day 30, 
(5.85 + 0.82 vs 0.87 ± 0.57 ug/ml); and day 90, (4.84 + 1.24 vs 
0.52 + 0.50 ug/ml). Although the total amount of allantoin excreted 
and the rate of allantoin formation at steady state were similar in both 
groups on the three occasions, allantoin clearance was nine times 
higher in young than in elderly patients. It was concluded that the high 
concentrations of allantoin in the elderly was due to decreased renal 
excretion, while the increase in plasma allantoin concentration when 
the drugs were administered implies that these antituberculosis drugs 
induced oxidative stress in both the young and elderly patients. 
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8.1 INTRODUCTION 
Oxidative stress refers to excessive generation of free radicals in the 
body. Oxygen free radicals or reactive oxygen species namely, H20 2 , 
0 2 and -OH (ROS), have been incriminated in the pathophysiology of 
many biological reactions. When antioxidant defences are inadequate, 
ROS may lead to tissue damage. This is commonly due to disease but 
drug-derived radicals can also cause tissue damage (i .e toxicity). 
The involvement of reactive oxygen species in aetiology and 
manifestation of disease and drug toxicity makes them worthwhile 
species to monitor. Such information may be helpful because 
administration of an appropriate antioxidant at the right time and in the 
right place is the best approach to controlling free radical activity. 
Unfortunately, there is no reliable test for timely detection of free 
radicals in vivo. Controversy reigns over the percentage molar ratio 
test (i.e. 9, 11 linoleic:9.12-linoleic acid) because it may be influenced 
by disease (Jack et al, 1991) and diet (Britton et al, 1992). The 
desferrioxamine-chelatable iron test is unreliable because elements 
besides iron can propagate free radical activity. The thiobarbituric acid 
reacting substances (TBARS) test, a non-specific measure for lipid-
peroxidation, is the most widely used indicator for free radical cascade. 
However, by measuring the end products of lipid peroxidation, 
detection of free radicals by this method is possible after considerable 
tissue damage has occurred. Secondly, we have observed in our 
laboratory that hydrazine compounds (isoniazid and metabolites in 
plasma) interfere with this test by reacting with some lipid peroxides. 
A test whereby free radicals can be detected before tissue damage 
occurs would be more valuable in the clinic. 
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Allantoin, a product of purine metabolism, was suggested to be a good 
marker for tree radical activity. In humans, allantoin is formed by non-
enzymatic oxidation of uric acid because there is no enzyme to 
metabolise uric acid. During this process, uric acid acts as an 
antioxidant that protects other molecules or tissues against attack by 
free radicals (Ames et al, 1981; Becker, 1993). 
I envisaged that the amount of allantoin in the body is related to extent 
of free radical reaction with uric acid such that measurement of 
allantoin plasma profiles may help to predict the degree of oxidative 
stress during treatment with potentially toxic drugs. Such information 
may not only help to identify susceptible patients using the offending 
drug before organ damage occurs, but may be a clue to understanding 
the mechanism of toxicity. 
The mechanism of isoniazid induced toxicity is still unclear but recent 
reports have shown that hydrazine compounds, including isoniazid, can 
generate free radicals in the presence of oxygen (Gayathri et al, 1975; 
Hussein et al, 1985; Sushil snd Hochstein, 1979). It was postulated 
here that during isoniazid metabolism, isoniazid and its metabolites 
(hydrazine, acetylhydrazine, acetylisoniazid and diacetylhydrazine) form 
free radicals which may lead to toxicity, and this could be 
demonstrated in vivo by variations in allantoin profiles in body fluids. 
As adverse reactions during treatment of tuberculosis with isoniazid 
containing regimens are more common in elderly patients, this study 
was undertaken to compare oxidative stress induced by a combination 
of isoniazid, rifampicin and pyrazinamide in young and elderly 
tuberculosis patients, with a hope that the result would shed light on 
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why elderly patients are more susceptible to antituberculosis drug 
toxicity. 
8.2 METHODS 
8.2. 1. Materials. 
The Rifater tablets containing (mg) isoniazid, 80; rifampicin, 120 and 
pyrazinamide 250 were used as in section 7 .2.1. (Chapter seven). 
8.2.2. Clinical protocol 
As in section 7 .2.2 (Chapter seven). 
Allantoin was determined on all the samples, while only the pre-
treatment and six hour samples were used for assay of uric acid, 
TBRAS, liver, renal and haematological function tests. 
8.2.3. Analysis of samples 
Allantoin plasma concentration was assayed by HPLC using a 
procedure described by Ora et al ( 1992), after a slight modification. 
Briefly, using acetic acid (5 ul of 10% aq. acetic acid) as internal 
standard, 20 ul of the ultrafiltrate from 0.5 ml of plasma or urine (0.1 
ml urine diluted to 0.5 ml with water) was injected into the HPLC and 
eluted at 0.8 ml/min with 5 mM HSA in 5 mM phosphate buffer at pH 
3.2. The eluate was detected by UV at 224 nm. Samples were run 
in batches of 1 0 and peak height ratios were used for deriving 
concentrations. 
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Plasma uric acid concentration, liver, renal and haematolcgy function 
tests were assayed in the hospital laboratory. Uric acid was not 
assayed by the HPLC method because the high uric acid concentrations 
needed dilutions to come into the linear calibration range which made 
allantoin detection difficult. 
Antituberculosis drugs (isoniazid, pyrazinamide and rifampicin) and 
isoniazid metabolites (acetylisoniazid, monoacetylhydrazine, 
diacetylhydrazine and hydrazine) were tested and did not interfere with 
the assay (Walubo et al, 1994). Other metabolites such as pyrazinoic 
acid and desacetylrifampicin, although not tested would not appear in 
concentration similar to allantoin. 
TSARS were assayed using a procedure described by Mitsuru et al, 
1977. 
8.2.4. Kinetic analysis 
Renal clearances of allantoin, uric acid and creatinine were calculated 
using standard formula (Bennett, 1992): 
Utr (ml/min) * Uc (mg/di) 
Clearance (ml/min) = ----------------------------
pc (mg/di) 
Where Utr is urine flow rate, Uc and Pc are urine and plasma 
concentrations of the reference compound, respectively. 
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To assess total allantoin formed, it was assumed that at steady: 
Amount formed = CIPss x Css = Amount excreted. 
8.2.5. Statistical analysis 
The results were analysed by non-parametric methods using the 
StatGraphics computer package. The unpaired Mann-Whitney U test 
was used to test for level of significance with a P value < 0.05. 
8.3. RESULTS 
Tables 8.1 and 8.2 show the average plasma concentrations of 
allantoin and uric acid as well as liver and renal function tests in control 
and tuberculosis patients before and during treatment, respectively. 
Before treatment the function tests in patients were within normal 
range for age and, together with allantoin and uric acid values, were 
comparable to those of control group (Table 8. 1). Although alkaline 
phosphatase for elderly patients was in the upper range this did not 
reflect liver damage in the context of normal transferases. The liver 
enzymes and renal tests remained in the normal range over the study 
period and average weight gain by three months was 10.01 % for the 
young group and 6.08 % for the elderly (Table 8.2). The number of 
elderly patients on days 30 and 90 was less by two due to loss of the 
subjects by immigration back to their homelands (away from urban 
Cape Town) where they continued with their treatment. That this loss 
was not due to death was certified by their close relatives (children) or 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Analysis of samples: Allantoin and acetic acid resolved at 3.91 and 
6 .08 minutes, respectively (Fig. 8. 1). Regression coefficient (r) of the 
standard curves was 0.996 for plasma and 0.992 for urine while 
intrabatch coefficient of variation (CV) at 5 ug/ml (n = 8) was 9.3 ± 
2.43% for plasma and 11 .8 + 2.2% for urine (n = 5). 
Figures 8. 2 and 8. 3 illustrate, respectively, the plasma time profiles 
and age-distribution of allantoin over the three study days while table 
8.3 shows the plasma concentrations of allantoin, uric acid, TSARS 
and creatinine at six hours after dosing (Appendices C, D and E). 
In both groups, there was a rise in plasma allantoin after introduction 
of antituberculosis drugs and, the concentrations were higher in elderly 
than young patients on the three occasions. By day 90 allantoin 
concentrations were below the pre-treatment values for the young 
while that of elderly did not recover. Nevertheless, there was a 
general reduction in allantoin concentrations by day 90 in both groups. 
Although uric acid is important for the formation of allantoin, variations 
in allantoin concentrations were not related to uric acid (Table 8.3). 
For instance, before treatment uric acid concentrations were different 
in the two age groups while that of allantoin was similar. Also, on the 
study days uric acid levels for the two groups were comparable while 
allantoin levels were different. Most probably, the concentrations of 
uric acid are above values that would influence allantoin levels. 
In young patients, although uric acid concentration on day one was 
significantly higher than the pre-treatment value, subsequent 
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Figure 8. 1 The representative chromatograms of standard solution 
(A), drug free plasma (8), and a plasma extract from patient 
(C). 
1 = Allantoin (3.91 min.) 2 = Acetic acid (internal standard, 











Figure 8.2. Plasma concentrations of allantoin in young and elderly 
TB patients during TB treatment on the three days. 
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concentrations on days 30 and 90 were not. The elderly group did 
not exhibit this difference. Therefore, the rise in uric acid during 
antituberculosis therapy appears not to be significant. 
The concentration of TSARS were similar in young and elderly patients 
on the three occasions and, as for other reports (Jack et al, 1994), 
there was no difference in the concentration of the three occasions. 
Creatinine concentrations remained in the normal range over the study 
period. 
Table 8.4 illustrates the renal characteristics of allantoin, uric acid and 
creatinine in the two groups (Appendices F ant G). Renal function 
was better in the young than in elderly patients as indicated by higher 
urinary output, creatinine clearance and total creatinine excreted in the 
first 8 hours. Also, renal clearances for allantoin and uric acid were 
higher in young than elderly patients. Because of the high renal 
clearance of allantoin by young patients, total amount of allantoin 
excreted in the first 8 hours was similar to that excreted by the elderly. 
Table 8.5 illustrates the relationship between allantoin concentrations 
and clearances of elderly and young patients while table 8.6 shows the 
formation amd excretion rates of allantoin on the three days. The 
clearance and concentration ratios were similar. The amount of 
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Table 8.5 Ratios of allantoin plasma concentration (Cp) and clearance 
(CL) in young (Y) and elderly (E) patients. 
Day 1 30 90 
Cp ratio (E/Y) 4.32 ± 3.7 6.72 ± 5.4 9.31 + 4.8 





































































































































































It has been shown that a combination of isoniazid, rifampicin and 
pyrazinamide leads to increased production of allantoin in tuberculosis 
patients. As total allantoin formed in the first 8 hours was similar in 
both groups, the higher concentrations of allantoin in elderly patients 
are due to decreased clearance of allantoin in this group. This was 
paralleled by a low creatine clearance in the same people. However, 
according to current literature, the increase in allantoin concentration 
when antituberculosis drugs were administered in both young and 
elderly patients, is suggestive that ROS were produced. Hence, the 
subsequent fall in allantoin concentration during the treatment period 
would be due to improvement antioxidant defence mechanisms with 
clinical improvement. 
Allantoin concentrations should be more indicative of the extent of free 
radical activity than the TBARS test because uric acid being a small 
and lipid soluble molecule has access to free radical production sites 
where it interacts directly with the free radicals. The TBARS test 
although an indicator of free radical activity is ineffective at estimating 
extent of free radical activity because it excludes many non-lipid 
structures such as proteins and uric acid that are oxidised by free 
radicals. Ascorbic acid depletion was not used for comparison 
because it is unreliable for detecting free radical activity. Ascorbic 
acid may exhibit anti- or pro- oxidant activity depending on the 
availabilty of transitional metal ions and in the aqueous media only 
(Halliwell and Gutteridge, 1992). 
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As antituberculosis therapy in these patients was uneventful and there 
,s limited knowledge regarding the critical allantoin plasma 
concentrations which may have an effect, the results of this study 
indicate that; (i) oxidative stress occurs during antituberculosis 
chemotherapy with isoniazid, rifampicin and pyrazinamide regimen, and 
(ii) there degree of oxidative stress during antituberculosis treatment is 
similar in young and elderly patients. It suggests that antituberculosis 
drugs induce production of reactive oxygen species thereby underlining 
the importance of nutritive supplements like multivitamins used during 
antituberculosis therapy. Vitamins such as C, E and A are antioxidants 
which help the body to quench free radicals. Further studies are 
needed to address the implications of these observations, in particular, 
to examine the role of allantoin in predicting drug toxicity because 
changes in allantoin concentrations start at a time when liver and renal 
functions are relatively unchanged (i.e. before organ damage occurs). 
8.3.1 Allantoin as a toxin (hypothesis) 
The consequences of high plasma concentrations of allantoin cannot 
be realised at the moment, but recent reports on the use of allantoin in 
clinics have shown that allantoin has several effects on cell 
membranes. Allantoin is a component of cosmetics and several 
ointments used in treatment of many dermatological disorders including 
psoriasis (De Bumnan et al, 1987; Chadzynska, 1987). It is claimed 
to stimulate new skin growth and improve skin smoothness. This 
claim is supported by observations that when heparin preparations, 
with and without allantoin, were placed on the ear lobes of rabbits on 
opposite sides, those preparations containing allantoin showed a 
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several fold increase in thrombotic activity (Tausch el et al, 1984), 
indicating that allantoin improves permeability of cell membranes to 
drugs. In another study, movement of allantoin across cell membranes 
was associated with stimulation of Beta-receptors but not alpha-
receptors (Sugino et al, 1984). In presence of calcium ions, allantoin 
is believed to induce Reye's syndrome (Marterns et al, 1986). Given 
these observations, it is possible that the high concentrations of 
allantoin in elderly patients may play a role in increasing susceptibility 





1. A procedure for assay of rifampicin, pyrazinamide, and isoniazid with 
four of its hydrazide metabolites (acetylisoniazid, monoacetylhydrazine, 
diacetylhydrazine and hydrazine) in human plasma was developed. By this 
method plasma profiles of isoniazid, the four metabolites and co-administered 
drugs (rifampicin and pyrazinamide) can be assessed from one sample. This 
approach makes pharmacological evaluations of patients easier. 
2. lsoniazid and its metabolites; acetylisoniazid, monoacetylhydrazine and 
hydrazine can generate oxygen free radicals in the presence of 
oxyhaemoglobin. Although a pH of 9.2 does not occur in physiological 
situations, the physiological au milieu is a complex mixture of substances 
that can catalyse (enzymatically and non-enzymatically) reactive oxygen 
species formation at normal pH (7 .2 - 7 .4). Also, formation of other 
unidentified free radicals was noted. 
3. Because hydrazine induced significant lipid peroxidation in rat liver 
slices, it can be concluded that, depending on the amount of hydrazine 
formed during isoniazid metabolism, reactive oxygen species may contribute 
to isoniazid induced hepatotoxicity. It is well established that hydazine is a 
metabolite of hydrazide compounds which includes isoniazid, acetylisoniazid, 
184 
monoacetylhydrazine and diacetylhydrazine. Hydrazine is a potent toxin with 
no safe levels in man (Back and Thomas, 1960) and was incriminated for the 
death of an elderly patient (Woo et al, 1992). 
4. In this in vitro system, the pathognomonic feature of 
monoacetylhydrazine hepatotoxicity is vacuolation while that of hydrazine is 
cytoplasmic disintegration. This information is important not only to 
investigate toxicity but also during research for effective antidotes against 
either form of toxicity. 
5. The pharmacokinetics of isoniazid metabolites; acetylisoniazid, 
monoacetylhydrazine, diacetylhydrazine and hydrazine are similar in young 
and elderly patients at first dose and steady state. 
6. Administration of antituberculosis drugs increased plasma 
concentrations of allantoin in both young and eldelry patients. Therefore, 
antituberculosis drugs induced oxidative stress and this was of a similar 
degree in young and elderly patients. 
7. The plasma concentrations of allantoin were higher in elderly than 
young patients due to decreased renal clearance of allantoin in the elderly 
group and a similar amount of allantoin was formed in the elderly as in the 
young patients. 
8. The TSARS test, may not be a good marker for estimating oxidative 
stress during antituberculosis chemotherapy with isoniazid because the five 
hydrazide compounds may interfered with the test, making it less accurate. 
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9) During isoniazid metabolism, toxic metabolites (acetylisoniazid, 
monoacetylhydrazine, diacetylhydrazine and hydrazine) are produced. Of 
these, hydrazine metabolite induces formation of reactive oxygen species. 
This may be dangerous if anti-oxidant mechanisms of the body are 
compromised. 
In general, depending on the amount of hydrazine formed during isoniazid 




1 . This study opens a thought on the use of allantoin to predict 
isoniazid toxicity. Since oxidative stress precedes tissue 
damage, it would be plausible to monitor allantoin levels in 
tuberculosis patients and determine at what allantoin 
concentration (i.e. extent of oxidtative stress) does organ damage 
due to antituberculosis toxicity manifest. Then, it would be wise 
to take extra-precaution with antituberculosis chemotherapy in 
patients with high plasma level of allantoin. 
2. There is a need to formulate appropriate remedial measures 
against pro-oxidant mechanisms during antituberculosis therapy 
to prevent toxicity and improve quality of life in elderly patients. 
For instance a search for effective antioxidants that can be 
administered together with antituberculosis drugs. 
3. The use of tissue slices has not been well explored by South 
African researchers. This mode of experimentation can limit the 
use of animals, and may reduce extent of experimentation of new 
drugs in man. There is a need to open a tissue-slice bank in 
South African. 
4. The effect of allantoin on the permiability of animal cells to 
antituberculosis drugs is not known. There will be a need to 
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ADRENOCHROME FORMATION (ABS. UNITS) AT pH 9.2 
Column ID A B C D 
Column Label al bl cl dl 
Mean 0.1462 0.0652 0.0486 0.0084 
Sample Size 5 5 5 5 
SD 0.001483 0.002775 0.002881 0.001140 
SEM 0.0006633 0.001241 0.001288 0.0005099 
Median 0.1460 0.06500 0.04800 0.008000 
Lower 95% CI 0.1444 0.06176 0.04502 0.006985 
Upper 95% CI 0.1480 0.06864 0.05218 0.009815 
Minimum 0.1440 0.06200 0.04500 0.007000 
Maximum 0.1480 0.06800 0.05200 0.01000 
Column ID E F G H 
Column Label el fl gl 
Mean -0.0079 -0.00124 -0.11198 
Sample Size 5 5 5 0 
SD 0.002012 0.0002074 0.001582 
SEM 0.0009000 9.274000E-05 0.0007074 
Median -0.008000 -0.001200 -0.1119 
Lower 95% CI -0.01040 -0.001497 -0.1139 
Upper 95% CI -0.005402 -0.0009826 -0.1100 
Minimum -0.01000 -0.001500 -0.1140 
Maximum -0.005000 -0.001000 -0.1100 
Column ID I J K L 
Column Label a2 b2 c2 d2 
Mean 0.0376 0.00492 0.0064 0.00268 
Sample Size 5 5 5 5 
SD 0.002074 0.003300 0.001319 0.001190 
SEM 0.0009274 0.001476 0.0005899 0.0005324 
Median 0.03800 0.005000 0.005800 0.002900 
Lower 95% CI 0.03503 0.0008228 0.004762 0.001202 
Upper 95% CI 0.04017 0.009017 0.008038 0.004158 
Minimum 0.03500 0.001400 0.005000 0.001400 
Maximum 0.04000 0.009200 0.008000 0.004000 
Column ID M N 0 p 
Column Label a3 b3 c3 d3 
Mean 0.158 0.1578 0.023 0.00224 
Sample Size 5 5 5 5 
SD 0.003162 0.004604 0.002121 0.0005727 
SEM 0.001414 0.002059 0.0009487 0.0002561 
Median 0.1580 0.1580 0.02300 0.002200 
Lower 95% CI 0.1541 0.1521 0.02037 0.001529 
Upper 95% CI 0.1619 0.1635 0.02563 0.002951 
Minimum 0.1540 0.1520 0.02000 0.001600 
Maximum 0.1620 0.1640 0.02500 0.003000 
APPENDIX AA 1 
Column ID Q R s 
Column Label a4 b4 c4 
Mean 0.0954 -0.01092 0.0366 
Sample Size 5 5 5 
SD 0.003912 0.002448 0.003050 
SEM 0.001749 0.001095 0.001364 
Median 0.09500 -0.01000 0.03700 
Lower 95% CI 0.09054 -0.01396 0.03281 
Upper 95% CI 0.1003 -0.007881 0.04039 
Minimum 0.09200 -0.01400 0.03300 
Maximum 0.1020 -0.008400 0.04000 
APPENDIX AA2 
File INH1ELD ( 14/03/'i5 j·-'c'.gi::' l 
ro:-. Hlifl? Ca AUC Clp v' d Mrn ~-:e 
1 2.63 8 .41 ::4.3(, 16.46 70 .(17 4 .26 
~ 3.69 8 .20 3 ,.S. 01 8.89 46.1:, 5. '.:: ( , -- 4. (H) 11.07 :.1. .96 6 .16 37.04 6. 01 ·~· 
4 3 .84 9.14 4(1. 30 -.94 4:,. 9 0 5.78 I 
5 4.28 8.16 3~, . 36 9. (;=, 65. 73 7.26 
6 4.98 5 . 7::: :36.66 8.73 61.69 .. . 07 I 
7 2.76 9 .65 21.34 1.50 1a.10 5. 2:S 
8 3.67 8.89 39.10 8.18 45.81 ~ . . 6(• 
9 2.95 c:. 51 21.2: 1:,. oa 65. 2·+ a --, -"t. ·-·~ 
' File I l'-IHl. YG ( 14/()3/9 '.5 Page 1 
ro~~ h l i fl:! C,:i AUC Clp Vd MRT 
1 ,.., ~c= .:.. • -·..J 9.98 :::3.83 1:,.43 53.00 3.42 
~ 4.l)d 8. (Ji] 40. 2=1 9.94 58.44 5.88 '"-- 3 .28 [~. 22 29.74 1::.,i!.i 66.43 4.94 ~· 
4 2.29 23. !)7 40. 53 28.06 62.11 4.86 
,: 7.54 18. 5(, 39.1::i 1 0 .2= 45.91) 4.49 ~· 
,S 3.71 17.81 ~i8. 67 6.82 49.11 7.2(, 
7 5.57 1.60 11. (14 36 .23 79.94 8.14 
i3 2.48 8 -,._.., 2~.38 17.86 65.9 3 ::: • . ~9 
9 2.3l) h.86 l 7 • 72. 2(1.20 9 •) . (•5 4.b4 
Page 1 -
CLp Vd MRi" f :e 
1 1.87 7 .2~ 1=.:::~\ 32.38 96.32 2.97 
~ ~.82 7 . 3()-.,2~. 33 1 ::: .15 53. 59 4.07 
~· 2.06 11.15 ~ 19.45 75.=2 3.87 4 1.96 6.99 . 18.75 56.89 3.03 
5 2.53 10.26 26.23 12.20 50.18 4.11 
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File INH30YG 04/03/95 





3.24 6.90 24.52 16.13 
1.73 36.44 33.67 11.88 
2 .61 8 .35 22.08 18.12 
81.20 4.98 






4.56 19.76 2 0 .25 110.15 5.4~ 
5.02 31.12 12.8~ 94.50 7.35 
5.27 21.69 18.44 59.47 4.85 
4.64 24.70 16.19 114.80 7 . 09 
7.68 22.42 17.84 75.03 4.20 
9 3 .92 3 .45 53.91 24.98 140.66 5.63 
:=ile ! :'·IH 30!::1_0 04/U3/S5 
ro·,i Hlife Co AUC CLp Vd l"IRT Ke 
1 1.87 7.:: 12.35 32.38 9b.32 2.97 
~ 2.e:: 7 .30 24.·n 1 .:: .15 53. 59 4.1:,7 -
3 ;~. 06 11.15 16.45 19.45 75.22 3.87 
4 1..96 8.99 17.06 18.75 '.:i6.89 .:: • c,3 
s 2.55 11);26 ~6.23 12.20 50.18 4.11 
Fil~ R!Fl YG 04/<)3/95 
row Hli f •:::J Co AUC CLp '.Id Mr;;T ~ : ~ 
1 3.03 8.20 29.(17 2 U. 6··~ 89.57 4 - .,-, -~7 
~ 1. 9 .3 :::::, . <,6 .3""1-. 76 17.26 81. (12 3.69 -- 8.3.2 1. f:11) 20.87 :a.75 33.:::. 4611. 6 1) -· 
~ :.8(1 .1.1. :.;.1 i,.:,. e2 35.67 ~65.6~ 7.45 
:::, ~ "".';" ·-· . --... • 5. 07 4:i.46 40. 8 •.) 23~.06 5.74 
6 3. 01 9.41) 2:5. 09 23.91 128.36 5.37 
7 5. 17 3.20 18.54 32.36 268.04 8.28 
8 4.69 6.94 38.77 15.48 112. 69 7.28 




File RIFlELD 04/03/95 
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5 2.89 a.12 2s.oa 1 9 .1 4 85.98 ~.49 
6 5.19 4.84 31.54 15.22116.50 7.65 
7 4 .09 8.27 33.08 14.51105.62 7.26 
8 1 .70 21.~5 18.51 25.92102.E3 3.97 
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A:JC 
C•_p Vd MF:Y 
11. ·.:e 119.84 6.93 
"'""" ........... 9::.25 4.20 .L...:. . __
'.::.. 54 1~7.57 8 ... ~ . ..., .
32. 7,:_, 141.99 4.34 
9.36 163. ::,5 17.48 
2::.12 17 6. 4(1 7.44 
41.45 170. 24 4.11 
39.63 195.64 4.94 
::o . .;:: 99.77 4.88 




3.52 7.2~ 55.93 10.73109.77 10.2::: 
2 .51 6.49 16.94 28.34114.30 4.03 
2.98 1 0 .20 - .... 4 7 14.36 63.63 4.43 
5.06 5.68 36 . 79 13.05 9~.01 7.21 





Fil2 ;:·ZALYG 0 4/03/9:, 
ro,~ H l if e Co AUC C:Lp \/d MF:T ~: 






4 :, .31 703.51 
74. 2:. 5 .!.9. ::: ~) 
A9. 7 (• 481. 4 :) 








12 . . . :~ 
8.1 
.:.. ,:i. 9 
6 1::.1 0 51.43 a~7.42 1.,1 :::0. 09 : o . ~ 
7 6.90 5i.B5 493.43 2.s:: :7.45 10 .a 
6 11.74 ~S.36 876.87 1.4:: 25.23 :7.7 
File FZAlE~D 04/C3/95 




4. ,) '.:, 
63.07 757.19 1.65 
76.12 i 9 4.53 1.80 
~7.74 ~:.1.a2 1.01 
65.32 963.:b 1.04 
120.43 ;a~.10 2.os 
6 ~.56 ~4.20 350.j4 2.85 
- 1.t. J";. a 101.!.:. 9-,:,.00 o.53 
~ 3 .21 82.36 262.27 3.81 
q S.61 4i.72 329.03 3.04 
PZA30YG 1)-./03/95 
ro1•1 H l if,~ Co AUC CLp 
.t 5.77 131.08 938.77 1.::;::: 
2 l). 9 .l ':-'6. :::: 9 :)().18 1. 56 
·-· 15. 1LI 32.42 B•)l .10 0.78 
4 8.25 ..... • 99 516.99 2.42 - , 
=· 
., 4 ... 37.27 :-::s ,L ~:.:? 3.53 ' .·~ f:" r) L :>. c:;,"-' ,, 1.1.: ,; 55. T:'. 2.74 ., 
4. 76 8"1.82 3q2.98 3.18 ' 
8 7 .94 40.61 415. 63 :::.01 
9 7.6? 78.88 74-l. 27 1.68 
10 =·. 9(1 70.25 457.96 :.73 
File FZA30ELD 04/03/95 
:: ~:, 4 68 
17.74 
1 ·:i. ,:: 
17.73 
14.32 















r·o,, Hlife Co AUS CLp Vd 
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Fil:;:- ..; INH 1 YE 0 "1' / 03/'=t5 ;::·ag2 .i. -
r-0 : ... 1 Hli"f~YG' Cc;YG ,;ucyg HlifeELD CoELD f-iUCe ld 
------- -------- ------
1 6.07 9 .49 69.93 1.99 12. 2 ''J 23.44 
2 4.29 13.36 66.:,2 2.77 c .19 17.65 - 2.94 ,: . . 29 13.7'1 4.29 ::, .92 2 .=,. 24 ..., 
~ 1.26 1~.06 31.40 3. 7·:; 8.79 31.43 "T 
5 2.65 11.11 23 .10 2.68 14. 5 ,) 31.41 
6 1.83 18.33 11.61 2.71 12.12 26 .8\) 
7 6.40 1. 72 29.93 3.84 5.22 19.59 
8 4.82 :::. 75 17.63 ~ o-~. • C 6.17 19.69 
9 3.77 5.63 20.59 3.08 !:,.38 18.08 
l !) 3.61 4 .62 2 i).3=· 
11 1.67 39.16 18.89 
File AINH30Y::'. 1)4/03/93 Page:- 1 -
ro~, HlifeYG CoYG P,UCyg f-iliteELD CoELD AUCeld 
------- --------· ------
1 3.68 4.33 1G.20 2.15 16.83 33.41 ., 4.84 11. 78 59.46 2. 4..; 1.95 4.97 
·-· 6.77 1.09 17.04 1.92 13.00 ~4.37 
4 3.13 4.31 16.12 4.96 3.56 22.6:, 
C: ~· 4.45 8.79 40.19 3.89 7.22 35.56 
6 1. 78 4 .93 7.6C,' .. 8.07 - ·~ 83.02 I ·-·. -,. .~. 
a 6.33 3.96 ~.., ,..,,. .... •..:.. • .;.."'T 
9 2.32 7.91) 17.16 
;=i\2 i':HYul YE 1) 4 / 03 / '7 '.;i F'ag;,,; 1 -
row Hli7~'/G CoYG AIJCyg HlifeELD CcELD Ai.JCeld 
------- -------- ------
1 5.9:, 8 . 5.:: 35.19 3.30 5 .9(• 21.27 .... 5.90 9.52 34.52 3.97 9.21 42.82 .;. - 17.84 5.58 136.18 13.85 6.49 121.31 ·-· 
4 2.97 2.S. c:;3 48.96 3.05 16.49 40.64 
5 2.38 26.::::. 45.90 3.12 10.64 '27.85 
6 4.2~, 1'5.05 55.14 20.45 4.16 117 .85 
7 4.38 11.25 50.18 10.11 4.67 62.79 
G 3.86 5.51 21.49 
9 4.99 1::.2·:; 62.56 
10 3. s=, 6.53 32.71 
Appendix 86 
Fila MHYD30YE 04/03/95 
rcw HlifeYG CoYG AUCyg HlifeELD C~ELD AU~eld 
1 7 .69 1 ..... -, .-. --·:. .. ,_. 112 . . ~c,. 1. 7.:. :: . 7 .:;.. 
l.7.14 
:: . ii 
2 l : . . 82 
3 4.6~ l!.~~ 64.09 3.70 17.33 ~5~99 
6.02 ... ,- ,""'I I • ·t- 6 .12 :'•.48 ·=r a. 3:+ 
~::. ('.!. ::, 5.'"- """- ...,. l ...::...:, .. ,' ~ 
6 3.~0 11.63 42.G? 
7 7.28 7.20 22.05 
a 4.09 3 .87 15 .s: 
9 5.42 6.21 37 .39 
1 8 3 .7S 5.40 20.:1 
:= .1. l ~ H'/!)1 YE 04/,)3/95 
:·o•....i HlifeYG CoYG AUCyg Hl ifeELD 
------- --------
l 4.12 (1.33 2.24 12.42 .., 
6.21 1.38 11.18 7.46 ... 
.:: 13.15 0. ::o 7.33 13.02 
' 3 1).10 (1. 7'2 20.2') 6.07 .. 
:i 4 .8') l). 70 3.9(: 3.40 
6 3.~3 l ., -..... ..;:. 5.27 5. ::.!. .. 4.80 0 .96 5.37 12.76 I 
3 19. 7,ti. 
File H'/D30YE: (1 4/()3/95 
ro .A, HlifcYG CoYG AUCyg HlifeEI...D ------- ---------
1 10.52 (t. 46 11. 76 4.57 .., 
3.16 2.37 5.79 4.66 -
. ..:, 4.6(• o. ai:, 37.90 34.63 
4 8.64 0.84 9 .66 20.20 
C: 4.93 1. CJ1 5.80 2.27 ~· 
6 11.31 1.01 14.61 
CoELD r~uceld 
------
0. 18 3.02 






•) . 76 2<).83 
Cc2ld AUCeld 
------
0 .22 11. 2'1 
(• . 58 12.79 
0.68 36.62 
1).97 26.89 




File DHYDlYE 04/03/9:, ;::._,;~ 
ro1-1 Hl ifDYG Coyg AUCyg HlifeELC CoELD AUC~ld 
------- -------- ------
1 -~ . ..:;. 4.33 15.64 2.78 '.2.16 4.i!r7 ... ~=a .a 0.99 6.17 4.72 1.42 6.84 .;. 
3 4.4 1.97 6.65 1. 78 1..99 1.39 
4 4.3 1.27 :,.65 3.48 3.55 1 '). 1.5 
5 4.1 1.92 7.84 2.59 3.49 3 .50 
6 5.6 0.38 2.28 5. =,3 7 • C>! 18 . .!.6 
7 .,. .,. 1. O:, ~ .. ea 6.17 0.71 : ,. 1 (; .... . oJ 
8 1.8 2.67 1.46 17.0:, 0.48 :1. (,9 
9 4.14 4. 1(1 19.97 
1(• 4.0J 2.41 1. ... -•.,,,_•.,,;:_I 
File Dn'{D30 '/E (•.:;. /<)3 /9'3 Page 1 
ro'lif Hl ~ fe'(G CoY.3 AUCyg Hl .i. feELD CoELD AUCeld 
------- -------- ------
1 1.69 5.9:, 8.7S 2.78 2.16 4.47 
2 2.90 5.23 10. 7'5 .... -• 7 !. (l.48 17.84 ..::., I 
. ..;, 3.8'~ 1. 04 4.87 5.91 (1.12 (l.92 
4 2.9~ 0.89 2 .. 35 37.40 1.14 59.47 
C 5.33 :: . ~-7 13.57 -· 
Appendix BS 
07/29/1995 10:00 PM 
MEAN DATA FOR HYD CONTROL AND DRUG SLICES 
Column ID A B C D 
Column Label 2contrl 4contrl 6contrl 8contrl 
Mean 0.86 0.93666667 0.97333333 0.95666667 
Sample Size 3 3 3 3 
SD 0.1587 0.1159 0.02887 0.1193 
SEM 0.09165 0.06692 0.01667 0.06888 
Median 0.8000 0.8800 0.9900 1.010 
Lower 95% CI 0.4656 0.6487 0.9016 0.6603 
Upper 95% CI 1. 254 1.225 1.045 1.253 
Minimum 0.7400 0.8600 0.9400 0.8200 
Maximum 1.040 1. 070 0.9900 1.040 
Column ID E F G H 
Column Label lOcontrl 2drug 4drug 6drug 
Mean 1.12666667 1.01666667 0.97 1.00333333 
Sample Size 3 3 3 3 
SD 0.04041 0.1124 0.07000 0.1531 
SEM 0.02333 0.06489 0.04041 0.08838 
Median 1.120 0.9900 0.9400 1.060 
Lower 95% CI 1.026 0.7374 0.7961 0.6230 
Upper 95% CI 1.227 1. 296 1.144 1. 384 
Minimum 1. 090 0.9200 0.9200 0.8300 
Maximum 1.170 1.140 1. 050 1.120 
Column ID I J 
Column Label 8drug lOdrug 
Mean 1.14666667 1.35666667 
Sample Size 3 3 
SD 0.1102 0.01528 
SEM 0.06360 0.008819 
Median 1. 200 1.360 
Lower 95% CI 0.8730 1.319 (. 
Upper 95% CI 1.420 1.395 
Minimum 1.020 1. 340 
Maximum 1. 220 1. 370 
APPENDIX BB 1 
07/29/1995 10:00 PM 
MEAN DATA FOR HYD CONTROL AND DRUG SLICES 
One-way Analysis of Variance (ANOVA) 






Treatments (between columns) 9 
Residuals (within columns) 20 
Total 29 







The P value is 0.0007, considered extremely significant. 
Variation among column means is significantly greater than expected 
by chance. 
Bartlett's test for homogeneity of variances. 
ANOVA assumes that all columns come from populations with equal 
SDs. The following calculations test that assumption. 
Bartlett's test cannot be performed because a sample size is too 
small. 
Student-Newman-Keuls Multiple Comparisons Test 
Mean 
Comparison Difference q P value 
-- --- ----------------------------- ---------- ------- -----------
2contrl VS 4contrl -0 .07667 1.274 ns P>0.05 
2contrl vs 8contrl -0.09667 1.606 ns P>0.05 
2contrl vs 4drug -0.1100 1.828 ns P>0.05 
2contrl vs 6contrl -0.1133 1. 883 ns P>0.05 
2contrl VS 6drug -0.1433 2.382 ns P>0.05 
2contrl vs 2drug -0.1567 2.603 ns P>0.05 
2contrl vs lOcontrl -0.2667 4.431 ns P>0.05 
2contrl VS 8drug -0.2867 4.763 ns P>0.05 
2contrl vs lOdrug -0.4967 8.252 *** P<0.001 4contrl VS 8contrl -0.02000 0.3323 ns P>0.05 
4contrl VS 4drug -0.03333 0.5538 ns P>0.05 
4contrl vs 6contrl -0.03667 0.6092 ns P>0.05 
4contrl VS 6drug -0.06667 1.108 ns P>0.05 
4contrl VS 2drug -0.08000 1. 329 ns P>0.05 
4contrl VS lOcontrl -0.1900 3.157 ns P>0.05 
4contrl VS 8drug -0.2100 3.489 ns P>0.05 
4contrl vs lOdrug -0.4200 6.978 ** P<0.01 8contrl VS 4drug -0 .01333 0.2215 ns P>0.05 
8contrl vs 6contrl -0.01667 0.2769 ns P>0.05 
8contrl VS 6drug -0 .04667 0.7754 ns P>0.05 
APPENDIX BB2 
8contrl vs 2drug -0.06000 0.9969 ns P>0.05 
8contrl vs lOcontrl -0.1700 2.825 ns P>0.05 
8contrl vs 8drug -0.1900 3.157 ns P>0.05 
8contrl vs lOdrug -0.4000 6.646 ** P<0.01 
4drug vs 6contrl -0.003333 0.05538 ns P>0.05 
4drug vs 6drug -0.03333 0.5538 ns P>0.05 
4drug vs 2drug -0.04667 0.7754 ns P>0.05 
4drug vs lOcontrl -0.1567 2.603 ns P>0.05 
4drug vs 8drug -0.1767 2.935 ns P>0.05 
4drug VS lOdrug -0.3867 6.425 ** P<0.01 
6contrl vs 6drug -0.03000 0.4985 ns P>0.05 
6contrl VS 2drug -0.04333 0.7200 ns P>0.05 
6contrl vs lOcontrl -0.1533 2.548 ns P>0.05 
6contrl VS 8drug -0.1733 2.880 ns P>0.05 
6contrl vs lOdrug -0.3833 6.369 ** P<0.01 
6drug VS 2drug -0.01333 0.2215 ns P>0.05 
6drug vs lOcontrl -0.1233 2.049 ns P>0.05 
6drug vs 8drug -0.1433 2.382 ns P>0.05 
6drug vs lOdrug -0.3533 5.871 ** P<0.01 
2drug vs lOcontrl -0.1100 1.828 ns P>0.05 
2drug vs 8drug -0.1300 2.160 ns P>0.05 
2drug vs lOdrug -0.3400 5.649 ** P<0.01 
lOcontrl vs 8drug -0.02000 0.3323 ns P>0.05 
lOcontrl vs lOdrug -0.2300 3.822 * P<0.05 
8drug ·vs lOdrug -0.2100 3.489 * P<0.05 
Mean Lower Upper 
Difference Difference 95% CI 95% CI 
---------------------------------- ---------- ------- -------
2contrl - 4contrl -0.07667 -0.2542 0.1009 
2contrl - 8contrl -0.09667 -0.3120 0.1187 
2contrl - 4drug -0.1100 -0.3482 0.1282 
2contrl - 6contrl -0.1133 -0.3680 0.1414 
2contrl - 6drug -0.1433 -0.4109 0.1242 
2contrl - 2drug -0.1567 -0.4347 0.1214 
2contrl - lOcontrl -0.2667 -0.5536 0.02029 
2contrl - 8drug -0.2867 -0.5813 0.007999 
2contrl - lOdrug -0.4967 -0.7981 -0.1953 
4contrl - 8contrl -0.02000 -0.1975 0.1575 
4contrl - 4drug -0.03333 -0.2487 0.1820 
4contrl - 6contrl -0.03667 -0.2749 0.2015 
4contrl - 6drug -0.06667 -0.3214 0.1880 
4contrl - 2drug -0.08000 -0.3475 0.1875 
4contrl - lOcontrl -0.1900 -0.4681 0.08805 
4contrl - 8drug -0.2100 -0.4970 0.07696 
4contrl - lOdrug -0.4200 -0.7147 -0.1253 
8contrl - 4drug -0.01333 -0.1909 0.1642 
8contrl - 6contrl -0.01667 -0.2320 0.1987 
8contrl - 6drug -0.04667 -0 . 2849 0.1915 
8contrl - 2drug -0.06000 -0.3147 0.1947 
8contrl - lOcontrl -0.1700 -0.4375 0.09752 
8contrl - 8drug -0.1900 -0.4681 0.08805 
8contrl - lOdrug -0.4000 -0.6870 -0.1130 
4drug - 6contrl -0.003333 -0.1809 0.1742 
4drug - 6drug -0.03333 -0.2487 0.1820 
4drug - 2drug -0.04667 -0.2849 0.1915 
4drug - lOcontrl -0.1567 -0.4114 0.09804 
4drug - 8drug -0.1767 -0.4442 0.09086 
4drug - lOdrug -0.3867 -0.6647 -0.1086 
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Appendix C 
,· -· ~ ·; 
...  ~ ., . - .•, -
.L - · • ~- · : 
~- • Ii_ 
. .. ..... -,..:. 
File SE:RUf":1 ,:;.~/03 /95 
ro•,1 sera!::ryl seracry30 
-------- ---------
1 () . ::.:. 0.46 ... 0.84 0.33 
.::, 0.35 0~59 
4 (I. 5'2 0.69 
5 0.69 o. 75 
6 0.75 0.59 
7 0 .44 0.48 
8 o. 58 o. 53 
9 0.77 0.62 
10 0.57 0.76 
File SERUl'l1 1)4/(•3/95 
row sera1.1a--;3 1) s:?raLtay90 
--------- ---------. 6.67 8.27 .... 
2 6.92 9.38 
3 4.80 4.67 
~ 8.43 7.50 
5 12.57 7.85 
6 9.30 7.00 
7 6.52 
8 7 .o;:, 6.50 
9 8.18 5.0(' 
10 9.65 10. (•7 
se,-a•=ry9(• 
---------
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4734.4 4 -.S97 , ( 1 
5 5169.6 6436.0 :060 . 0 
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7 2688. 0 ~094.4 4686.7 
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1:a. ·16 ,. ~2.1: 
87. E'3 16(•. ~ .. 















l 2.761.C. -. - .. , . -~, .. w-t • Q .=:-6 0:::: ~ =· .::.., f.:.. '~; I 4 i . • • • ..,._. - ·· . ·.· 
·-· 0~52 .. =· 
" 4.!.::7 .. : 
6(,66 .. ·-~· 
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6 2003 .. C :::::;.:·, . . ) 77::c .. ,:, 


















1 415.:::.s :43,7.:; 
2 7 0 1. 19 ::si.::. 9,-:, 
3 146.~~ 131.3~ 
4 111. o.:: :::.:is .1::: 
5 4,:,9. : ·:; .!.c:>O. •l (, 
6 40:. ~s 4a8.4~ 
7 719.7j :01.94 
8 424.20 : 79.82 
9 634.10 j j,.62 
10 538.7E ~40.27 
5t.:;:: 
76.48 
92 .. O<• 
33.9 ''1 
64.91 
c .... l .. ., 
- ' 0 • ..::, ,~ 
1 ,, .. 
5 ~::: .(1(, ::: . (,l) 
15. t~l l l 
: .1.65 
::.1. 51 
6 ~2.6 1 70.5Q 
7 .. ~.-:,. o: 37. 9~~ 
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: ,::•. 4 
:'.•.). ,:, 
.. :.._· .. . ,:. 
, :, . .j.,.· 
File CLEAF:EN o,i;o3;95 
r-ow acly aclyl ac: l y31) 
------
1 l 9.8<) :25.0S 
2 2 2. 5l: . .' 8.9\) 
~ . .;., 16.88 11. t,1 
4 4 7·.95 7.72 
C 5 1.47 ~· 11. 78 
6 6 2.91 19.6a 
7 7 12.98 3 0 .85 
8 9 1.11 2.46 
9 9 3.97 
10 1 0 8.72 33.40 
11 
File CLEA~ E N 04/03 iS 5 
.~cN crc!el 
! 
_;, 7.:. 71 
L~ 1 . . '::J •• 
:, 23.57 
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~S·'i. 5 7 ::, .. ::,-7 
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7 .) . b3 8 . 6 3 
15. ::.1 
:::a • .;.o 
.,4. 62 
12.1? =~. CJ'-) 
7.11 
ac:lel ac: le3(' a:!~~0 ~clyl crc1 y30 crc iy7 ~ 
------
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11.1.. 1 0 
1 5 2. 3 7 
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Appendix G 
